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ABSTRACT 
Mephenoxalone is a mild central nervous system depressant with 
activity resembling that of meprobamate. Since its introduction in 
1961 mephenoxalone has been used as an anxiolytic and as a muscle 
relaxant, although the latter effect is weak. 
Preliminary studies on the absorption and disposition of mephenoxalone 
have been conducted in beagle dogs but no pharmacokinetic data from 
human studies have been reported, except for a single study in which 
the biotransformation products present in human urine were identified. 
Methods presently available for the determination of mephenoxalone in 
biological fluids lack the sensitivity, specificity and precision 
requ i red for deta i led pharmacok inet i c stud i es. In th i s study, a 
rapid, sensitive, precise reverse-phase high-performance liquid 
chromatographic method with ultraviolet detection at 200nm was 
employed for the determination of mephenoxalone in biological fluids. 
Serum and urine samples were prepared for chromatographic analysis 
using simple liquid-liquid extraction techniques . . The application of 
the assay to pharmacokinetic studies in humans is presented. 
After admi n i strat i on of a single ora 1 dose of 400mg mephenoxa lone 
dispersed in 150ml water to six young, healthy volunteers, the 
compound was rapidly absorbed with the peak concentration of /lilg/ml 
occurring after about 1 hour. The elimination half-life was 
xii 
approximately 3 hours. The drug was extensively metabolized with only 
about 1 percent of the administered dose being excreted unchanged in 
the urine after 24 hours . 
The bioavailability of a newly developed mephenoxalone-containing 
tablet was also investigated. The drug was absorbed more rapidly from 
the tablet than from the dispersed dose. This was attributed to a 
shorter in vivo dissolution time on the basis of in vitro tests, but 
this effect is not expected to be clinically significant. 
In addition, two human urinary metabolites of mephenoxalone were 
identified as unconjugated hydroxylated derivatives using thermospray 
HPLC-mass spectrometry. The plasma protein-binding properties of 
mephenoxalone were also investigated. 
CHAPTER ONE 
INTRODUCTION 
~ PHYSICO-CHEMICAL PROPERTIES OF MEPHENOXALONE 
Mephenoxalone (methoxydone, methoxydon, methoxadone, metoxadone) is 
5 - (2 - methoxyphenoxymethyl) oxazolidin - 2 - one (1-3). It has the 
structural formula shown in Fig.1.1. It possesses a cyclic carbamate 
structure and, as such, differs from meprobamate, the prototype for 
this series of drugs, which is an open-chain dicarbamate (3,4). 
FIGURE 1.1 Mephenoxalone 
Mephenoxalone occurs as a tasteless, odourless, white to slightly 
yellowish-white crystalline powder with a melting point of 143 to 
1450C (2). One part of drug is soluble in 100 parts of chloroform, in 
110 parts of methylene chloride (dichloromethane), in 170 parts of 
methano 1, in 330 parts of ethano 1 and in 100 parts of acetone. It is 
also soluble in propylene glycol but practically insoluble in water 
and in solvent ether (3, 5) . 
Although it has been reported that the compound absorbs energy in the 
ultraviolet (UV) range, with an absorption maximum at 274nm in 
2 
chloroformic solution (5), no report exists of a full UV spectrum. A 
spectrum was therefore determined in this study, the results of which 
are shown in Fig.2.3. A discussion of the results is presented in 
Sect i on 2.5.3. Mephenoxa lone has a 1 so been reported to fluoresce 
using an excitation wavelength of 300nm and measuring the emitted 
light at 330nm (uncorrected wavelengths) in ethylene dichloride (6). 
The infrared spectrum of mephenoxa lone is dep i cted in Fig.1. 2. (7). 
Absorpt i on at 3250cm-1 corresponds to the stretch i ng frequency of 
the N - H bond. The absorptions at 1720 and 1740cm-1 arise from 
the carbonyl group and at 1510cm-1 from the amide functional group. 
100r----------------------------------------------------, 
4000 3000 2000 1500 
Frequency (cm-l) 
1000 
FIGURE 1.2 Infared spectrum of mephenoxalone 
Reprinted from Pares et a 1. (7). 
1.2 CLINICAL PHARMACOLOGY OF MEPHENOXALONE 
1. 2.1 Mode of Action and Clinical Uses 
700 
Pharmacologically, mephenoxalone resembles meprobamate (2,8-11). Both 
compounds are classed as central relaxants because they are central 
nervous system (CNS) depressants with muscle relaxant properties (12). 
Members of this class may thus be described as mild sedatives with 
3 
weak muscle relaxant activities, and their main application is in the 
management of anxiety and tension states. 
Although the action of these agents at a molecular level remains 
unknown, it is clear that, at a neurophysiological level, reflexes 
involving interneuronal circuits are depressed (12). 
The major sites of the sedat ive effects of these compounds are the 
brain stem and subcortical areas. They block the passage of stimuli 
at the level of the ascending reticular formation (ARF), which is 
responsible for transmitting and maintaining a state of arousal. The 
result is a reduced response to sensory stimuli i.e. eNS depression 
(13) . 
Skeletal muscle relaxation (i.e. a reduction in muscle tone) is 
produced by the blockade of impulses at the interneurons of 
polysynaptic reflex arcs, mainly at the level of the spinal cord 
(12,14). This fact is demonstrated by the abolition or diminition of 
the flexor and crossed extensor reflexes which possess one or more 
interneurons between the afferent (sensory) and efferent (motor) 
fibres (12). 
The majority of pharmacologic studies of mephenoxalone have been 
conducted in 1 aboratory an ima 1 s. Fischer and Szabo (15) and Gray et 
al. (16) have demonstrated that its neuropharmacologic activities are 
restricted mainly to the supraspinal level. A general sedative action 
occurs in rats and dogs, the duration of which is approximately four 
hours following oral administration . A cataleptic action is observed 
in rats, while the reactions of cats to environmental stimuli are 
diminished (16). In mice, it modifies seizures resulting from 
electroshock treatment, reduces motor activity and caffeine 
hyperactivity, specifically inhibits discriminative avoidance, and 
mollifies aggressive behaviour induced by electroshock or isolation . 
Low doses resu lt in reduced recta 1 temperatures and a sign if i cant 
reduction in the toxicity of dl-amphetamine. Other observed 
neuropharmacologic actions of mephenoxalone include a potentiation of 
barbiturate narcosis in mice and an enhancement of the analgesic 
action of morphine in rats. A more recent study by Fischer et a I. 
4 
(17) shows that mephenoxalone increases the analgesic action not only 
of morphine but also of dihydrocodeine and aminopyrine. 
Large doses of the drug injected intraperitoneally into dogs and cats 
slightly reduce blood pressure (16) but this effect is not observed in 
rats with stress-induced elevated blood pressure (18). Mephenoxalone 
has no specific adrenergic or ganglion-blocking actions, but a weak 
anticholinergic action may be responsible for the reduction in pH and 
volume of gastric secretions and in gastro-intestinal motility in rats 
(16). The motility of the bladder and intestine of dogs, however, is 
unaffected (19) . 
Clinical studies in man show that mephenoxalone has a tranquilizing 
action and that it possesses mephenesin-like muscle relaxant 
properties (16, 20-22) . A preliminary investigation using 1000 
patients indicated that it had little or no anaesthetic or hypnotic 
action (20) . The use of mephenoxalone (in combination with 
paracetamol) was investigated in patients with 
muscular contractions accompanied by pain (22) . 
obta i ned in approx imate ly fi fty percent of cases. 
acute or chronic 
Good resu lts were 
A further study, 
concerning the effect of the drug in various subchronic and chronic 
rheumatic diseases, verified the myorelaxant properties of 
mephenoxalone (21). 
Repeated administration of a mephenoxalone-paracetamol combination 
has been shown to be of value in postoperative pain therapy (23), the 
pain relief obtained being greater with the combination than with 
paracetamol alone. Since mephenoxalone has no analgesic activity per 
se, a possible explanation rests on either a delayed cumulative effect 
or its influence on the perception of pain. 
Mephenoxa lone is a low potency agent with a moderate dose-response 
curve and is recommended as being most useful for the treatment of 
anxiety and tension associated with somatic disorders (16,24). It 
calms the patient without causing significant drowsiness, thus 
allowing the person to maintain his usual activity (20). The drug has 
I ittle or no anaesthetic or hypnotic action and has no therapeutic 
value in the treatment of psychoses (2,11). Mephenoxalone has a weak 
5 
muscle relaxant action which may be useful in the treatment of a 
variety of conditions where muscle spasm exists e.g. torticollis, 
cervical syndrome, lumbago, myalgia, hernia disci, spasms at bone 
fractures, arthroses, parap legi a, spondylarthroses, coxarthroses, 
immobilisations and extensions, and for improvement of flexibility in 
phys iotherapy (2). Ske leta 1 musc le spasm is generally caused by 
trauma involving muscular overextension or bruising. This results in 
an acute episode of involuntary muscle contractions . This is often 
accompan i ed by pa in, interference wi th funct i on and, occas i ona lly, 
postural distortion. Treatment may therefore involve muscle relaxant-
analgesic combinations. In some cases, tension headaches are 
responsible for local, sustained muscle contractions which can be 
treated as above or with muscle relaxant-antianxiety drugs. 
1.2.2 Recommended Dosage 
Mephenoxa lone is admi n i stered ora lly ina tab 1 et dosage form. The 
recommended adult dose varies from 200 to 400mg, three to four times a 
day, to a maximum of 2.0g daily. In children (6 to 15 years), the 
dose is reduced to 100mg three times daily (2). 
1.2.3 Adverse Effects and Toxicity 
After therapeutic doses of mephenoxalone, the most common adverse drug 
responses are headache, drowsiness, insomnia, nausea and skin rashes. 
These effects are generally mild and transient, and occur less 
frequently than with the prototype, meprobamate (3,9,11). 
Although no acute or chronic toxicity has been observed in man, 
studies on laboratory animals show that serious toxic effects are 
produced when high doses are used for extended peri ods . Da ily ora 1 
doses of 400 to 600mg/kg administered to dogs for 3 to 4 weeks 
resulted in anorexia, loss of body weight, ataxia, haemolytic anaemia 
and sequelae (25) . However, no toxicity was observed with daily doses 
of 120mg/kg for a six month period. Acute toxicity studies in mice 
and rats have shown that oral LD50 values for mephenoxalone are 
greater than 4g/kg body weight (16,26), though it has a greater acute 
toxicity in newborn rats than in adult rats , the oral LD50 values 
6 
being approximately 650mg/kg and 3820mg/kg, respectively (26). The 
increased toxicity in the newborn as compared with adult rats is 
attributed to their greater sensitivity to CNS depression. 
No patho log i ca 1 changes have been observed in the 1 i ver, kidneys, 
adrenal glands or brains of mice, even after chronic intraperitoneal 
administration (27). 
1.2.4 Drug Interactions, Dependence and Precautions 
The concomitant administration of other psychotropic drugs (especially 
phenothiazines or monoamineoxidase inhibitors), which may potentiate 
the action of mephenoxalone, should be avoided (9,11) . It has been 
reported that mephenoxalone may reduce tolerance to alcohol and 
a lthough there is no ev i dence to suggest that it is a dependence-
producing substance, the possibility should not be overlooked, 
especially if the patient has a tendency to abuse drugs (9). For the 
same reason, the drug should not be discontinued abruptly if the 
patient has been taking mephenoxalone for a long period of time. 
The drug should be discontinued if a skin rash or other 
hypersensitivity reaction occurs, and patients should be cautioned not 
to operate a motor vehicle or heavy machinery if they become drowsy or 
dizzy whilst taking the drug. When mephenoxalone is given in large 
doses or for extended periods, haemograms and liver function tests 
should be conducted at regular intervals (9). 
~ PHARMACOKINETICS OF MEPHENOXALONE 
Very 1 itt 1 e is known about the pharmacok i net i cs of mephenoxa lone in 
man. The metabolites present in urine have been identified (28) but 
only one extensive study of the absorption, excretion and metabol ic 
fate of the drug (in beagle dogs) has been reported in the 
literature (6). 
7 
1.3.1. Absorption and Distribution 
Morrison (6) showed that in dogs the absorption of mephenoxalone is 
rapid and almost complete after oral administration. Peak plasma 
levels of 65 to 68~g/ml were attained 2 to 4 hours after a single oral 
dose of 100mg/kg, administered in gelatin capsules. An apparent 
volume of distribution of 110 to 120 percent of body mass was evident. 
Following oral administration, unchanged mephenoxalone was a major 
plasma component up to 6 hours after dosing . Since metabolic 
alteration occurred rapidly after intravenous administration, it is 
likely that absorption was continuous throughout this interval. 
1. 3. 2 Metabolism 
Following oral or intravenous administration, mephenoxalone is almost 
quantitatively metabolized by dogs to two isomeric phenolic compounds, 
wh i ch are excreted both in the free form and as conjugates wi th 
glucuronic acid . Only 1 to 4 percent of the dose is excreted 
unchanged. The met abo 1 i c pathway of mephenoxa lone in both cats and 
rats appears to be identical to the pathway in dogs (6). 
The phenolic metabolites are assumed to be the 4'- and 5'-hydroxyl 
derivatives, formed by hydroxylation para to the alkoxyl and methoxyl 
groups . Th i s pattern of hydroxyl at ion is assumed because although 
hydroxylation of substituted benzene rings conventionally occurs or tho 
or para to groups which are ortho-para directing , e .g. alkoxyl and 
methoxyl, the steric effects of these groups on the mephenoxa lone 
molecule are l ikely to prevent ortho substitution (6). 
Morrison (6) identif ied these same phenolic metabolites and their 
conjugates in the urine of human subjects, the major components 
comprising the conjugated derivatives . A more recent study conducted 
by Eckhardt et a 7. (28) demonstrated the presence of ten human 
urinary metabolites of mephenoxalone. The proposed biotransformation 
pathway is shown in Fig.1.3 . Although some parent drug is excreted 
unchanged, the majority is degraded by 6 pr incipal routes : 
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1. The phenoxymethyl ether bond is c leaved to form o-methoxypheno 1 
(Metabo 1 i te I) and Metabo 1 ite II, the 1 atter be i ng i dent ifi ed by 
the formation of 3-amino-1,2-propanediol (IIa) after alkaline 
hydrolysis . 
2. Hydroxyl at ion of the benzene ring produces pheno 1 i c der i vat i ves 
(Metabolites IlIa and IIIb). 
3. Demethylation to demethylmephenoxalone (Metabolite IV) occurs . 
4. Opening of the oxazolidine ring to form 1 - (o-methoxyphenoxy)-3-
aminopropan-2-ol (Metabolite V). 
5. 1-(o-Hydroxyphenoxy)-3-aminopropene (Metabolite VI) may be an 
artefact. 
6. Formation of dehydromephenoxalone (Metabolite VII) . 
Three further unidentified metabol ites are present in urine. 
Metabolites II, IV, V, VI and VII appear to be present as conjugates, 
and acid hydrolysis or enzymatic cleavage is necessary prior to their 
isolation and identification. 
1. 3. 3 Elimination 
Mephenoxalone is eliminated in a biphasic manner following intravenous 
administration of the drug to dogs (6) . An initial equilibration 
period of 1 hour is the result of rapid metabolic alteration of the 
parent compound . The second phase is a first order process i n wh i ch 
the metabolic rate is limited by some other process such as the rate 
of conjugat ion or excretion of the transformation products. The 
plasma half-life (t ,/,) during the latter phase is 2.5 to 3.0 hours. 
The metabol ites are excreted in both urine and faeces after 
intravenous dosing . The major component found in the faeces is the 
free form of the less polar of the two phenolic metabolites, while 
both phenols are excreted, primarily as conjugates , in the urine . 
Sma 11 amounts of the conjugates are, however , a 1 so found in the 
faeces . A possible explanation for the presence of one phenol ic 
metabolite and two conjugated derivatives in the faeces is that 
conjugates are excreted in the bile and are subsequently almost 
quantitatively hydrolyzed by glucuronidase in the i ntestinal tract to 
form the free phenols, the more polar phenol being reabsorbed into the 
systemic circulation . 
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Using either an oral or intravenous administration route in dogs, 80 
to 90 percent of the dose is excreted within 24 hours, of which more 
than 60 percent is excreted in the urine. Repeated oral dosing for 
four consecutive days, with each dose being larger than the previous 
one, has shown that the percentage of the dose excreted decreases as 
the dose increases. This suggests that saturation of a process (e.g. 
rate of conjugation or excretion) has occurred (6). 
OOCH3 I 4' OH 
Metabolite I 
Metabo 1 He II I a 
Mephenoxalone 
I 
Cll H11°1, 
Metabo 1 He V II b 
_(Y'H d H 
VO-CH2 oJo 
"'-, ~ Motabol ito IV b 
OOCH3 I 4' O-CHrCH-CHrNH2 
I 
OOH I ~ O-CH=CH-CH 2- NH2 
OH 
Metabolite vb Metabol ite VI b 
FIGURE 1.3 Biotransformation of mephenoxalone 
Adapted from Eckhardt et a I. (28). 
(a) Morrison (6) reported 2 hydroxylated derivatives, 
Metabolites IlIa and IIIb, which exist as free and 
conjugated products 
(b) exist as conjugates 
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CHAPTER TWO 
OEVELOPMENT OF A HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD FOR 
THE ANALYSIS OF MEPHENOXALONE 
2.1 INTRODUCTION 
High-performance liquid chromatography (HPLC) is a well established 
technique in pharmaceutical analysis. High efficiency, versatility, 
selectivity, speed and precision have all contributed to its 
popularity as a routine analytical tool for drug analysis (29-31). 
The majority of HPLC separations are performed on reverse-phase, 
chemically bonded column packing materials (32). Reverse-phase 
chromatography (RPC) employs a non-polar stationary phase and a polar 
mobile phase, thus allowing polar solutes to elute first . This is 
advantageous for chromatographing biological samples because the 
hydrophilic endogenous compounds elute first , thereby avoiding the 
excessively long retention times associated with normal phase packing 
materials. The microparticulate packing materials also possess the 
advantages of stability, high efficiency, reproducibility and rapid 
equilibration. In addition, they allow a broad range of non-polar and 
polar compounds to be analyzed simultaneously and elution order is 
often predictable based on the degree of hydrophobicity of each solute 
(the more hydrophobic the molecule, the greater is the chromatographic 
retention) . 
The separation of compounds as they migrate through the column depends 
on three factors: retention, co lumn efficiency and column selectivity 
(33, 34). The retention of a compound relies upon the strength of the 
eluent used, which is usually adjusted to obtain values between 1 and 
10 for the column capacity factor, k'. The capacity factor is 
calculated from Equation 2.1. It may be noted, however, that when the 
sample contains few components, or when many plates are available, a 
somewhat lower range (1 to 5 or 0.5 to 2.0) may be preferred (35). 
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tr tm 
k' = Equation 2.1 
tm 
where tm = the time for solvent molecules (or an unretained 
compound) to traverse the column 
tr = the retention time for the compound of interest 
The efficiency of the column depends not only upon the size of the 
packing particles and the quality of the packing material, but also on 
the packing technique employed, the operating temperature of the 
column and the eluent flow rate employed. When comparing efficiencies 
of co 1 umns of the same 1 ength, the theoret i ca 1 plate number, N, is a 
usefu l parameter . This value is calculated from Equation 2.2 (36) . 
tr 2 
N = 5.54 Equation 2.2 
wh 
where tr = peak retention 
wh peak width at half the peak height 
Both these values are measured in the same terms of time, volume or 
distance. 
The determination of efficiency is performed with the column placed 
in-l ine with the chromatographic system. The efficiency may, 
therefore, be affected by extraco 1 umn effects such as inject i on of 
mass or volume overloads onto the column and detector cell volume 
effects . 
Column selectivity , ~ is the ratio of the capacity factors, k'l and 
k' 2, of two compounds, 1 and 2 respectively, and is a function of the 
stationary phase properties and mobile phase eluting power (33, 37) . 
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The optimization of separation has been covered by many authors (33, 
35, 38, 39) and, to a large extent, it can be brought about by changes 
in mobile phase alone, the stationary phase having been selected in 
the first place to provide a suitable chromatographic mode for the 
analysis. 
High quality stationary phase packing materials are commercially 
ava i 1 ab 1 e. A wi de ly adopted method for co 1 umn pack ing is the high 
pressure slurry technique in which the particles, suspended in a 
liquid (slurry solvent), are forced into the column by a displacement 
1 iquid (packing solvent) under high pressure (40-42). A good slurry 
solvent is generally found by trial and error but must be capable of 
removing trapped air from the particle pores and avoiding the 
formation of agglomerates of packing material. Trapped air is removed 
by complete wetting of the packing material by the slurry solvent, and 
the breakdown of agglomerates is encouraged by ultrasonication. 
The 1 ife of a co 1 umn depends both on the chemi ca 1 stabi 1 i ty of the 
packing material and on the physical stability of the packed bed. The 
chemical stability of silica-based packing materials is primarily 
affected by mobile phases with pH values below pH 2 and above pH 7 but 
most drugs can be analyzed withi n the stable pH range (43). Of more 
concern are the phys i ca 1 factors wh i ch can contri bute to a loss of 
column efficiency during use, including frequent solvent changes, high 
flow rates and pressures, the injection of air, and the presence of 
extraneous materials in either the sample or the mobile phase of the 
HPLC system. Column life, therefore, depends on the analytical 
conditions employed and the intensity of column use. 
Mobile phases employed in RPC with bonded non-polar stationary phases 
are generally polar solvents or mixtures of polar solvents e.g. 
acetonitrile-water. Mobile phase strengths are usually measured in 
terms of the solvent polarity and are presented as the elutotropic 
ser i es. The propert ies of pure so 1 vents, the ir sources, and virtues 
in RPC have been widely published (40, 44). Pre-requisites for an HPLC 
solvent include high purity, immiscibi lity with the stationary phase, 
absence of react i vi ty with the stat i onary phase, low bo il i ng po i nt, 
low viscosity, low cost and good ultraviolet cut-off (if ultraviolet 
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detection is to be employed). Acetonitrile is one of the most popular 
reverse phase solvents because of its low viscosity, favourable vapour 
pressure, UV transparency and elution strength. Given a choice 
between two solvents of similar polarity, the less viscous is always 
chosen; the lower operating pressures this affords extends column 
1 ife. 
Detection systems employed in HPLC are designed to measure a 
particular physical or chemical property of a solute in the LC column 
effluent (45) . The fundamental requirements of a detector include a 
wide linear dynamic range, low drift and noise level, high response, 
fast response time, ease of operation, and reliability (45, 46). The 
ultraviolet detector is, at present, the most widely used LC detector 
because of its high selectivity, reproducibility, low noise 
characteristics and wide range of application. 
A photo-conductivity detector has been used to selectively detect 
nitrogen-containing compounds (47). This detector measures ionic 
species in solution and operates either as a selective detector for 
monitoring photo-reactive compounds or as a general purpose 
conductivity detector for measuring ionic compounds . When operated in 
the selective mode, it detects compounds which contain functional 
groups that are converted to ionic species upon exposure to 
ultraviolet 1 ight. The selectivity of the detector depends on the 
photo-chemistry of the compounds involved. An overall schematic of a 
typical photo-conductivity detector is shown in Fig.2.1. In this 
arrangement the LC column effluent is divided into two equal streams, 
one leg of which is directed into a UV reactor and then into the 
analytical side of a different i al electrolytic conductivity cell. The 
other solvent stream passes through a delay coi 1 and into the 
reference side of the cell. The electrolytic conductivities of the 
reference and analytical sides of the cell are differentially summed 
by a conductivity bridge and the resulting output is passed to a 
recording device . Any compound which is photolyzed in the UV reactor 
will be detected by this technique . Solvents employed for LC with a 
photo-conduct i vity detector must be free from ha logens and must be 
devoid of buffers and salts . 
RESER VOI R 
• 
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FIGURE 2.1 Photo-conductivity detector 
Reproduced from "Photo-conductivity detector 
operations manua 1" (47) . 
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Errors incurred in an analytical procedure can be minimized by the use 
of an internal standard technique in which a known compound is added 
to the sample solution prior to analysis (48, 49). Errors may be 
incurred in sample preparation or by variable injection volumes, 
apparatus and techniques. A basic requirement for an internal 
standard is that it bears a close structural s imi larity to the 
compound being measured. In addition, it must elute near to, and be 
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completely resolved from, other peaks of interest, it should be added 
at a concentrat i on wh i ch wi 11 gi ve a simi 1 ar peak he i ght to the 
compound being analyzed, it must not be present in the original 
sample, and it must behave like the compound of interest during any 
sample pretreatment. The limitations of the internal standard 
technique and guidelines for its proper application to the analysis of 
drugs in biological fluids have been reported (50). 
2.2 METHODS AVAILABLE FOR THE ANALYSIS OF MEPHENOXALONE 
Few methods have been published in the literature concerning the 
quantitative analysis of mephenoxalone. The first reported assays 
were developed by Morrison (6) to analyze mephenoxalone and its 
metabolites in the biological fluids of laboratory animals. 
Spectrophotofl uorimetri c and rad iometr i c procedures were ut i 1 i zed, 
the former to quantitate parent drug and the latter to measure a total 
of drug plus metabo 1 i tes. Ali qu i d- 1 i qu i d extract ion procedure was 
emp loyed to i so 1 ate mephenoxa lone from serum and uri ne, and the, 
ethylene dichloride extracts were measured in a 
spectrophotofluorimeter by excitation at 300~m and measuring the 
emitted light at 330~m. This method was reasonably sensitive with a 
detection 1 imit for mephenoxalone in serum of 0.2~g/ml. Radioactive 
tracer techn i ques were emp loyed to determi ne the tota 1 drug plus 
metabolite concentration at various intervals after dosing with 
mephenoxalone. Urine samples were counted directly in a liquid 
scintillation spectrometer, while faecal samples were homogenised in 
water and combusted (oxygen flask combustion procedure) prior to 
counting. Blood samples were combusted and plasma samples were either 
counted directly or combusted first. This technique was time-
consuming and the results obtained (total drug plus metabolites 
concentration) had little significance until combined with those from 
fluorimetric analysis (parent drug concentration). 
An u ltrav i 0 1 et spectrophotometr i c method has been emp 1 oyed for the 
determination of mephenoxalone in a tablet dosage form (5). The drug 
concentration, in chloroformic solution, was measured at a wavelength 
of 274nm. This method, like spectrophotofluorimetry, has poor 
selectivity and endogenous interferences from the sample are likely to 
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occur, particularly when biological fluids are analyzed (48). The 
sensitivities of these spectrophotometric techniques are typical of 
direct chemical assay values and are usually not sufficient for 
measur i ng the low concentrat ions found in serum and uri ne fo llowi ng 
drug administration. 
The most advanced analytical procedure reported to date. utilises HPLC 
to separate mephenoxalone from other sample constituents present in a 
combination tablet dosage form (2). A reverse phase system with a 
methanol-water (30/70) mobile phase flowing at 2.0ml/min and a 10~m 
octadecylsilane (C18) stationary phase gave a retention time of 7.2 
mi nutes. Measurement of mephenoxa lone was by u ltravi 0 let detect i on 
at 276nm. The 1 imitations of this method centre around the high 
flow rate used, which, as discussed earlier, produces a high operating 
pressure and consequent ly decreases co 1 umn 1 ife and reduces co 1 umn 
efficiency. In addition , UV detection at 276nm does not provide 
adequate sens it i vity for measuri ng the low 1 eve 1 s of mephenoxa lone 
found in biological samples. 
Reverse-phase HPLC was chosen for this study because of its previous 
app 1 i cat i on to the determi nat i on of mephenoxa lone and its inherent 
advantages over other analytical methods. A 5~m C18 column was 
employed for the analysis. A range of slurry solvent-packing solvent 
comb i nat ions were ut i 1 i zed in the co 1 umn pack i ng procedure and the 
column life of each packed bed was examined. 
Although it is known that mephenoxalone has an absorption maximum at 
274nm (5), no record exists of a complete ultraviolet spectrum. The 
determination of such a spectrum facilitates the choice of a 
wavelength at which maximum absorption of UV light (A max) by 
mephenoxa lone occurs, thereby ach i ev ing maximum sens it i vi ty. The 
solubility of mephenoxalone in a range of common laboratory solvents 
was determined in an attempt to find a suitable solvent, not only for 
the above-stated determination but also for the routine preparation of 
stock solutions of the drug. 
The application of ultraviolet and photo-conductivity detection 
methods for the determi nat i on of mephenoxa lone inhuman serum and 
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urine was investigated. 
2.3 MATERIALS AND APPARATUS 
2.3.1 Materi a 1 s 
The following drugs were used as supplied: 
Mephenoxalone (Adcock-Ingram Laboratories Ltd . , Johannesburg, 
South Africa) 
Phenacetin (Maybaker (S.A.) (Pty) Ltd., Port Elizabeth, South Africa) 
Methocarbamol (Lennon Ltd., Port Elizabeth, South Africa) 
All the organic solvents employed in this study were distilled-in-
glass grade and were purchased from Burdick and Jackson Laboratories, 
Muskegon, Mich., USA, with the exception of chloroform which was 
supplied by Waters Associates, Milford, Mass., USA and 1,2-
dichloroethane which was purchased from Riedel-de-Haen, Seelze, W. 
Germany. 
All other reagents were of at least analytical grade quality. 
Hydrochloric acid and sodium hydroxide were supplied by BDH Chemicals, 
Poole, England, while phosphoric acid was supplied by Carlo Erba, 
Milan, Italy. 
HPLC-grade water was prepared by reverse osmosis purification followed 
by passage through a Milli-Q (Millipore Corp., Beford, Mass., USA) 
system. 
2.3.2 High-Performance Liguid Chromatographic System 
The HPLC system employed was as follows: 
Model M51D liquid chromatographic pump (Waters Associates, 
Milford, Mass., USA) 
Model 710B WISP automated sample injector (Waters Associates, Milford, 
Mass., USA) 
Column packed with 5~m C18 packing material (see Section 2.4.4) 
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Model LC-UV variable wavelength detector (pye-Unicam Ltd., Cambridge, 
England) 
Model 561 strip-chart recorder (Perkin Elmer Corp., Norwalk, 
Conn., USA) 
2. 3. 3 Additional Equipment 
The following were employed throughout the study: 
Type 2004 MP6 five - figure precision balance (Sartorius BmbH, 
Gottingen, W. Germany) 
Model 601 digital ionalyser (Orion Research Incorp., Cambridge, Mass., 
USA) 
Model 8845-30 ultrasonic cleaner (Cole-Parmer Instrument Co., Chicago, 
Ill., USA) 
N-Evap Model 112 analytical evaporator (Organomation Associates Inc., 
South Berlin, Mass., USA) 
Model HN-SII general purpose centrifuge (Internation Equipment Co., 
Needham Heights, Mass . , USA) 
Model M-16710-12 'maxi-mix' vortex mixer (Thermolyne Corp., Dubuque, 
Iowa, USA) 
Model 3521 reciprocating mechanical shaker (Lab-Line Instruments, 
Inc., Melrose Park, Ill., USA) 
Fixed and variable volume Transferpettes (Brand, W. Germany), 
Magnetic stirrer (Gallenkamp, England) 
Grade A glassware was employed throughout the study. Before use, all 
glassware was cleaned in Decon 75 concentrate (Atomic Export Import 
Corp. (Pty) Ltd . , Johannesburg, South Africa), thoroughly rinsed with 
distilled water and HPLC-grade water, and then dried. 
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2.4 EXPERIMENTAL 
2.4 .1 Standard Solutions 
Each stock solution was prepared by dissolving 25mg of the appropriate 
drug sample in acetonitrile and making up to volume with acetonitrile 
in a 25ml volumetric flask. Dilutions were made, with either water or 
mobile phase, to produce the required concentrations . 
A standard C18 column test mixture was prepared by mixing 10~g each of 
benzamide, benzophenone and biphenyl with O. Sml of a 1 in SO dilution 
of benzene in acetonitrile in a 20ml volumetric flask and making up to 
volume with acetonitrile . 
2.4 .2 Chromatographic Conditions 
The following chromatographic conditions were utilized: 
2.4.3 
HPLC system 
UV detection wavelength 
Sensitivity 
Chartspeed 
Flow rate 
Pressure 
Temperature 
Mobile phase 
Mobile Phase Preparation 
see Section 2.3.2 . 
200nm 
0.16 AUFS 
back -off (coarse) 5 
recorder input 10mV 
Smm/min 
1.0ml/min 
3000 psi 
ambient 
acetonitrile-water (3S/6S) 
All mobile phases used in this study were prepared without correcting 
for the volume changes that occur upon mixing of the aqueous and 
organ ic components. The solvent mixtures were degassed and filtered 
through a 0 . 4S~m membrane filter (Type HVLP, Millipore Corp., Bedford , 
20 
Mass., USA) prior to use. All mixtures were freshly prepared on the 
day of analysis. 
The phosphate buffers were prepared by transferring a specific volume 
of phosphoric acid (depending upon the required molarity) to a 1 litre 
volumetric flask and making up to volume with HPLC-grade water. 
Sodi urn hydroxi de pe 11 ets were then added to the ac i d/water mixture, 
with constant stirring on a magnetic stirrer, until the desired pH was 
attained. 
2.4.4 Columns and Column Packing Procedure 
Empty steel columns, 25cm x 3.9mm i . d. were packed with Techsil 5~m 
octadecylsilane (C18) material (HPLC Technology Ltd., Cheshire, 
England) by a high pressure slurry technique using an HPLC column 
packer (HPLC Technology Ltd., Cheshire, England). The following slurry 
solvent 
to pack 
1. 
2. 
3. 
4. 
- di sp 1 acement so 1 vent comb i nat ions, respect i ve ly, were used 
four different columns of the pack ing material: 
methanol 
methanol 
isopropanol 
carbon tetrachloride 
carbon tetrachloride - carbon tetrachloride 
carbon tetrachloride - methanol 
Packing Procedure 
Remova 1 of old pack i ng contents was fo 11 owed by thorough ri ns i ng of 
the empty steel column with methanol, after which the tubing was 
dried. The column end-fittings and frits were sonicated in nitric 
acid and rinsed with methanol. For every column packed, three grams 
of packing material was slurried in 30ml of slurry solvent and then 
sonicated for one minute. The slurry was transferred without delay 
into the column packing reservoir and slurry solvent added to fill the 
reservoi r . The pack i ng process was then started. One hundred and 
twenty millilitres of degassed and filtered displacement solvent was 
allowed to pump through the column before the assembly was inverted, 
without interruption of flow, and a further 120ml pumped through the 
co 1 umn . The pump was then depressuri sed and, after a ha If hour 
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stabilization period, the column was disconnected. Any residual 
material at the top of the column was carefully removed before placing 
the frit and end fitting onto the column. Finally, the packed column 
was washed with 30ml of methanol, followed by 50ml of acetonitrile-
water (75/25), and then tested, as described below. 
2.4.5. Column Performance Testing 
The following chromatographic conditions were employed: 
HPLC system 
UV detection wavelength 
Sensitivity 
see Section 2.3.2 
254nm 
0.04 AUFS 
back-off (coarse) 5 
recorder input 10mV 
Charts peed 1cm/min 
Temperature ambient 
Mobile phase acetonitrile-water (75/25) 
Flow rate 1.0ml/min 
Aliquots of 5pl of a 1 in 50 dilution of standard C18 column test 
mixture (section 2.4.1) were injected into the HPLC system. The 
number of theoretical plates for each column was calculated (Equation 
2.2). Column performance was measured again at the end of the column 
1 ife and factors which contributed to any drop in efficiency were 
noted. The effectiveness of repairing a top-end column void by the 
app 1 i cat ion of a paste of Techs i 1 5pm C18 materi ali n methano 1 was 
examined. 
2.4. 6 Mephenoxalone Solubility Study 
The solubility of mephenoxalone in each of the solvents listed below 
was determined by the progressive addition of solvent to 25.0mg 
samp les of the drug. After each so 1 vent add it i on, the samp le was 
sonicated for one minute and dissolution was ascertained as being 
complete when particulate matter was no longer visible. 
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The following solvents were tested: 
Wate r , acetonitrile, methanol, chloroform, methylene chloride 
(d i ch 1 oromethane), ethyl acetate, d i ethyl ether, heptane, benzene, 
carbon tetrach 1 or i de, i sopropano 1, amyl a lcoho 1, hydroch lori c ac i d 
(O.lN), sodium hydroxide (O.l N). 
2. 4.7 Mephenoxalone Ultraviolet Spectrum 
The UV spectrum of mephenoxa lone was determined using a 
spectrophotometer (Model Acta MVI, Beckman Instruments, 
scanning 
Inc., San 
Ramon, California). A 10~g/ml solution of the drug in acetonitrile 
was transferred to a standard 1cm path length cuvette while pure 
solvent was placed in the reference cuvette. A plot of absorbance 
versus wave length was automatically generated under the following 
conditions: 
Sensitivity 
Scan speed 
Upper wavelength 
Lower wavelength 
Mode selector 
Slit program selector 
1 
1/4nm/second 
310nm 
200nm 
DB Servo slit position 
Program mode 
An ultraviolet spectrum of mephenoxalone in methanol was determined by 
the same procedure. 
2.4.8 Detectors 
2.4.8.1 Ultraviolet Detector 
Aliquots of 10pl of a l.Spg/ml solution of mephenoxalone in mob i le 
phase were injected into the liquid chromatographic system under the 
conditions previously described (Section 2.4.2). Samples were then re-
injected using detector wavelengths of 221nm and 276nm. The limit of 
detection for the drug at 200nm was ascerta ined by injecting 10pl 
samples of serially diluted mephenoxalone solutions until a signal-to-
noise (S/N) ratio of 3:1 was obtained. 
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2.4 .8.2 Photo-conductivity Detector 
The use of a photo-conduct i v ity detector (Mode 1 965, Tracor, Inc., 
Austin, Texas) was also investigated . The following detector 
operating conditions were utilized: 
Mode 
UV Source 
Sensitivity range 
Output attenuation 
Opr Fltr 
Zinc lamp 
1 
10 
On-column loads of 1.0~g of mephenoxalone in 10pl of acetonitrile were 
injected into the chromatographic system using a mobile phase of 
acetonitrile-water at a flow rate of 1.Oml/min. The composition of the 
mobile phase was varied from a 40/60 to a 30/70 ratio of 
organic/aqueous components. Using a 30/70 mobile phase, the flow rate 
was then reduced to 0.8ml/min in an attempt to enhance sensitivity by 
increasing the residence period of the sample in the UV reaction 
system. 
2.4.9 Mobile Phase Development 
The studies performed in this section pertain to optimization of the 
mobile phase composition with respect to ultraviolet detection. 
Preliminary studies were performed with a methanol-water (30/70) 
mobi le phase. The organic component was then substituted with 
acetonitrile, and numerous mobile phases, differing only in 
organic/aqueous ratios, were tested for their ability to resolve 
mephenoxalone from the two internal standards, methocarbamol and 
phenacetin. The effect of varying the flow rate, between 0.4ml/min and 
1. 2ml /mi n, on the retent i on characteri st ics and capac i ty factors of 
these compounds was investigated. 
The effect of added buffer, buffer strength and pH on the e 1 ut ion 
patterns of these compounds was a 1 so exami ned. A mobile phase of 
35/65 acetonitrile-phosphate buffer (0.005 - D.lmoles/litrej pH 2 - 7) 
at a flow rate of 1.Oml/min was used for this purpose. 
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2.4.10 Internal Standards 
The following drug standards were tested as possible candidates for 
use as an internal standard : phenacetin, methocarbamol, meprobamate, 
phenyto in, hexoprena 1 i ne hydroch 1 ori de, caffei ne and phenobarb i tone . 
Stock solutions containing Img/ml in appropriate solvents were freshly 
prepared and then diluted 1 in 20. Ten microlitre aliquots were then 
injected into the HPLC system under the conditions previously 
described (Section 2.4.2). 
2.5 RESULTS AND DISCUSSION 
2.5.1 Column 
2. 5.1.1 Column Performance and Stability 
The number of theoret i ca 1 plates for each packed co 1 umn, ca 1 cu 1 ated 
from Equation 2.2 using the third eluting peak (benzophenone) of the 
standard test mixture, is shown in Table 2. 1. The plate number at the 
end of the column 1 ife is also shown. The end of column 1 ife was 
ascertained as being the point at which a loss of resolution occurred 
between mephenoxalone and internal standard (phenacetin) as a result 
of the overlap of peaks or pronounced peak tailing . 
TABLE 2.1 Efficiencies of packed 5~m C18 columns 
SLURRY SOLVENT PACKING SOLVENT INITIAL PLATE PLATE NUMBER AT 
NUMBER <a) END OF COLUMN 
LIFE 
Methanol Isopropanol 1000 700 
Methanol Carbon tetrachloride 2000 1000 
Carbon tetrachloride Carbon tetrachloride >6000 1000 
Carbon tetrachloride Methanol >6000 1000 
<a) 25cm column 
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When carbon tetrachloride was employed as the slurry solvent with 
either methanol or carbon tetrachloride as the displacement solvent, 
superior columns (in terms of efficiency) were produced by comparison 
to co 1 umns packed wi th the a lternat ive so 1 vent combi nat ions (Sect i on 
2 . 4.4). Carbon tetrachloride appeared to completely wet the packing 
materials whereas the other slurry solvents did not. It has been 
reported that the addition of small amounts of methanol to a carbon 
tetrachloride slurry of 5~m C8 packings produces columns with higher 
plate counts than those slurried in carbon tetrachloride alone (5) but 
this effect was not investigated in this study. 
A dramatic reduction in the performance of the column packed using a 
methano 1 slurry so 1 vent and an i sopropano 1 pack ing so 1 vent occurred 
over a period of one month of continuous use. The short column life 
may have been the result of poor wetting properties of the slurry 
so 1 vent but it was more 1 ike ly the resu lt of frequent changes in 
mobile phase composition during the method development stages or the 
high operating pressures (3000 to 3500 psi) of the column. The 
chromatograms produced at the end of the column life showed pronounced 
peak ta i 1 i ng and loss of reso lut i on between mephenoxa lone and the 
internal standard, phenacetin, as depicted in Fig.2.2(a). The top of 
the column was opened and a void was observed. An attempt was made to 
rejuvenate column performance by filling the void with a methanolic 
paste of 5~m C18 packing material but this did not produce any 
improvement in peak shapes or resolution between the two compounds 
(Fig.2.2(b)). 
The co 1 umn packed with methano 1 as the slurry so 1 vent and carbon 
tetrachloride as the displacement solvent also had a very short life . 
This column was employed for the initial stages of the development of 
an extract i on method to i so 1 ate mephenoxa lone from serum and ur i ne 
samples. A guard column was not, however, used prior to the main 
column and contaminants from the injected samples thus built up at the 
top of the column, causing excessive back-pressure. Cleaning the 
column frits by sonication in nitric acid and rinsing with methanol 
reduced the pressure on the column but a void had already formed at 
the top of the co 1 umn . As before, no improvement in reso 1 ut i on 
between mephenoxalone and phenacetin was obtained by application of a 
FIGURE 2.2 
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paste of packing material. 
When carbon tetrachloride was employed as both the slurry solvent and 
the packing solvent, a stable column was produced. No loss of 
performance was observed until buffered mobile phases were utilized; 
after using solvents varying over a wide pH range (2.5 to 7.0), a 
thirty percent drop in effiency was observed. The high operating 
pressures (3000 psi) also contributed to a loss of performance over a 
long .period of time . The accidental injection of air in nearly fifty 
samp 1 es caused a th irty percent drop in p late number and eventua lly 
destroyed the column. 
The column packed with carbon tetrachloride as the slurry solvent and 
methanol as the displacement solvent was employed for validation of 
the method developed for measuring mephenoxalone in biological fluids 
and also for analyzing the samples from the first set of clinical 
trials. The gradual build up of pressure, resulting in compaction of 
the column bed, was responsible for reducing column performance. The 
column life, however, exceeded six months, which was regarded as 
reasonable considering the intensity of use . The advantage of using 
methano 1 instead of carbon tetrachloride as the di sp lacement solvent 
is that the former is compatible with the HPLC packing apparatus 
whereas the latter tends to be corrosive due to the formation of HC1. 
2.5.1.2 Choice of Column 
A 10~m C18 column has been previously applied to the determination of 
mephenoxalone (2). However, 5~m pack i ng materi a 1 offers improved 
efficiency compared with 10j.lm materials and a 5~m C18 column was 
therefore adopted for this study. The most suitable packing procedure 
was that using methanol as the packing solvent and carbon 
tetrachloride as the slurry solvent; a high efficiency column with a 
relatively long analytical life was thus produced. 
2. 5.2 . Mephenoxalone Solubility 
The so 1 ub il i ty of mephenoxa lone ina range of so 1 vents is shown in 
Table 2.2. The values obtained for methanol, methylene chloride, 
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diethyl ether and water compare favourably with reported values (2, 
5) . Of the solvents tested, acetonitrile and methylene chloride were 
the best, requiring 30 to 100ml of solvent to dissolve lmg of solute. 
TABLE 2.2 Solubility of mephenoxalone 
SOLVENT 
Acetonitrile 
Methylene chloride 
Methanol 
Chloroform 
Isopropanol 
Amyl alcohol 
Ethyl acetate 
Benzene 
Carbon tetrachloride 
Heptane 
D i ethy 1 ether 
Water 
O.lN hydrochloric acid 
O.lN sodium hydroxide 
MILLILITRES OF SOLVENT REQUIRED SOLUBILITY TERMa 
TO DISSOLVE ONE MILLIGRAM OF 
SOLUTE 
30 to 100 
100 to 1000 
1000 to 10 000 
10 000 and over 
Sparingly soluble 
Slightly soluble 
Very slightly soluble 
Practically insoluble 
or insoluble 
a according to the US? XX 
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2.5.3 Mephenoxalone Ultraviolet Spectrum 
For the purpose of recording an ultraviolet spectrum of mephenoxalone 
over the range 200-310nm, a solvent with a sufficiently low UV cut-off 
wavelength must be used. Acetonitrile, heptane, methanol, isopropanol 
and water have cut-off values below 202nm (44, 45) but only the first 
two have favourable properties as solvents for dissolving 
mephenoxalone at the required concentrations. 
The ultraviolet spectrum of mephenoxalone in acetonitrile and in 
methanol is shown in Fig.2.3. The compound has three absorption 
maxima in the wavelength range examined (190-310nm). The maxima are 
276nm, 220nm and 200nm, the latter being the wavelength of maximum UV 
absorption for the drug. These maxima are in agreement with 
predictions made according to the chemical structure of the compound: 
alkyl and o-alkyl substituted benzene derivatives containing not more 
than three substituents exhibit characteristic UV absorption maxima at 
226 ~ 6nm and 273 ~ 7nm in aqueous acid (52). Mephenoxalone, as an 0-
alkyl substituted benzene derivative, was therefore expected to 
display these maxima. 
2.5.4 Detectors 
2.5.4.1 Ultraviolet Detection 
The LC detector response at wavelengths correspond i ng to the three 
absorption maxima of mephenoxalone are shown in Fig.2.4 . The 
chromatograms were generated under i dent i ca 1 cond it ions, except for 
the change in wavelength. The greatest sensitivity, in terms of 
detector response, was obtained at 200nm. The noise level is lower at 
the longer wavelengths (220nm, 276nm) but the sensitivity is poor. The 
limit of detection at 200nm was a 2ng on-column load of mephenoxalone 
(Fig . 2. 5) . The detector response was reproducible and stable to 
ambient temperature fluctuations. 
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Ultraviolet spectrum of mephenoxalone 
in (1) acetonitrile and (2) methanol 
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Chromatograms showing detector response to a 15ng 
on-column load of mephenoxalone1 at detector 
wavelengths of (a) 200nm (b) 220nm and (c) 276nm 
(chromatographic conditions as in Section 2.4.2) 
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Chromatogram showing the 
mephenoxa lone at 200nm 
chromatographic conditions as 
limit of detection 
(on-column load = 
in Section 2.4.8.1) 
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2.5.4.2 Photo-conductivity Detection 
for 
2ng: 
Mephenoxalone appears to undergo weak ionization under the conditions 
employed (Section 2.4.8.2). A mobile phase of acetonitrile-water 
30/70 at 1. 0ml/min resolved mephenoxalone and the large solvent peaks, 
and a mi n imum detectab le 1 imi t of SOOng was obta i ned herewi th. The 
chromatograms generated using flow rates of 0.8ml/min and 1.0ml/min 
are depicted in Fig.2.6 . Theoretically, the longer the time a 
compound is exposed to UV light in the reaction system of the 
FIGURE 2.6 
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Chromatograms showing photo-conductivity detection 
of mephenoxalone1 at (a) O.8ml/min (b) l.Oml/min 
(on-column load = 1 fig; chromatographic conditions 
as in Section 2.4.8 . 2) 
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detector, the more sample ionization is obtained. The results of this 
study however, show that there was no significant increase in the 
sensitivity of the analysis at the lower flow rate (0 .8ml/min), 
although the short-term baseline noise and drift were less than at the 
higher flow rate (l.Oml/min). 
2.5 .4.3 Choice of Detector 
A sensitive mode of detection is required for the determination of 
mephenoxalone in biological fluids. Photo-conductivity detection 
lacked the required sensitivity. Ultraviolet detection, on the other 
provided an adequate detection sensitivity for monitoring realistic 
drug concentrations. In addition, UV detection was a more convenient 
and a more reproducible means of monitoring the LC column effluent and 
was, therefore, adopted for all further studies. 
2.5.5 Choice of Mobile Phase 
The choice of mobile phase is governed by the need for adequate 
retention of mephenoxalone on the column, resolution from the internal 
standard, good peak shape, and a reasonable analysis time and 
operating pressure. If the method is to be applied to biological 
fluids, a retention time of at least 4 minutes is necessary to allow 
for the prior clearance of endogenous compounds from the column. The 
use of ultraviolet detection at 200nm limits the choice of mobile 
phase constituents to those with UV cut-off values below 200nm (44). 
Methanol, despite having a UV cut-off at 205nm, can be used in small 
amounts. Acetonitrile (UV cut-off at 200nm) has supplanted methanol 
as the most widely used reverse-phase organic modifier because of its 
numerous favourable properties, as discussed earlier. 
A methanol-water (30/70) mobile phase has been previously employed for 
the HPLC analysis of mephenoxalone (2). This mixture, however, has a 
high viscosity (40) and the maximum flow rate which can be used is 
limited by the back-pressure generated. A maximum flow rate of 
1.Oml/min at an operating pressure of 4000psi could be used in this 
1 abora tory. However, under these cond i t ions mephenoxa lone was 
retained on the column for more than 14 minutes and a peak with poor 
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symmetry and shape was obtained in the chromatogram. Substitution of 
methanol with acetonitrile, in the same proportion (30/70) and at the 
same flow rate (1.0ml/min), provided greatly improved results but the 
co 1 umn pressure (3600ps i) was st ill cons i dered to be excess i ve for 
routine analysis. Since mobile phase viscosity 
proportion of acetonitrile is increased (40), 
(35/65) solvent mixture, flowing at 1.0ml/min, was 
is reduced as the 
an organic-aqueous 
tested. Using this 
mobile phase, a good compromise was achieved between analysis time, 
resolution from internal standards, and column pressure. Under these 
cond it ions, the retent i on times of mephenoxa lone and the i nterna 1 
standards, methocarbamol and phenacetin, were 5.2, 4.0 and 6.5 
minutes, respectively, as shown in Fig.2.7. It is well known that the 
efficiency of a column is optimum at a particular flow rate (40). For 
a 5~m C18 column, this maximum value lies closest to 1.0ml/min. 
An investigation of the effect of adding buffers to the mobile phase 
on the retention characteristics of mephenoxalone, phenacetin and 
methocarbamo 1 revea 1 ed that the capac ity factors of these compounds 
did not change with variations in either pH (2 - 7) or phosphoric acid 
molarity (0.005 - 0.1 moles/litre). This indicates these drug 
molecules do not possess any significantly ionizable functional 
groups. 
2.5.6 Choice of Internal Standard 
Of a 11 the compounds tested, on ly methocarbamo 1 and phenacet in were 
suitable candidates for use as internal standards in the analysis of 
mephenoxalone. Both substances are structurally similar to the 
compound of interest (Fig.2.8), both have comparable extraction ratios 
to that of mephenoxa lone and both are readily detectable at 200nm. 
Using the HPLC conditions described in Section 2.4.2, these compounds 
were resolved from the analyte substance, as shown in Fig.2.7. 
Methocarbamol eluted prior to mephenoxalone and co-eluted with a 
mephenoxalone metabolite present in extracted biological fluids. This 
internal standard is, therefore, suitable only for aqueous studies. 
In addition to the fact that phenacetin has a greater retention time 
than mephenoxalone, it is no longer used clinically and it is, 
FIGURE 2.7 
36 
Chromatogram showing elution profile of methocarbamol 1, 
mephenoxa lone2, and phenacet i n3, us i ng a mobile phase of 
acetonitrile-water (35/65) at 1.Oml/min (chromatographic 
conditions as in Section 2.4.2; injection volume lO~l) 
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therefore, the i nterna 1 standard of choi ce for the determi nat ion of 
mephenoxalone in serum and urine. 
FIGURE 2.8 Structures of (1) phenacetin and (2) methocarbamol 
(1) (2) 
2. 6 CONCLUSIONS 
An HPLC method using a Techsil 5~m C18 stationary phase and an 
acetonitrile-water (35/65) mobile phase was suitable for the analysis 
of mephenoxalone in aqueous samples and in biological fluids. A 
column packed using a slurry solvent of carbon tetrachloride and a 
displacement solvent of methanol provided excellent effienciency, 
stabi 1 ity and column 1 ife. The column was operated at ambient 
temperature and at an optimum flow rate of l.Oml/min. Methocarbamol 
was a suitable internal standard for aqueous studies while phenacetin 
proved to be the compound of choi ce for the ana lys i s of b i 0 1 og i ca 1 
fluids. Ultraviolet detection at 200nm provided adequate sensitivity 
for the determination of mephenoxalone in serum and urine following 
oral administration of the drug. The use of a photo-conductivity 
detector for measuring mephenoxalone was excluded from further 
investigation because of its low sensitivity. 
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CHAPTER THREE 
DETERMINATION OF MEPHENOXALONE IN BIOLOGICAL FLUIDS 
~ INTRODUCTION 
The quantitative measurement of drugs in biological fluids can rarely 
be applied directly to the sample matrices and purification procedures 
prior to chromatographic analysis are generally required (48). 
Sample preparation techniques and strategies for selecting an 
appropriate procedure for selectively isolating the compound of 
interest from biological fluids have been extensively reviewed (48,53-
57) . The most commonly employed extraction techniques are solvent 
extraction (liquid-solid or liquid-liquid) and separation with a solid 
additive or column packing material. The method employed will depend 
not only on the physico-chemical properties of the drug but also on 
the type of biological fluid being analyzed and the sensitivity 
requirements of the analysis. Biological factors such as protein-
binding properties of the drug are also important since the drug may 
have to be freed from protein prior to extraction. 
Two methods for isolating mephenoxalone from biological fluids, both 
liquid extraction procedures, have been reported (6,28). Eckhardt 
et aT. (28) isolated the parent compound and several biotransformation 
products from human ur i ne us i ng ch loroform as the organic so 1 vent. 
The parent drug was extracted directly from urine while the 
unconjugated metabolites were extracted under acidic as well as basic 
cond it ions . Conjugated deri vat i ves were subjected to aci d/enzyme 
hydrolysis prior to extraction under acidic/basic conditions. The 
compounds were identified by TLC but no quantitative ana lyses were 
performed. 
Morrison (6) isolated mephenoxalone from biological samples of 
laboratory animals using chloroform as the organic solvent. The 
addition of an equal volume of sodium hydroxide (IN) to plasma or 
urine (1-3ml) was followed by extraction with 10ml ethylene 
dichloride. Samples were centrifuged and the upper phase was removed 
by aspiration and discarded. The concentration of mephenoxalone in 
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the organic phase was then determined by spectrophotofluorimetry. 
The extraction efficiency for spiked samples was 85 to 100 percent for 
plasma and 90 to 100 percent for urine. The metabol ites were not 
extracted and therefore not measured under these conditions. 
In this study. a liquid-liquid extraction procedure was employed for 
the analysis of mephenoxalone in human serum and urine. The 
biological samples were assayed for unchanged drug by HPLC using UV 
detection at 200nm. HPLC involves a separation process and therefore 
lends itself to simplified techniques for sample preparation prior to 
analysis. 
A protein-precipation step will often suffice provided that adequate 
detection sensitivity can be obtained. However when UV detection of 
200nm is used it is essent i a 1 that more ri gorous samp 1 e preparat i on 
procedures be employed in order to improve the condition of the 
sample. The exclusion from the sample of endogenous components of 
the biological matrix not only provides the required selectivity but 
a 1 so affords protect ion of equ ipment from damage and deteriorat i on . 
The use of a guard column before the main column is advocated for all 
biological fluid analyses to prolong the life of the analytical column 
(53) • 
A systematic approach to the development of a method for isolating 
mephenoxalone from human serum and urine is presented. 
3.2 MATERIALS AND APPARATUS 
3.2.1. Materials 
As in Section 2.3.1 
3.2.2 Source of Biological Samples 
Drug-free human serum was obtained from the local blood transfusion 
centre and stored frozen at -200C until required. 
thawed at room temperature before use. 
The serum was 
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Drug-free urine was freshly collected from a human volunteer on the 
day of the analysis. 
3.2.3 HPLC System 
The HPLC system used in this study has been previously described 
(Section 2.3 .2). A 10~m C18 guard column (HPLC Technology Ltd . , 
Chesire, England) was used before the main column. 
3.2 .4 Additional Equipment 
As in Section 2.3.3. 
3.3 DETERMINATION OF ~ OF MEPHENOXALONE 
The dissociation constant of a drug is an important parameter in 
pharmacokinetic investigations . Once the pKa is known, the degree of 
dissociation of a compound at physiological pH can be easily 
determined (58) and, since only unionized molecules generally pass 
through biological membranes, predictions concerning the access of a 
drug to tissue sites can be made. 
The advantage of knowing the pKa value prior 
method for extracting a drug from biological 
to the development of a 
fluids is obvious. In 
liquid-liquid extraction, partitioning of a compound into the organic 
phase is maximum when the drug is in its unionized form. The pH of 
the aqueous phase can therefore be manipulated to provide maximum drug 
recovery . 
The accurate determination of the aqueous dissociation constant of an 
organ i c compound is rout i ne ly performed us i ng potent iometri c or UV 
spectrophotometric methods (59,60) . These methods are not , however, 
applicable to the determination of pKa values of drugs, such as 
mephenoxalone, which are insuffic i ently soluble in aqueous media . 
A lternative methods can be used in such cases (61-68) . The recent 
method of Hasegawa et al. (68) was used for this study. 
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3. 3. 1 Experimental 
3.3.1.1 Sample Preparation 
Aqueous buffer solutions (0.1 moles/litre, pH 3 and ph 5) containing 
mephenoxalone (0.06mg/ml) were prepared by dissolving 6mg quantities 
of mephenoxa lone in phosphate buffer (see be 1 ow) and mak i ng up to 
volume with buffer in 100ml volumetric flasks. The pH values were 
accurately adjusted using sodium hydroxide pellets with constant 
stirring on a magnetic stirrer, to produce two solutions of pH 3.00 ~ 
0.01 and pH 5.00 ~ 0.01 respectively. 
Phosphate buffer (0 . 1 moles/litre) was prepared by the addition of 
3. 35ml phosphoric acid to a 500ml volumetric flask and making up to 
volume with HPLC-grade water. 
An internal standard stock solution was prepared as in Section 
3.4 . 1.1. Appropriate dilutions of this solution were made with 
acetonitrile to provide the required concentration. 
3.3.1.2 Determination of ~ 
The partitioning of mephenoxalone between an aqueous and a water-
immiscible organic solvent was investigated at two different aqueous 
phase pH values (3 . 00, 5.00) . The organic solvents used in this 
study were methylene chloride and diethyl ether. Each sample was 
assayed in triplicate as follows. 
Fi ve mi 11 il itres of aqueous buffer so 1 ut ion conta i n i ng mephenoxa lone 
(see Section 3.3 . 1) and 5.0ml organic solvent were added to a screw-
capped 15ml Kimax tube (Kimble Products, New Jersey, USA) and gently 
agitated on a mechanical reciprocating shaker fo r 3 hours . The tube 
was then centrifuged at 3000rpm for 5 mi nutes. Ali quots of 1. Oml 
each of the organic and aqueous phases were transferred to clean test 
tubes, to which 200~1 of internal standard solution (0.3mg/ -ml 
phenacet i n in aceton itr i 1 e) had been added. Ten mi cro 1 itres of the 
aqueous sample mixture was injected into the HPLC system under the 
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conditions described in Section 2.4.2. The organic sample mixture 
was evaporated to dryness under a gentle stream of nitrogen at 370C 
and the residue was reconstituted in 102ml HPLC-grade water. A 10~1 
al iquot was injected onto the column under the same conditions as 
above. 
3.3.2 Results and Discussion 
Table 3.1 shows the results obtained in this study . The pKa of 
mephenoxalone was found to be approximately 4.6 using either methylene 
chloride or diethyl ether as the organic phase. This value may not 
be representative of the true pKa value since there are many potential 
sources of error in the method employed: 
(1) Methylene chloride and diethyl ether are partially miscible with 
the aqueous phase and, since the determination of pKa depends 
on the accurate measurement of drug concentrations in both the 
aqueous and organic phase, if there is phase miscibility, a 
dev i at ion from the true resu lt wi 11 be obta i ned . The use of 
paraffinic hydrocarbons have been advocated to minimize such an 
error (68). 
(2) Hasegawa et al. (68) have demonstrated that both the drug 
concentration and the buffer concentration may alter the pKa 
va 1 ue; the lowest poss i b 1 e concentrat ions have been advocated 
as opt ima 1. 
this study . 
However, these variables were not investigated in 
(3) To interpret the absorption and disposition of a drug in terms 
of pKa, the determi nat i on shou ld be performed at 370C (68). 
This study was however conducted at room temperature. 
The low pKa values obtained in this investigation are in agreement 
with values that can be expected for mephenoxalone since the drug 
molecule contains a very weakly basic carbamate moiety. However, the 
results were not conclusive and a more extensive investigation of the 
variables that may affect the pKa of mephenoxalone would be necessary 
for the determination of the true value. 
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TABLE ~ pKa Values of mephenoxalone as determined by the partition 
method 
ORGANIC AQUEOUS Pappa (SO) Pmb pKa b 
PHASE PHASE 
pH 
METHYLENE 3. 00 8. 19 (0.34) 
356.60 4.63 
CHLORIDE 5.00 6. 10 (0 . 31) 
-
OIETHYL 3.00 0.85 (0.08) 
39.68 4.66 
ETHER 5.00 0.72 (0.08) 
a determined at ambient temperature 
b calculated by the solution of simultaneous equations as described 
by Hasegawa et al (68). 
3.4 SAMPLE EXTRACTION PROCEDURE 
Data relating to concentrations of mephenoxalone in biological fluids 
of humans after therapeutic doses of the drug have not been published 
in the literature. The sensitivity requirements of the assay were 
therefore not known. Since drugs and their metabo lites are usually 
present in serum and urine in low concentrations (55), the extraction 
method was directed towards providing maximum sensitivity. 
3.4.1 Experimental 
3.4 .1.1 Sample Preparation 
Mephenoxalone stock solution was pre pared as follows : Fifty 
milligrams of mephenoxalone were dissolved in 25.0ml acetonitrile and 
10.0ml of this solution was transferred to a 20ml volumetric flask and 
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made up to volume with HPLC-grade water to produce a 1mg/ml solution. 
Appropriate dilutions of this solution were made with water to provide 
the required concentrations. 
Internal standard stock solution was prepared by dissolving 25mg 
phenacetin in 25 . 0ml acetonitrile to produce a 1mg/ml solution. A 
50~g/m l solution was prepared by diluting 2.5ml of stock solution to 
50.0ml with HPLC-grade water. This solution was used for the 
determi nat i on of mephenoxa lone concentrat ions between 1. 0 and 
15.0ug/ml. For the ana lys i s of concentrat ions between 0.1 and 
1.0Ilg/ml, an internal standard solution containing 5~g/ml phenacetin 
was used. This was prepared by making a 1 in 10 dilution of the 
50llg/ml solution with water. 
Spiked serum and urine samples were prepared by the addition of 
appropriate amounts of a standard solution of mephenoxalone to drug-
free biological fluid. Serum samples were sp iked with mephenoxalone 
in the concentration range 0.1 to 15~g/ml. Urine samples were spiked 
with mephenoxalone in the concentration range 1 to 10~g/ml. 
3.4 . 1.2 Chromatographic Conditions 
The HPLC condit ions emp 1 oyed throughout th i s study are descri bed in 
Section 2.4.2 . 
3.4.1.3 Development of ~ Extraction Procedure 
A preliminary investigation was conducted to examine the partitioning 
of mephenoxalone between 1.0ml water and 5.0ml aliquots of several 
common laboratory solvents. Thorough mixing of the biphasic solvent 
system, to which 5.0ug mephenoxalone had been added, was followed by 
centrifugation for 10 minutes at 3000rpm. The organic fraction was 
transferred to a clean col lection tube and evaporated to dryness under 
a gent le stream of nitrogen at 370C . The res i due was reconst ituted 
in a minimum volume of 200~1 mobile phase and 10~1 aliquots were 
injected into the liquid chromatograph. Ten microlitre aliquots of 
mephenoxa lone standard so 1 ut ion (0. 25ug/ml) were injected onto the 
column to provide a means of assessing the maximum recovery possible. 
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A selected range of organic solvents into which mephenoxalone 
exhibited favourable partitioning were then tested for their 
applicability to serum and uri ne extract ions. These so 1 vents 
included methylene chlor ide , chloroform, 1,2-dichloroethane, ethyl 
acetate and diethyl ether. Spiked serum samples (1.0ml) containing 
5j.Jg/m 1 mephenoxa lone were extracted, as previ ous ly descr i bed, with 
5.0ml aliquots of the organic solvents. The quality of each extract, 
in terms of extraction efficiency and cleanliness, was examined. A 
su itab 1 e organi c so 1 vent was thus se 1 ected for the determinat ion of 
mephenoxalone in serum, after which an investigation of the 
partitioning of phenacetin, the internal standard, into the chosen 
solvent was conducted . The conditions for the extraction procedure 
were then optimized by examining the effects of changes in the volume 
ratio (serum:solvent), different mixing times, pH of the extracted 
sample, and reconstitution techniques. 
The extraction procedure developed for the analysis in serum had to be 
modified for the determination of mephenoxalone in urine. The use of 
mixed solvents for extracting the drug was examined. 
The extraction procedure developed for the analysis in serum had to be 
modified for the determination of mephenoxalone in urine. The use of 
mixed solvents for extracting the drug was examined. 
3.4.2 Results and Discussion 
3.4.2.1 Extraction of Aqueous Samples 
A range of solvents for the preliminary partitioning investigation was 
selected on the basis of previous solvents that had been applied to 
the determination of mephenoxalone in biological fluids as well as 
other common laboratory solvents . However, only a few of the 
so 1 vents tested had favourab le mephenoxa lone part i t i on i ng propert ies 
in the aqueous study. These comprised methylene chloride, 1,2-
dichloroethane, chloroform, ethyl acetate and amyl alcohol. More that 
70 percent of the amount of mephenoxalone added to the aqueous 
fraction was recovered in the organic fraction using these solvents. 
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The need to maximize the sensitivity of the method by concentrating 
the extracted organic fraction to a small end-volume meant that the 
non-volatile solvent, amyl alcohol, had to be excluded as a possible 
solvent. Chromatograms obtained from ethyl acetate extractions showed 
the presence of numerous contaminants, the source of wh ich was 
ascertained to be the solvent itself; the evaporation to dryness of 
pure solvent followed by reconstitution and injection onto the column 
produced the chromatogram shown in Fig.3.1 . The contaminant peaks do 
not, however, co-elute with mephenoxalone and this solvent was 
therefore not precluded as a possible extractant at this stage of the 
method development. The manipulative advantage of using ethyl 
acetate, which in contrast to the other solvents forms the upper phase 
of the aqueous-organic solvent system, is obvious. 
FIGURE 3.1 
5 MINS 
Chromatogram showing contaminaints present in ethyl acetate 
(chromatographic conditions as in Section 2.4.2; injection 
volume 1°111) 
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3.4.2.2. Extraction of Serum Samples 
Preliminary extractions of drug-free serum samples (1.0ml) with ethyl 
acetate, chloroform, methlene chloride and 1,2-dichloroethane produced 
the chromatograms depicted in Fig.3.2. The extraction efficiency for 
mephenoxalone was more than 70 percent using these solvents but 
d i ethyl ether and ethyl acetate extracted numerous endogenous 
components from serum and were therefore excluded from further study . 
1,2-0 i ch 1 oroethane extracted more serum contami nants than did 
chloroform or methylene chloride. 
Difficulties were experienced in penetrating the 'plug' that formed at 
the interface of the serum-chloroform solvent system. Plug formation 
was however reduced when serum proteins were precipitated prior to 
solvent addition. Protein precipitation was performed by the 
addition of 1.0ml acetonitrile to the 1.0ml serum sample, followed by 
centrifugation and transfer of the supernatant to a clean test tube . 
An extra manipulative step had, therefore, to be introduced. 
Another disadvantage of using chloroform was that it randomly formed 
emulsions when mixed with serum. The same effect was observed with 
1,2-dichloroethane. Numerous methods for minimizing gel formation 
are cited in the literature (56,57) but have the disadvantage of 
additional sample manipulation steps. 
Of all the solvents investigated, methylene chloride was the most 
suitable extractant in terms of cleanl iness of the extract, lack of 
gel formation and relative ease of sample manipulation, and it was 
therefore employed for the routine determination of mephenoxalone in 
serum. The internal standard partitioned highly into methylene 
chloride, with approximately 85 percent of the added amount being 
recovered in the solvent. The optimum volume ratio (serum:organic 
solvent) was ascertained by increasing the organic volume until no 
further increase in drug recovery was obta i ned. A compromi se 
between extraction efficiency and sample evaporating time was however 
necessary . The use of an 8. 0ml aliquot of methylene chloride 
provided an extraction effic i ency of 96.8 ~ 3.8 percent whereas 5.0ml 
organic extractions extracted 92.2 ~ 3.4 percent of the amount of 
mephenoxalone originally present in the sample. The time taken to 
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FIGURE 3.2 Chromatograms of drug-free serum extracted with (a) ethyl 
acetate, (b) chloroform, (c) methylene chloride and (d) 
1,2-dichloroethane (chromatographic conditions as in 
Section 2.4.2; 10~1 injection volume). 
( a) (b) 
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evaporate 8.0ml was however almost double that of the 5.0ml samples; 
the small increase in extraction efficiency that it provided did not 
warrant the use of an 8.0ml aliquot as the objective was to develop a 
rapid method whereby large numbers of samples could be routinely 
analyzed. 
No significant increase in drug recovery was observed when spiked 
serum samp 1 es were vortex-mi xed with methy 1 ene ch 1 or i de for longer 
than 15 seconds. Th i s va 1 ue was therefore adopted as the standard 
vortex-mixing time for the analysis. 
An i nves t i gat i on of the effect that samp 1 e pH changes had on 
extract ion efficiency showed that the partitioning of mephenoxalone 
into methylene chloride was unaltered by either acidification or 
basification of the serum samples. In preliminary serum extraction 
studies, a decrease in drug recovery was observed when sodium 
hydroxide (lmole/litre) was added to the samples. This was found to 
be the resu It of drug entrapment in the emu 1 s ions that formed as a 
result of basificiation. When a protein precipitation step was 
included prior to solvent extraction, emulsification was no longer 
observed. The fact that samp le pH does not affect the extract i on 
efficiency may be of value in analyses which require co-extraction of 
other compounds of interest present in biological samples. 
It was found that methylene chloride extracts which have been 
evaporated to dryness could be reconstituted in either water, mobile 
phase, acetonitrile or methanol without affecting drug recovery. It 
was initially thought that the insolubility of mephenoxalone in water 
might preclude this solvent as a possible candidate for reconstituting 
the dried extracts. However, at the concentrations employed in the 
study the compound was within the limits of its solubility in water 
and it was therefore employed for all further reconstitutions. 
3.4.2.3 Extraction of Urine Samples 
Extraction of urine with methylene chloride was found to yield a high 
mephenoxa lone extract i on eff i c i ency but the chromatograms conta i ned 
numerous contami nant peaks which interfered with the analysis 
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(Fig.3.3(b)). A typical chromatogram of a blank urine extract is 
shown in Fig.3.3(a). In addition the reconstituted extract was yellow 
in colour, possibly due to extraction by methylene chloride of various 
urine pigments. The use of a more non-polar extraction solvent, 
comprising a mixture of cyclohexane and methylene chloride (3:2 
vol/vol), was found to dramatically improve the condition of the 
extract in terms of background interference. A typical chromatogram 
of a blank extract is shown in Fig.3.4. Using a 3:2 
(cyclohexane:methylene chloride) volume ratio, a useful lowering of 
density was achieved and the organic mixture comprised the upper 
phase of the biphasic system. The manipulative advantage of such a 
system is obvious. 
The internal standard was well extracted using the solvent and the 
extraction efficiency for mephenoxalone was approximately 80 percent, 
wh i ch was adequate foY.' the determinat ion of mephenoxa lone in uri ne 
after oral administration of the compound. 
3.4.2.4 Choice of Extraction Method for Serum and Urine 
Liquid-liquid extraction is generally easy to perform, rapid and 
relatively economical. It is the ideal method if a single extraction 
provides a good recovery in terms of the amount and condition of the 
desired compound (56) . The suitability and requirements of solvents 
employed in this technique have been reported in the literature 
(54,56). The final solvent choice depends not only on the recovery 
it affords but also on its purity, toxicity and cost. It is well-
known that the least polar solvent that affords a reasonable drug 
recovery should be employed because it extracts minimal interfering 
sample components (48). 
Liquid-liquid extraction processes are not without difficulties. 
Emulsion formation and adsorption of analyte molecules onto glassware 
comprise the most commonly encountered problems, both of wh ich can be 
relatively easily minimized or avoided altogether (54,56) . 
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FIGURE 3.3 Chromatograms of (a) an extract of drug-free urine and (b) 
an extract of urine containing 5.0pg/ml mephenoxal one l 
using 5.0 ml methylene chloride as the extraction solvent 
(chromatographic conditions as in Section 2.4.2; 10pl 
injection volume). 
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FIGURE 3.4 Chromatogram of an extract of drug-free urine using 5.0ml 
cyclohexane-methylene chloride (3:2) as the extraction 
solvent (chromatographic conditions as in Section 2.4.2; 
10~1 injection volume). 
5 MINS 
The liquid-liquid extraction methods reported in the literature 
employed chloroform and ethylene dichloride as the organic solvents 
(6,28) . In th is study, ne i ther of these so 1 vents were found to be 
suitable for mephenoxalone analysis in serum although chloroform could 
be used if steps were taken to prevent random emulsification of 
samples; the use of acetonitrile to precipitate the serum proteins 
was demonstrated to be effective. The use of 1,2-dichloroethane did 
not provide sufficiently clear extracts for HPLC analysis at 200nm. 
Methlene chloride was the solvent of choice for serum analysis for the 
following reasons: 
(1) No emulsion formation was observed; 
(2) The aqueous and organic layers were easily separated; 
(3) A high extraction efficiency was obtained and the extract was 
sufficiently clean; 
(4) The extraction was performed in a simple, rapid one-step process; 
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(5) The procedure was sufficiently sensitive for the routine 
determination of mephenoxa lone in human serum and urine after 
oral dosing. 
The above method was not however applicable to urine analyses because 
methyl ene ch 1 ori de extracted numerous endogenous samp le components. 
The use of a mixture of cyclohexane and methylene chloride (3:2) 
provided a sufficiently non-polar solvent to prevent the extraction of 
contaminants without significantly affecting the extraction 
efficiency, and this was therefore the solvent of choice for the 
routine estimation of large numbers of urine samples. 
3.S ANALYSIS OF MEPHENOXALONE IN SERUM 
3.S.1 Experimental 
3.S.1.1 Sample Preparation 
Mephenoxa lone stock so 1 ut i on (lmg/ml) was prepared as descri bed in 
Section 3.4.1.1. 
Internal standard solutions (S~g/ml and SOpg/ml) were prepared as 
described in Section 3.4.1.1. 
A serum stock solution containing mephenoxalone was prepared as 
follows: 
One millilitre of mephenoxalone stock solution (1mg/ml) was added to 
drug-free serum in a SO.Oml volumetric flask. After thorough mixing 
for 1 hour on a reciprocating mechanical shaker, appropriate dilutions 
of this solution were then made (Section 3. S.1.4), each diluted 
solution being mixed as before. 
3.S.1.2 Chromatographic Conditions 
As in Section 2.4.2. 
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3.5.1 . 3 Extraction Procedure 
One millilitre of serum was mixed with 200~1 
solution (5!Jg/ml or 50~g/ml, Section 3.4.1.1.) 
internal standard 
in a test tube. 
Addition of 5.0ml methylene chloride was followed by vortex mixing for 
15 seconds and centrifugation for 10 minutes at 3000rpm. The upper 
layer was removed by aspiration and discarded. A pasteur pipette was 
used to transfer the methylene chloride fraction to a clean test tube 
for evaporation to dryness under a gentle stream of nitrogen at 370C. 
The res i due was reconst ituted i n 200~ 1 water and vortexed for 30 
seconds to dissolve. Aliquots of 2 to 10~1 were then injected onto 
the column. 
3.5.1 .4 Calibration Curves 
Two calibration curves were constructed because of the wide range of 
concentrat ions of mephenoxa lone found in serum after ora 1 dos i ng; 
concentrations falling outside of the initial range of quantitation 
(1.0-15.0!Jg/ml) were found and it was thus necessary to re-validate 
the new calibration range (0.1-1.0~g/ml). 
(a) Mephenoxalone serum concentration 1.0 to 15.0ug/ml 
The serum stock solution (20~g/ml) was diluted to yield five different 
concentrations (15.0, 10.0, 5.0, 2.0 and 1.0~g/ml) each of which was 
assayed in triplicate . 
(b) Mephenoxalone serum concentration 0.1 to 1.0ug/ml. The 1.0~g/ml 
mephenoxalone serum solution, prepared as above was diluted to yield 
four different concentrations (0.8, 0.5, 0.2, O.l~g/ml), the 1.0~g/ml 
solution itself providing the fifth concentration. Each 
concentration was assayed in triplicate. 
The calibration curves were constructed by plotting the ratios of peak 
hei ght of mephenoxa lone to that of the i nterna 1 standard versus the 
respective mephenoxalone concentrations. A straight line fit of the 
data was made by least-squares linear regression analysis. 
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3.5.1.5 Precision 
Within-run precision was assessed by extracting six spiked serum 
samp les each at the highest and lowest mephenoxa lone con cent rat ions 
determined in the calibration curves. 
15.0, 1.0 and O.l~g/ml. 
3.5 . 1.6 Extraction Efficiency 
These con cent rat ions were 
The analytical recovery of mephenoxalone from serum was assessed as 
follows: 
Three different concentrations of spiked serum samples were extracted 
as described in Section 3.5.1.3 except that the internal standard was 
incorporated into the 200~1 aliquot used in the final reconstitution 
step and was thus not carried through the extraction procedure. All 
samples were assayed in triplicate. 
Standard so 1 ut ions of mephenoxa lone correspond i ng to those extracted 
above were taken to dryness under a gentle stream of nitrogen at 370C. 
These samples were then reconstituted as for the serum samples, with 
the internal standard being included in the 200~1 aliquot. 
To determi ne the percentage recovery, the rat i os obta i ned from the 
serum extracts were compared to those resu It i ng from the equ iva 1 ent 
concentrations of standard solutions. 
3.5.2 Results and Discussion 
3.5.2.1. Linearity and Calibration Curves 
Linearity was establ ished for both of the ranges of concentrations 
studied (0.1 to 1.0~g/ml and 1.0 to 15.0~g/ml) . Details of the 
linearity data and the calibration curves for mephenoxalone in serum 
are shown in Table 3.2 and Fig.3.5, respectively. 
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Chromatograms of a blank serum extract and a serum extract containing 
mephenoxa lone and i nterna 1 standard are dep i cted in Figs . 3.6 (a) and 
3.6 (b), respectively. The retention time of mephenoxalone was 5.3 
minutes and that of the internal standard (phenacetin), 6.6 minutes. 
3.5.2.2 Precision 
Results of the within-run precision study are depicted in Table 3.3. 
Relative standard deviations (RSD) at the upper and lower limits of 
the concentration range fall within the acceptable limits for drug 
determinations (56). The method, as indicated by the above results, 
was found to be reproducible. 
3.5 . 2.3. Extraction Efficiency 
Table 3.4 shows the analytical recoveries of mephenoxalone from serum. 
Resu lts i nd i cate that the recovery of mephenoxa lone is constant and 
quantitative over the range of concentrations studied. 
3.5.2.4 Sensitivity and Detection Limits 
Under the conditions of this assay and based upon a signal-to-noise 
ratio of 3, the detection limit for mephenoxalone in serum was 
O.04~g/ml. Although it was not necessary to increase the sensitivity 
of the determi nat i on, it cou 1 d be increased by the use of a 1 arger 
injection volume. 
3.6 ANALYSIS OF MEPHENOXALONE IN URINE 
3.6.1 Experimental 
3.6.1.1 Sample Preparation 
Mephenoxa lone stock solution (l~g/ml) was prepared as in Section 
3.4.1.1. 
Internal standard solution (50~g/ml) was prepared as in Section 
3.4.1.1. 
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TABLE 3.2 Linearity data for mephenoxalone in serum 
CON CENTRA TI ON 
RANGE 
(~g/ml ) 
0.1 to 1.0 
1.0 to 15.0 
FIGURE 3.5 
SLOPE Y-INTERCEPT CORRELATION 
COEFFICIENT 
1. 7135 0.0571 0.9999 
0.1612 0.06281 0.9993 
Calibration curves for mephenoxalone in serum 
(a) 0.1 to 1 .0~g/ml (b) 1.0 to 15.0~g/ml 
(a) (b) 
Sensitivity 
Injection volume 
0.02 AUFS, 
recorder input 10 mV 
10~1 
Sensitivity 
Injection volume 
0.16 AUFS, 
recorder input 10mV 
2 - 10~1 
3 
\.5 
2 
\.0 
0.5 
O.O+------r----~-----,------r_--__, o+-----~----r_----._----._----r__ 
0.0 0.2 0.4 0.6 0.8 1 .0 0 3: 6 9 12 \5 
CONCENTRATION (MG/L) CONCENTRAT I ON (MG/Ll 
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FIGURE 3.6 Chromatograms of (a) an extract of drug-free serum and (b) 
an extract of serum containing 5.0~g/ml mephenoxa lone1 
and 5.0~g/ml phenacetin2 (chromatographic conditions as 
in Section 2.4.2; lO~l injection volume). 
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Urine stock solution containing mephenoxalone (10~g/ml) was prepared 
as follows: 
Five hundred microlitres of mephenoxalone stock solution (l~g/ml) was 
added to drug-free urine in a 50.0ml volumetric flask . Appropriate 
dilutions were then made. 
3.6.1.2 Chromatographic Conditions 
These were identical to those in Section 3.5.1.2. 
0.16 AUFS was employed. 
An attenuation of 
3.6.1.3 Extraction Procedure 
One millilitre of urine was mixed with 200~1 internal standard 
solution in a test-tube. Addition of 5.0ml cyclohexane-methylene 
chloride (3/2 vol/vol) was followed by vortex-mixing for 15 seconds 
and centrifugation for 10 minutes at 3000rpm. A pasteur pipette was 
used to transfer the organic extract to a clean test tube and the 
samp 1 es were then treated as for serum samp 1 es (Sect ion 3.5.1. 3) . 
Aliquots of 10~1 were injected onto the column. 
3.6.1.4 Calibration Curve 
The urine stock solution (10.0~g/ml) was diluted to yield 
different concentrations, (8.0, 5.0, 2.0 and 1.0~g/ml), with the 
solution itself providing the fifth concentration. 
four 
stock 
Each 
concentration was assayed in triplicate. 
constructed as in Section 3.5.1.4 . 
A ca 1 i brat i on curve was 
3.6.1.5 Precision 
Within-run precision was assessed by extracting six spiked urine 
samples each at the upper and lower limits of the concentration range 
studied. These concentrations comprised 1.0 and 10.0~g/ml. 
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TABLE 3.3 Within-run precision study on serum assay 
CONCENTRATION SPIKED CONCENTRATION MEASURED (~9/ml) MEAN (SO) RSo 
RANGE CONCENTRATION 
(~g/ml) (~g/ml) SAMPLE NUMBER 
I 2 3 4 5 6 
0.1 to 1.0 0.1 0.11 0.11 0. 10 0.11 0.11 0.11 0.11 (0.003) 3.44% 
1.0 1.07 1.04 1.06 1.05 1.08 1.05 1.06(0 .01) 1.27% 
1.0 to 15 .0 1.0 0.80 0.81 0.92 0.82 0.85 0.86 0.84(0.04) 4.78% 
15 .0 16.33 15.63 15.60 15 .67 15.81 15.76 15 .80(0.25) 1.57% 
TABLE 3.4 Analytical recoveries of mephenoxalone in serum 
SERUM PERCENTAGE RECOVERY MEAN (SO) RSO 
CONCENTRATION 
(~g/ml) SAMPLE NUMBER 
I 2 3 
0.1 92.9 90.5 88.0 90.5(2.0) 2.2% 
1.0 90.4 90.1 87.3 89.3(1.4) 1.6% 
15 .0 88 .2 87.1 89.5 88.3(1.0) 1.1% 
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3.6.1.6 Extraction Efficiency 
The ana lyt i ca 1 recovery of mephenoxa lone in ur i ne was assessed ina 
manner similar to that described in Section 3.5.1.6. 
3.6.2 Results and Discussion 
3.6 .2.1 Linearity and Calibration Curve 
Linearity was established for the range of concentrations studied (1.0 
to 10. O~g/ml ) . Deta il s of the 1 i neari ty data and the ca 1 i brat ion 
curve for mephenoxalone in urine are shown in Table 3.5 and Fig . 3.7, 
respectively . 
Chromatograms of a blank urine extract and a urine extract containing 
mephenoxalone and internal standard are depicted in Figs.3.8 (a) and 
3.8 (b), respectively. 
Initial studies using methylene chloride for extracting urine samples 
showed that linearity existed over the range of concentrations studied 
(1.0 to 10 . 0~g/ml). The calibration curve had a slope of 0.1687, a 
y-intercept at 0.0026 and a correlation coefficient of 0.9953 . 
Chromatograms of a blank urine extract and a urine extract containing 
mephoxalone are depicted in Figs.3 . 3 (a) and 3.3 (b), respectively 
(Section 3.4.2.3) . By comparing the correlation coefficient obtained 
using methylene chloride alone, the calibration curve using 
cyclohexane-methylene chloride (3 :2) had a better correlation 
coefficient (0.9987) because the extracts obta ined using the latter 
extracting solvent contained no contaminants that co-eluted with 
mephenoxalone. The mixed solvent was therefore adopted throughout 
this study. 
3.6 .2.2 Precision 
Results of the within-run preclslon study are shown in Table 3.6. 
The relative standard deviations (RSD) at the concentrations studied 
fall within the acceptable limits for drug determinations (56). 
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TABLE 3. 5 Linearity data for mephenoxalone in urine 
CONCENTRATION 
RANGE 
SLOPE Y-INTERCEPT CORRELATION 
COEFFICIENT 
(~g/ml) 
1.0 to 10.0 0. 1536 -0.0018 0.9987 
FIGURE 3.7 
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Calibration curve for mephenoxalone in urine (1.0 
to 10.0~g/ml) 
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3.8 Chromatograms of (a) an extract of drug-free urine and (bl 
an extract of urine containing 5.0~g/ml mephenoxalone1 
and 5.0~g/ml phenacetin 2 using 5.0 ml cyclohexane-
methylene chloride (3:2) as the extraction solvent 
(chromatographic conditions as in Section 2.4.2; 10~1 
injection volume). 
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3. 6.2 . 3 Extraction Efficiency 
Table 3. 7. shows the analytical recoveries of mephenoxalone from 
urine. The mean recovery was 80 .2 percent which is well within the 
accepted 1 imits for drug determinations (56). The mean recovery for 
ur ine extracted with methylene chloride was 89 .8 percent. 
3. 6. 2.4 Sensitivity and Detection Limits 
The mi n imum detectab 1 e 1 imi t for mephenoxa lone in urine, us i ng the 
conditions described previously, was 0.2pg/ml. This was lower than 
the sens i t i v i ty requ i red for the determi nat i on of mephenoxa lone in 
human urine after oral dosing. 
TABLE 3.6 Within-run precision study on urine assay 
SPIKED CONCENTRATION MEASURED (~g/ml) MEAN (SO) RSO 
CONCENTRATION 
(~g/ml) SAMPLE NUMER 
1 2 3 4 5 6 
1.0 0.93 0.92 0.92 0.91 0.92 0.94 0.92(0.01) 1.02% 
10.0 9.28 9.19 9.22 9.26 9. 20 9.14 9.22(0.05) 0.50% 
TABLE 3.7 Analytical recoveries of mephenoxalone in urine 
URINE PERCENTAGE RECOVERY MEAN (SO) RSO 
CONCENTRATION 
(~g/ml ) SAMPLE NUMBER 
1 2 3 
1.0 78.0 79 . 4 80.7 79.4(1.1) 1.4% 
10 .0 81.2 79.5 82.1 80 .9(1.1) 1. 3% 
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3.7 STABILITY OF SERUM AND URINE SAMPLES ON STORAGE 
The stab il i ty of a compound in 
aspect of drug development. 
biological fluids is an important 
The majority of stability studies 
reported in the literature do not, however, adequately describe either 
the experimental procedure or the statistical treatment of the data. 
Some procedures entirely avoid statistical treatment and judge 
stability on the basis of a measured response difference, D, between 
stored and freshly prepared samples (69-71). Several studies have 
reported the use of a t-test to ascerta i n whether any sign if i cant 
difference exists between the stored and freshly prepared samples (72-
75). These methods do not consider the precision or number of 
measurements and are unable to distinguish between a significant and a 
pharmacok ineti ca lly relevant degradation. A novel approach for 
dealing with the stability of drugs in biological fluids which account 
for these factors has been recently reported (76). The procedure is 
based on sound experimental design and allows conclusions to be drawn 
concerning drug stability with an acceptable degree of certainty . 
The application of this method to determine the stability of 
mephenoxalone in human serum and urine was evaluated for various drug 
concentrations, storage temperatures and storage times. The samples 
tested comprised spiked serum and urine samples as well as samples 
collected from human voluteers following oral administration of 
mephenoxalone. 
3.7.1 Experimental 
3.7.1.1 Sample Preparation 
Mephenoxalone stock solution (lmg/ml) was prepared as in Section 
3.4 . 1.1. Appropriate dilutions of this solution were then made with 
water. 
Internal standard stock solution (lmg/ml) was prepared as in Section 
3.4.1. 1. A 50~g/ml solution was prepared as previously described. 
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Mephenoxalone spiked serum samples (1 and 10~g/ml) were prepared as 
fo llows: 
One millilitre of mephenoxalone stock solution was diluted to 100.0ml 
with blank serum to provide a concentration of 10~g/ml. One 
milli1itre of a 1 in 10 dilution of mephenoxalone stock solution was 
added to a 100ml volumetric flask and made up to volume using blank 
serum. This solution had a concentration of l~g/ml. 
Mephenoxalone spiked urine samples (1 and 10~g/ml) were prepared in a 
similar manner to the mephenoxalone spiked serum samples. 
Serum and urine samples were collected from human volunteers as 
described in Section 5.1. 1.6 and Section 5.1.1.7, respectively. 
3.7.1.2 Storage Conditions 
Six millilitre aliquots of the spiked serum and urine samples were 
stored under the following conditions: 
Storage temperature 
Ambient 
40C 
-20oC 
Period of Storage 
24 h 
24 h, 48 h, 1 week 
1, 4, 8 weeks 
Six millilitre aliquots of urine collected from human volunteers after 
oral dosing were stored as above but an insufficient volume of serum 
meant that only 3.5ml aliquots were stored, the conditions being the 
same as above. 
3.7.1.3 Chromatographic Conditions 
As in Section 3.5 .1.2 
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3. 7.1.4 Extraction of Serum and Urine Samples 
Serum and urine samples were analyzed as described in Section 3. 5.1.3 
and Section 3.6.1.3 respectively . 
3. 7.1.5 Statistical Interpretation of the Data 
The data were treated according to the procedure described by Timm et 
al. (76). The measured response difference (D) and the true percentage 
difference in response (~) between stored and freshly prepared samples 
were calculated by applying the equations given in Table A3.1. The 
true percentage change of concentration may differ from 0 because of 
the imprecision of the analytical method. The true change of 
response on storage was enclosed by a lower limit (LL) and an upper 
limit (UL) of a 90% confidence interval, with a probability of 5% that 
it was lower than LL and 5% that it was higher than UL. A change of 
response was 
degradat i on of 
considered pharmacokinetically relevant 
~ =-10% was found. The relationship 
when a 
between 
significant 
Fig.3 . 9. 
and relevant changes of response on storage is shown in 
LL IJl 
a 
-
b 
c 
-
d 
e 
- , 
-10 o 11("4) 
The relationship between significant and relevant 
change of response on storage. The bars above the 
axis characterize the ranges of the 90% confidence 
interva l s for the true percentage response 
differences, 6.. between stored and freshly 
prepared samples. (ll =: lower limit; UL =: upper 
1 imit of the conf i dence i nterva 1); (a) change of 
response, not significant and not relevant; (b) 
decrease of response, Significant but not 
relevant; (e) decrease of response, significant 
and possibly relevant; (d) decrease of response 
significant and relevant; (e) decrease of 
response, not significant but possibly relevantj 
(f) increase of response, significant . 
Reprinted from Timm et al. (76) 
3.7.1.6 Stab i 1 ity 
Storage 
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Qf. Mephenoxalone in. Serum and Urine Q!l 
On the date the stored samples were to be analyzed, freshly prepared 
samples were made up from fresh stock solutions using the same 
mephenoxalone substance batch and biological fluid batches as were 
used for the stored samples. Five 1.0ml aliquots of the freshly 
spiked samples were analyzed together with five 1.0 ml samples of the 
stored serum and urine according to the procedure previously 
described. Calibrators were analyzed at the same time (as in 
Sections 3.5.1.4 and 3.6 .1.4) 
The measured responses (peak height ratios mephenoxalone:internal 
standard) were converted to concentrations using the calibration data. 
The statistical treatment was then applied to the concentrations of 
the stored and fresh ly prepared samp 1 es. The measured response 
difference (D) and the true percentage difference in concentrat i on 
after storage (c,) were calculated for each storage condition 
investigated. 
3.7.2 Results and Discussion 
A detailed example demonstrating the statistical calculations for 
assessing the stability of mephenoxalone in serum and urine is 
presented in Table A3 . 2. The results from the studies of 
mephenoxalone stability in biological fluids are shown in Fig.3.10. 
When mephenoxa lone was stored inhuman serum (sp i ked and c 1 in i ca 1 
trial samples) under the conditions tested, no significant decrease in 
concentration was detected . However, mephenoxalone stored in both 
spiked and clinical trial urine samples showed a trend towards 
instability when stored for 4 weeks at -200C. The instability 
appeared to be con cent rat i on - independent. Accord i ng to the 
definition of Timm et aT. (76), the decrease of response was 
significant and possibly relevant. A relevant degradation of 10 per 
cent or more could not be excluded with a statistical probability of 
95%, and the drug was therefore not stable under these conditions. 
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FIGURE 3.10 Stability of mephenoxalone in human serum and urine 
(_ concentrati on of lO~g /ml j Oconcentration of l~g /m l) 
(a) Spiked serum samples 
-20 -10 o 
(c) Spiked urine samples 
-
- --~ -
CJ 
(b) Serum samples collected after 
oral administration of 
the drug 
Ambient I 24 h 
40e I 24 h 
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-
- - - . 
CJ 
-
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(d) Urine samples collected after 
oral administration of 
the drug 
Ambient I 24 h 
I 24 h 
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o 
-
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A significant and pharmacokinetically relevant decrease in 
concentrat i on was observed when mephenoxa lone was stored in spiked 
urine samples for 8 weeks at -200C. Therefore, the time for storing 
urine samples at -200C should be limited to 1 week. Serum samples 
on the other hand, may be stored for 8 weeks at -20oC wi thout any 
significant or relevant degradation taking place. 
Using the procedure described by Timm et a 1. (76), a comprehensive 
study of the stability of mephenoxalone in human serum and urine under 
various storage conditions was facilitated. The procedure accounted 
for the prec i s i on of the measurements and the number of rep 1 i cate 
determinations performed. The presentation of the data obtained was 
simple and permitted a distinction to be made between 
pharmacokinetically relevant and statistically significant 
degradation. 
3.8 PLASMA PROTEIN-BINDING OF MEPHENOXALONE 
Drug binding to plasma proteins is an important biological factor of 
pharmacological and pharmacokinetic significance (77-79). Only the 
free drug, unbound by protein, is available for membrane transport . 
Bound drug is therefore not available for tissue distribution, 
receptor interaction or excretion. However, it is only when the 
extent of binding is high and when the drug-protein complex formed is 
not readily dissociable that binding becomes significant in the 
practical sense (78). The importance of determining the extent of 
protein-binding of a drug is thus obvious. 
The binding properties of mephenoxalone have not been reported in the 
1 iterature, probab ly due to the 1 ack of a sens it i ve and prec i se 
ana lyt i ca 1 procedure for the measurement of the drug in b io 1 og i ca 1 
fluids. The newly developed HPLC method for the assay of 
mephenoxalone was applied to the determination of mephenoxalone 
protein-binding. The extent of binding was determined by equilibrium 
dialysis. 
Equilibrium dialysis involves the equilibration of unbound drug 
between a protein solution (plasma/serum) and a protein-free solution 
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(buffer) separated by a semi-permeable membrane. It is now known that 
vo 1 ume sh ifts occur during d i a lys i s from the buffer side to protein 
side of the membrane as a consequence of osmotic differences in the 
flu i ds (81, 82) . The free drug fract i on has convent i ona lly been 
ca 1 cu 1 ated as the rat i 0 of the drug concentrat ion in the buffer to 
that in the plasma, the volume shift being ignored (83). This 
results in an under-estimation of the true binding extent . Several 
methods have been proposed for correcting the volume shift that occurs 
during dialysis (80-82, 84). The most applicable to this study is 
the method of Sun et al. (80) because the vol ume shift is quantitated 
and incorporated into the calculation of the true extent of binding 
without any need to know the concentration of protein. 
3.8.1 Experimental 
3.8.1.1 Sample Preparation 
Serum samples spiked with mephenoxalone (0.5 to 15.0~g/ml) were 
prepared as described in Section 3.5.1.1. 
Clinical trial serum samples were collected from Subject KZ at 1.17 , 
3. 0 and 6.0 hours after ora 1 admi n i strat ion of two tab 1 ets, each 
containing 200mg mephenoxalone (see Section 5.1 .1.6) . 
3.8 .1.2 Eguibilibrium Dialysis 
Equilibrium dialysis was performed using two-chambered dialysis cells, 
each of 1.0 ml capacity (The Chemical Rubber Company, Ohio, USA). 
The cells were separated by a semi-permeable membrane (Spectra/Por 2, 
Spectrum Medical Industries, Inc . , Los Angeles, Cal., USA) with a 
molecular weight cutoff of 12 000 - 14 OOOamu . Pr ior to use the 
membranes were boiled for 90 minutes in distilled water and stored for 
at least 24 hours at 40C in phosphate buffer (0 .1 moles/litre; 
pH 7.4) . 
Human serum (l . 00ml) containing mephenoxalone was one half- cell while 
phosphate buffer solution (0 . 1 moles/litre, pH 7.4) of an equal volume 
was placed in the other. The dialysis cells were then left on a 
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reciprocating mechanical shaker at ambient temperature to equil i brate 
for 24 hours (prolonged incubation was verified not to change the 
plasma dialysate concentrations further). Gentle mixing was further 
facilitated by the inclusion into each half-cell of two glass beads. 
After equilibration the volumes of plasma and dialysate were 
accurately measured using a 2.0ml micro-volumetr i c syringe (Hamilton 
Co., Reno, Nev . , USA). Ali quots of 750~ 1 were transferred to clean 
test-tubes and prepared for HPLC analysis as described in Section 3. 5. 
The d i a lys i s procedure was performed in tri p 1 i cate for each samp le 
concentration. 
3.B.1.3 Calculation of Protein-Binding 
The degree of mephenoxalone binding to serum proteins (fB) was 
calculated using Equation 3.1 (BO). 
fB = 1 CF(l- V) 
Equat ion 3.1 
CT(1+ V) 
where CF is the unbound drug concentration, and 
3.B.2 
CT is the total drug concentration after equil i bration. 
V is the fractional increase of plasma volume after 
equ il i bra t i on. 
Results and Discussion 
The mean data for mephenoxalone binding to human serum proteins for 
spiked and clinical trial samples are presented in Table 3.B. 
A comparison of the percentage bound when volume changes were included 
(Method A) and when the changes were excluded (Method B) from the 
bind i ng 
binding 
calculat ions is shown . Using Method B, the true extent of 
was under-estimated, the difference being greater at the lower 
binding levels, thus demonstrating the importance of monitoring volume 
shifts . 
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The volume loss from plasma samples during dialysis ranged from 10 to 
18 percent of the original volume (1.00ml). The recovery of samples 
from the dialysis cells was almost complete, with more than 96 percent 
of the volume added being recovered after dialysis. 
A graphical presentation of mephenoxalone-binding to human serum 
proteins using Method A (Fig.3.11) showed that mephenoxalone exhibited 
a relatively concentration-independent change in the extent of binding 
for both the spi ked and the tr i a 1 samp les . The sharp increase in 
binding from 50 percent at 0.5~g/ml up to 88 percent at 2.0~g/ml and 
subsequent decline to 50 percent bound at la.O~g/ml for spiked serum 
samples has not yet been explained. Whether these results were true 
or produced by methodological artefacts is not known. Factors other 
than volume shifts have been shown to influence the in-vitro protein-
binding of some drugs during dialysis (82, 84). These include the 
Donnan effect, non-specific binding of the drug to membranes, and pH 
differences between protein and buffer solutions. The effects of the 
above were not investigated. 
Although the results obtained in this study were not conclusive in any 
way, an examinat i on of the chemi ca 1 structure and phys i co-chemi ca 1 
properties of mephenoxalone did provide some insight into the possible 
binding properties of the drug. 
Mephenoxalone is a low molecular mass, hydrophobic, water-insoluble 
compound, and is therefore likely to be considerably bound to plasma 
proteins (77). The compound is not, however, expected to be tightly 
bound to these proteins because the forces involved in the binding are 
likely to be due only to lipophilic attractions of the aromatic ring 
(pi) electrons and the non-polar alkyl chains of the drug molecule 
(78). The compound has a very weakly basic carbamate moiety . For 
the above reasons it is expected that the binding of mephenoxalone to 
serum proteins, although reasonably high, is readily dissociable and 
therefore without clinical importance. 
TABLE 3.8 
SPIKED 
SAMPLES 
CLINICAL 
TRIAL 
SAMPLES 
a 
b 
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Binding of mephenoxa1one to serum proteins 
CONCENTRATION METHOD Aa METHOD Bb 
(~g/ml) % BOUND (SO) % BOUND (SO) 
0.5 50.2 (2.5) 27.3 (4.4) 
0.8 67 .4 (3.8) 51.0 (4.8) 
2.0 88.3 (1. 0) 80.9 (1.1 ) 
5.0 82.6 (5.6) 75.1 (7.8) 
10.0 56.4 (4.1) 42.9 (3.6) 
15.0 47.8 (3.8) 34.7 (5.1 ) 
4.2 66.8 (1.1) 63.0 (4.9) 
7.9 70.2 (3.6) 63.6 (4.4) 
10 .7 54.8 (2.7) 38.8 ( 1.8) 
Volume change accounted for, calculated using Equation 3.1 
Volume change not accounted for, calculated according to 
method of Bender et al. (83) 
FIGURE 3.11 Protein-binding of mephenoxa1one in (a) spiked serum 
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4.2 EXPERIMENTAL 
4.2.1 Conditions for Dissolution Testing 
Dissolution apparatus 
Rotation rate of the paddles 
Temperature of dissolution medium 
Sample withdrawal position 
Dissolution media 
as in Section 4.1.2, and set up 
according to the specifications in 
the USP XXI (Apparatus 2) (85) 
100 rpm 
370C 
mi dway between the shaft of the 
paddle and the side of the 
containing vessel and half the 
distance from the surface of the 
medium t o t he bottom of the paddle 
blade. 
3 dissolution media were used for 
this study: 
(a) HPLC - grade water 
(b) Simulated gastric fluid (GF) 
(c) Simulated intestinal fluid (IF) 
GF and IF were prepared according to the USP (86) with the exception 
that pepsin and pancreatin, respectively, were excluded. One hundred 
milligrams of methocarbamol, as the internal standard, was included in 
every litre of dissolution medium. The solutions were degassed and 
filtered through a 0.45~m membrane filter (Type HVLP, Millipore Corp., 
Bedford, Mass., USA) prior to use. 
4.2.2 Chromatographic Conditions 
The chromatographic conditions employed throughout this study are 
described in Section 2.4.2 . 
4.2 . 3 Tablet Assay 
No official monographs on mephenoxalone dosage forms appear in the BP 
or the USP, thus no methods are specified for their analysis. 
However, the manufacturer of the new mephenoxalone-containing tablet 
77 
has proposed an assay method (2), and although the method was used for 
this study, it was adapted to include an internal standard as well as 
an HPLC analytical technique. 
a) Standard Solution 
Two hundred milligrams of mephenoxalone powder was accurately weighed 
into a 100ml volumetric flask to which was added 60ml methanol 
containing O.lmg/ml methocarbamol as the internal standard . The drug 
was dissolved with the aid of ultrasonication and the resulting 
solution was made up to volume with the methanolic internal standard 
solution. Five millilitres of this solution were pipetted into a 
100ml volumetric flask and made up to volume as before . Aliquots of 
Spl were injected onto the HPLC column. 
b) Sample Preparation 
Twenty tablets were weighed, finely crushed, and a mass of powder 
approximately equivalent to the weight of one tablet was accurately 
weighed into a 100ml volumetric flask. The procedure described under 
"standard solution" (a) was then followed. The final suspension was 
sonicated once more and then filtered through a O.4Spm fi lter (Type 
HVLP, Mi 11 i pore Corp., Bedford, Mass . , USA) . The fi rst part of the 
f i 1 trate was discarded and Su 1 ali quots of the subsequent filtrate 
were injected onto the HPLC column. The tablet assay was carried out 
in triplicate using further portions of the powdered tablets. 
4. 2.4 In Vitro Dissolution Study 
4. 2. 4. 1 Intrinsic Dissolution of Mephenoxalone Powder 
I n it i a lly, three different med ia were eva 1 uated for their effect on 
the dissolution of 200mg pure mephenoxalone powder: 
(i) 1000ml HPLC-grade water 
(ii) 1000ml GF 
( iii) 1 OOOm 1 IF 
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Two hundred milligrams of powder was placed in the dissolution medium 
and the rotating paddle was immediately lowered into the medium. 
Using a microvolumetric syringe (Hamilton Co., Reno, Nev., USA) 100~1 
samples were withdrawn at 10 minute intervals and transferred to 
clean, limited volume WISP inserts. Five microlitre aliquots of the 
samples were then injected onto the HPLC column under the conditions 
described in Section 4.2.2. The peak height ratios 
(mephenoxa 1 one/ i nterna 1 standard) were used in conjunct ion with an 
aqueous calibration curve to determine the amount of drug dissolved. 
Three dissolution runs were carried out for each medium. 
4.2.4.2 Dissolution of Mephenoxalone-containing Tablets 
At the time of this study, a limited supply of the new tablet dosage 
form was ava il ab 1 e. The d i sso 1 ut ion study was therefore conducted 
only in simulated gastric fluid. Six tablets were assayed as follows. 
Each tablet was placed in 1000ml dissolution medium, immediately after 
which the rotating paddle was lowered into the medium. Samples of 
100~1 were withdrawn at 10 minute intervals as before, transferred to 
clean, limited volume WISP inserts and then injected (5~1 aliquots) 
onto the HPLC column. The peak height ratios were used to determine 
the amount of drug dissolved, as before. The samples, which had been 
co 11 ected over a 2 hour peri od, were re- injected at the end of the 
HPLC run to ascertain whether or not any undissolved material that may 
have been withdrawn with the samples had dissolved upon standing in 
the WISP inserts. 
4.3 RESULTS AND DISCUSSION 
The mephenoxalone content of the tablet dosage form, as determined by 
HPLC analysis, was found to be 98.7 ~ 1. 0% of the stated amount . The 
HPLC method was rapid and accurate, and neither codeine phosphate nor 
paracetamo 1 (both of wh i ch were a 1 so present in the dosage form) 
interfered with the determination of mephenoxalone or of 
methocarbamol; under the conditions of the analysis codeine was 
retained on the column, while paracetamol eluted prior to the 
compounds of interest. 
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Methocarbamo 1 was chosen as the i nterna 1 standard for reasons 
discussed in Section 2.5.6 and because of its favourable elution time. 
Incorporation of the internal standard into the dissolution medium had 
numer.ous associated advantages. In addition to compensating for any 
loss in the total volume of dissolution fluids due to evaporation 
during the dissolution run and from the withdrawn sample, it enabled 
the sample to be injected directly onto the column without additional 
manipulative steps. The dissolution characteristics of mephenoxa1one 
powder were not affected by the presence of the internal standard as 
shown by the fact that i dent i ca 1 prof iles were obta i ned when the 
internal standard was added after sampling. 
Sampling with a microvo1umetric syringe enabled rapid, accurate 
remova 1 of the samp 1 e. On 1y 100~ 1 was wi thdrawn for each samp 1 e and 
rep 1 acement of the med ium was therefore not necessary. When the 
samples were re-injected at the end of the initial HPLC run, there was 
no detectable increase in the amount of drug dissolved, thus 
demonstrating that direct withdrawal of the samples using the 
microvo1umetric syringe was a valid technique. 
The dissolution curves of the pure powder in different dissolution 
media are depicted in Fig.4.1. while the individual results are listed 
in Table A4 .1. It can be seen that mephenoxa10ne initially dissolves 
more slowly in water than in GF or IF; only after 40 minutes were the 
three dissolution profiles comparable. Mephenoxalone dissolved 
sl ight1y faster in IF than in GF for the first 10 minutes, but 
thereafter the profiles were comparable. 
The individual results for the dissolution of mephenoxa10ne from the 
tablet dosage form in GF are listed in Table A4.2 and the mean 
dissolution curve for 6 tablets is depicted in Fig.4.2. For 
comparative purposes, the dissolution curve for the pure powder in GF 
has been superimposed . It can be seen that, for the first 30 minutes, 
the release of mephenoxa10ne from the tablets proceeded more rapidly 
than the dissolution of the powder; while approximately 88 percent of 
the stated dose had dissolved from the tablets after 10 minutes, only 
about 56 percent of the powder had dissolved after the same length of 
time . However, after half an hour , more than 90 percent of the 
30 
FIGURE 4.1 Dissolution profiles for mephenoxalone powder (200 mg) in 
water, GF and IF 
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mephenoxalone had dissolved from both the powder and the tablets. The 
dissolution of mephenoxalone from both dosage forms was essentially 
complete after 1 hour. 
The faster initial rate of in vitro dissolution from the tablets has 
been explained by the manufacturer. In order to overcome any 
anticipated difficulty with in vivo absorption of mephenoxalone, 
resulting from its poor solubility in water, the tablets were 
specifically formulated to facilitate a rapid release and dissolution 
of the drug from the dosage form. 
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CHAPTER FIVE 
CLINICAL TRIALS AND IN VIVO ASSESSMENT OF PHARMACOKINETICS OF 
MEPHENOXALONE 
~ CLINICAL TRIALS 
In vivo trials, using healthy human volunteers were conducted to 
enable the elucidation of the pharmacokinetic parameters of 
mephenoxa lone after a sing 1 e ora 1 dose of 400mg powder dispersed in 
150ml water. A comparison of the relative bioavailability of a new 
mephenoxalone-containing tablet (Adcock-Ingram Laboratories Ltd., 
Johannesburg, South Africa) with that of the pure powdered drug, was 
also conducted . 
5.1.1 Experimental 
5.1.1.1 Pilot Trial 
A pilot study, us i ng one vo 1 unteer, was conducted for the fo 11 owi ng 
reasons : 
(a) to assess the effectiveness of the analytical method to 
measuring serum and urine concentrations of mephenoxalone after 
a single oral dose of 400mg dispersed in water, 
(b) to estab 1 ish the expected serum and uri ne concentrat ions of 
mephenoxalone after the dispersed dosage form, and 
(c) to establish the frequency and times of sampling necessary to 
adequately describe the absorption and disposition of 
mephenoxalone in terms of pharmacokinetic parameters. 
The volunteer was a healthy 20 year old male, weighing 74kg, who was a 
non-smoker with no previous history of kidney or liver disease and who 
infrequently partook of alcoholic beverages. Blood and urine samples, 
co 11 ected pri or to the tri a 1, were subjected to haemato logy, blood 
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chemistry and urinalysis tests (Section 5. 1.1.2) and were found to be 
normal . Prior to admission to the trial, the patient received a typed 
copy of the trial protocol, and signed a consent form. He received an 
honorari urn for part i c i pat i ng in the tri a 1 and adhered to the same 
standard procedures as those described in Section 5.1.1.4. 
The patient received a single oral dose of 400mg mephenoxalone powder 
dispersed in 150ml water followed by a further 100ml water. Blood 
samples were collected as described in Section 5.1.1.6 at 0, 0.5, 1, 
1.5, 2, 2. 5, 3, 4, 5, 6, 8, 10, 12 and 24 hours after ingestion of the 
test dose. Urine samples were collected as described in Section 
5.1.1.7 during the time intervals 0-2, 2-4, 4-6, 6-10, 10-14 and 14-24 
hours. Serum and urine samples were analyzed according to the methods 
described in Sections 5.1.1.8 and 5.1.1.9, respectively. 
5. 1.1.2 Six Patient Study 
Six young, healthy human volunteers who were non-smokers and 
infrequent dri nkers or absta i ners part i c i pated in the tri a 1. The 
demographic data of the volunteers are summarized in Table 5.1. 
Volunteers were chosen on the basis of physical health and the 
following haematology, blood chemistry and urinalysis tests: 
Haematology: 
Blood chemistry: 
Urinalysis: 
haemoglobin, haematocrit, WBC, RBC, platelet 
count, differential count. 
serum creatinine, serum urea, blood glucose, 
serum bilirubin, serum alkaline phosphatase, SGPT 
and SGOT. 
specific gravity, bile, pH, protein, glucose, 
RBC, WBC, epithelial cells, granular casts. 
Prior to admission to the trial, each volunteer received a typed copy 
of the trial protocol and signed a consent form. Volunteers were paid 
an honorarium for participating in the trial and adhered to the 
standard procedures described in Section 5.1.1.4. 
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TABLE ~ Details of volunteers 
CODE NAME SEX AGE BODY MASS HEIGHT 
(KG) (CM) 
WA male 22 63 170 
OW male 21 75 180 
MG male 24 70 181 
KZ female 22 62 165 
KR female 21 59 175 
KD female 19 57 155 
5.1.1.3 Treatments 
Trial 1: Test dose 1 consisted of a single oral dose of 400mg 
mephenoxalone powder, dispersed in 150ml of water. 
Ingestion of this dose at 0 hours was immediately followed 
by a further 100ml water. 
Trial 2: Test dose 2 consisted of a single oral dose of two tablets 
(each tablet containing a combination of paracetamol, 
codeine phosphate and 200mg mephenoxalone). This dose was 
ingested, at a hours, with 250ml water . 
5.1.1.4 Standardization Procedures 
All volunteers had to conform to the following restrictions: 
(a) No drugs, including over-the-counter preparations, were allowed 
for at least a week before the trial and for the duration of the 
trial. 
(b) No alcohol was to be consumed for at least 48 hours before the 
trial and for the duration of the trial. 
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(c) No caffeine-containing foods or drinks, including coffee, tea, 
chocolate and cola drinks, were to be ingested for at least 48 
hours before, and for the duration of the trial. 
(d) No food or dr i nk was to be ingested for 10 hours before the 
start of the trial. 
The volunteers were allowed to move about freely during the trial but 
had to refrain from strenuous activities. 
A standardized breakfast consisting of toast, with margarine and jam, 
and 250m 1 orange ju i ce was served 2 hours after the start of the 
trial. A standard low fat lunch consisting of chicken, rice and 
vegetables followed by fresh fruit-salad was given to all the 
volunteers 3 hours later. 
5.1.1.5 Sampling Schedules for the Trials 
The sampling schedule used for both Trial 1 and Trial 2 is given in 
Table 5.2 . 
5.1.1.6 Collection and Storage of Blood Samples 
An indwelling 0.8mm butterfly catheter (21G, Terumo Corporation, 
Tokyo, Japan) was inserted into a suitable vein in the forearm and 
securely strapped into position with adhesive tape so as to facilitate 
comp 1 ete mobil ity of the arm. Each 10ml blood samp 1 e was wi thdrawn 
from the butterfly through a sterile hypodermic needle (0.8mm, Promex 
(pty) Ltd., Bergvlei, South Africa) by syringe aspiration. The 
butterfly was flushed, after sample withdrawl, with 1.5ml sterile 
saline solution (Keagrams Ltd . , Johannesburg, South Africa) containing 
50 i.u./ml heparin. Immediately prior to sampling, the butterfly was 
cleared of the hepari n so 1 ut ion by the withdrawa 1 of 2m 1 of blood 
which was then discarded, a new syringe and needle being used for 
withdrawing the 10ml blood sample. The sample was transferred to a 
clean, 1 abe 11 ed Vacuta i ner tube wh i ch was stoppered and a 11 owed to 
stand for 20 minutes for the blood to clot . The tube was centrifuged 
at 3000rpm for 10 minutes whereafter the serum was transferred to a 
clean, labelled Vacutainer tube. 
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TABLE 5.2 Sampling schedule for Trials 1 - 2 
BLOOD SAI'IPLING URINE SAMPLING TIME 
INTERVAL INTERVAL 
a b 
0 0 8.00am 
10 min 8. lOam 
20 min 8.20am 
30 min B.30arn 
4 0 min 8.40am 
50 min 8. SDam 
h 9.0Dam 
h 10 min 9.10arn 
h 20 min 9.20am 
h 30 min 9.30am 
h 45 min 9.45am 
2 h 2 h lO.ODam 
BREAKFAST 
2 h 30 min l O.3Qarn 
3 h 11.0Dam 
4 h 4 h 12 noon 
• h 1 . 00pm 
LUNC H 
6 h 2.00pm 
8 h 8 h 4.00pm 
10 h 6.00pm 
12 h 6.00pm 
12 h 12 h 8.00pm 
1. h 10.00pm 
24 h 2. h B.ODam 
a Test dose ingested after collecting a blank 
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The serum samples, collected at the appropriate sampling times in the 
manner described above, were stored at -200C for a maximum of 2 weeks 
until analysis . 
5.1.1 .7 Collection and Storage of Urine Samples 
The collection of urine samples was controlled by the volunteers 
themse 1 ves and was, therefore, not subject to the same degree of 
control as the collection of blood samples . The importance of strict 
adherence to the samp 1 i ng procedure was stressed in both verba 1 and 
written instructions to the volunteers. 
The total urine output for each sampling interval was collected in a 
large measuring cylinder. Volunteers were requested to empty their 
bladders completely at the end of each interval. The total volume of 
urine was measured and a representative sample of 10ml was transferred 
to a clean, 1 abe 11 ed Vacuta iner tube; the rema i nder of the ur i ne was 
discarded. Urine samples were stored at -20oC for a maximum of 1 week 
until analysis. Urine passed at times other than those specified in 
the trial protocol was collected as previously described, the volume 
and the time of voiding being accurately recorded. 
5.1.1 .8 The Analysis of Serum Samples 
Serum samp 1 es were brought to room temperature and then mi xed on a 
vortex mixer before being analyzed. The order in which they were 
analyzed was randomized so as to avoid sequential effects. The 
samples were prepared for injection according to the method described 
inSect i on 3.5.1. 3, and 10~ 1 ali quots of the reconst i tuted res i dues 
were injected onto the column (he chromatographic employed conditions 
are described in Section 3.5.1.2). 
The peak height ratios (mephenoxalone/internal standard) were used to 
determine the concentration of drug in serum from the calibration 
curve of mephenoxalone in serum (Section 3.5.1.4). 
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5.1.1.9 The Analysis of Urine Samples 
Urine samples were brought to room temperature, mixed using a vortex 
mixer, and then analyzed according to the method described in Section 
3.6.1. 3. Ten mi cro 1 itre samples were injected onto the column (the 
chromatographic conditions aredescribed in Section 3.6.1.2). 
The peak height ratios (mephenoxalone/internal standard) were used to 
determine the concentration of drug in urine from the calibration 
curve of mephenoxalone in urine (Section 3. 6.1.4). 
5.1.2 Results and Discussion 
5. 1.2.1 Pilot Trial 
In the pilot study, the concentrations of mephenoxalone in serum 
ranged from below 0.lfl9/ml up to 7fl9/ml over 24 hours. The 
sensitivity of the analytical procedure was adequate for the purpose 
of this study. The method of analysis proved to be rapid, accurate 
and reproducible. 
It was found that absorption of the drug was rapid, with the peak 
blood concentration occuring between 30 and 60 minutes after ingestion 
of the test dose. It was not possible, however, to determine either 
the exact time of peak concentration (tmax) or the corresponding 
concentration (Cmax) because insufficient blood samples were collected 
during the early phase of the trial. The sampling schedule for 
subsequent trials was, therefore, rearranged to accommodate 10 minute 
blood sampling intervals of 10 minutes for the first 1.5 hours and one 
extra sample at 1.75 hours. 
The analysis of urine samples collected in the pilot study indicated 
that only a small percentage (0.9%) of the administered dose was 
excreted as unchanged mephenoxa lone after 24 hours. In order to 
confirm this finding, urine samples were collected for the duration of 
Trial 1. 
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5.1.2.2 Six Patient Study 
Six healthy volunteers, aged 21.5 ~ 1.5 years, weighing 64.3 ~ 6.3 kg 
and of average height 171.0 ~ 9.0 cm, participated in the clinical 
study. The volunteers comprised both males (3) and females (3) so as 
to inc 1 ude both sexes even though the samp le sizes were not 
statistically sufficient. The scale of the study was limited not only 
by the 1 ack of su i tab le vo 1 unteers but a 1 so by the 1 ack of su itab 1 e 
facilities for a large-scale trial. 
in both Trial 1 and Trial 2 but 
The same volunteers participated 
one subject (KD) was unable to 
participate in Trial 2 which was therefore conducted using only 5 
volunteers. Subject KR was admitted to the trials prior to the 
knowledge that she suffered from a mild case of Gilberts' syndrome. 
The pathology of this condition is reported in the literature (87). 
The impl ications of this disorder on the results of the study are 
discussed in Section 5.2.2. 
Mephenoxalone was well tolerated by the volunteers for the duration of 
Trial 1. FollowinQ the administration of the tablet dosage form 
(Tr i a 1 2), however, two subjects experi enced untoward effects wh i ch 
were unrelated to the blood concentration of mephenoxalone; subject KZ 
reported an onset of nausea at 15 minutes after dosing, while subject 
KR reported feeling drowsy at 30 minutes after dosing. These effects, 
however, were mild and transient. 
The test dose for Trial 1 should, ideally, have been administered as a 
solution. Mephenoxalone is, however, insoluble in water (2), and the 
dose was therefore administered as a dispersion (400mg powder, 
dispersed in 150ml water). This was immediately followed by a further 
100ml water ingested in small amounts to ensure that any powder that 
may have remained in the mouth was subsequently swallowed. No report 
was received of either bitterness of the dosage form or manipulative 
difficulty of the procedure. 
The use of an indwelling butterfly catheter for collecting blood 
samples was found to be convenient. However, in one subject (KZ) the 
butterfly became blocked as a result of insufficient flushing with 
heparin. The delay in sampling caused by the removal and subsequent 
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rep 1 acement of the 'butterf ly' resu lted in the omi ss i on of a blood 
sample scheduled to be drawn at 1 hour 10 minutes. Apart from the 
above omission, the in vivo study followed the prescribed protocol . 
The individual concentration-time data for Trials 1 - 2 are listed in 
Tables A5.1 and A5.2, and the curves are depicted in Fig.5.l. The 
mean serum concentration profi les after the ingestion of the test 
doses are shown in Fig . 5.2. 
Urinary excretion data for Trial 1 are shown in Table A5.3 and plotted 
in Fig.5.3. After 24 hours, the percentage of the administered dose 
recovered from urine as unchanged mephenoxalone was 1. 17 ~ 0.58 
percent. This agrees well with values published for beagle dogs (6). 
In Trial 1 the recovery of mephenoxalone from urine was not monitored 
for longer than 24 hours, because ur i ne concentrat ions of the drug 
could not be accurately measured after this time. The urine data were 
excluded from pharmacokinetic ana lysis because of the low recovery of 
mephenoxalone. 
5.2 PHARMACOKINETIC ANALYSIS OF DATA 
The ana lys i s of concentrat i on-t ime data by pharmacok inet i c methods 
traditionally involves the use of compartment models e.g. one 
compartment, two-compartment and multi-compartment models (88). These 
class i ca 1 methods of data ana 1 ys i s are based upon 1 i near processes, 
and each model is represented mathematically as a linear equation in 
the form of a sum of coeff i c i ents and exponent i a 1 terms. However, a 
compartment model characterizes only the rate-limiting steps that 
occur during a drug-biological system interaction and, as such, it is 
only an approximation of a biological system. The use of a 
pharmacokinetic compartment model to describe drug disposition does, 
however, permit the simulation and prediction of pharmacokinetic data. 
In the last decade there has been a move away from the traditional 
approach towards alternative methods for the pharmacokinetic analysis 
of drug disposition e.g. non-compartmental and model-independent 
approaches. These have been extensively reported and reviewed in the 
literature (89, 90, 91) . The most popular of these approaches is the 
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FIGURE 5.1 Individual serum concentration-time profiles after the 
ingestion of 400 mg mephenoxalone administered as a 
dispersion (.) and as tablets (0) 
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FIGURE 5.2 Mean serum concentration-time profiles after ingestion of 
400 mg mephenoxalone administered as (a) a dispersion, and 
(b) tablets . 
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FIGURE 5. 3 Plots of cumulative urinary excretion versus time after 
the ingestion of 400 mg mephenoxalone dispersed in water. 
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mode 1 - independent method us ing stat i st i ca 1 moments. The method was 
first reported in 1978 by Yamaoka et al. (89) and Cutler (92), and the 
concepts, methods of calculation and potential errors in moment 
analysis have been extensively reviewed by Riegelman and Collier (93). 
This approach assumes only that all dispositional processes are 
described by first order kinetics, with elimination occurring from the 
rapidly equilibrating or central compartment. The advantage of using 
statistical moments is that they are dependent only on the observed 
time course data and not on the pharmacok inet i c compartment mode 1. 
This approach has many significant applications, particu l arly in cases 
where a drug is admi n i stered by a non- instantaneous input (n. i . v. ) 
e .g. orally; it allows the estimation of the times involved in the in 
vivo release and absorption processes that occur . Statistical moment 
analysis has also found widespread application in comparative 
bioavailability studies . 
B ioava i 1 ab i 1 ity of a drug is defi ned as the rate and the extent to 
which a drug becomes available at the site of action (94). Currently, 
the most common procedure for assessing and comparing rates of 
absorption is to use peak plasma concentration (Cmax) and time to peak 
(tmax); these are, however, on ly rough est imates conta in i ng min ima 1 
i nformat ion about the absorpt i on process (95). Idea lly, the rate of 
absorption should be expressed either numerically or as a mathematical 
function. The methods that have been developed to obtain an 
expression for the rate of absorption, in such terms, have been 
extensively reported and reviewed (89, 90, 92, 93, 96-115). The rate 
of absorption is commonly expressed in terms of ka, a hybrid constant 
wh i ch is cons i dered to describe the overa 11 rate of appearance of a 
drug in the plasma. When only oral data are available, the estimation 
of this parameter is usually performed using either the method of 
res i dua 1 s , i.e . feathering (88). or the Wagner-Nelson method (97). 
However, in cases where the drug is extremely rapidly absorbed and few 
data points are available during the absorption phase, these methods 
are difficult to apply. An alternative method of characterizing the 
rate of absorption is by statistical moment analysis (93). The 
statistical moment that is most frequently used to describe the 
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absorption process is the mean absorption time (MAT); this is defined 
as the mean time involved in the in vivo release and absorption 
processes as they occur in the compartment. 
Knowledge of the rate of absorption does not, by itself, enable 
complete characterization of the absorption process; both the rate and 
the extent of absorption must be known. The extent of absorption is 
refl ected by the fract i on, F, of the dose, D, wh i ch reaches the 
general circulation. This parameter is usually estimated by 
calculating the area under the concentration-time curve (AUC), and it 
is most popularly calculated by the linear trapezoidal method . 
However, in the absence of i .v. data this parameter cannot be 
accurately assessed (94). 
In this study, both compartment models and model-independent methods 
were used for the pharmacokinetic analysis of mephenoxalone 
concentration-time data. 
5.2 . 1 Methods of Clinical Trial Data Analysis 
The experimental data obtained from Trial 1 and Trial 2 were initially 
treated using model-independent methods . The parameters Cmax and tmax 
were obtained directly from the individual serum concentration-time 
data. The areas under the concentration-time curves, from time zero 
to infinity (AUCo~m) were calculated by the linear trapezoidal 
method, with extrapolation to infinity. The terminal rate constant, 
A. was ca 1 cu 1 ated by 1 i near regress ion of the termi na lsI ope of a 
semi log p lot of serum concentrat i on of mephenoxa lone versus time . 
From this value, the elimination half-life, t y, ' was calculated 
(Equation 5.1). 
t'l, = 0. 693 
Az 
Equation 5.1 
The clinical trial data were then analyzed by the method of residuals, 
in an attempt to calculate the values of ka and to assign a possible 
compartment model to drug behaviour . Assuming a linear one-
compartment model with first order absorption, the Wagner-Nelson 
equation (103) was appl ied to the serum concentration-time data to 
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yield absorption plots of fraction absorbed versus time. The 
absorption rates were calculated from the slopes of semi log plots of 
the fraction of the dose remaining to be absorbed versus time. 
The nonlinear regression computer program NONLIN (116) was applied to 
the data in an attempt to fit the experimental data to either a one 
body-compartment model (lBCM) or a two body-compartment model (2BCM). 
The set of differential equations that describes these models are 
listed, together with their exponential functions, in Table 5.3. The 
DFUNC subroutine of the computer program was modified for each model. 
The individual data sets were fitted to obtain the least squares 
estimates of the pharmacokinetic parameters (NONLIN uses the sum of 
squares, and not the correlation coefficient as the fitting 
criterion) . 
Symbols are defined as follows: 
C plasma concentration at time, t, after administration 
A, B, E hybrid intercept terms 
a: , B hybrid rate constants 
ka first order absorption rate constant 
klO first order constant associated with elimination of drug 
from the central compartment 
k12, k2l first order rate constants associated with movement of 
drug from central compartment to peripheral compartment 
(kl2), and vica-versa (k2l) . 
del 
dt 
dA2 
dt 
C1 
C2 
D 
rate of change 
compartment 
rate of change 
compartment 
concentration in 
concentration in 
dose of the drug 
of 
in 
the 
the 
V1 volume of the body 
drug concentration in the central 
amount of drug in the peripheral 
central compartment 
peripheral compartment 
The absorpt i on and d i spos it ion of mephenoxa lone, after ora 1 dos i n9, 
were also evaluated using statistical moment analysis (93). The 
parameters, mean residence time after oral dosing (MRTpo), mean 
TABLE 5.3 Differential equations and exponential functions describing a 1BCM and a 2BCM 
COMPARTMENT MODEL DIFFERENTIAL EQUATIONS DESCRIBING THE EXPONENTIAL FUNCTION 
RATE OF CHANGE OF DRUG 
, BCM 
-k t 
-k,ot -k t , k , linear dC K De a 
- k, OC, 
a C Be - Ee 
a dt a-
elimination V 
Peripheral compartment 
2BCM dA2 K'2 C,V, - k 2,A2 dt 
-~t 
-8t 
, k , linear Central compartment C Ae + Be - Ee 
a 
elimination -k t 
dC, k De 
a 
+ k2' ~2 - k'2 C' - k,OC, a -
dt V, V, 
-k t 
a 
<D 
"" 
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absorption time (MAT) and mean (in vivo) dissolution time (MDT) were 
calculated as follows: 
MRTpo = AUMC w Equation 5.2 
AUC w 
where AUMC is the area under the first moment of the plasma 
w 
curve, and 
AUC is the area under the concentration-time curve 
w 
MAT = MRTpo - MRTiv Equation 5.3 
where MRTiv is the mean residence time after an i.v. dose 
Since i.v. data were not available in the studies, MRTiv was estimated 
indirectly from the oral data, according to the method of Riegelman 
and Co 11 i er (93). The d i spos i t i on of mephenoxa lone was genera 11y 
described by a mono-exponential decline, and MRTiv was therefore 
determined from Equation 5.4. 
MRTiv = 1 Equation 5.4 
Calculation of the mean (in vivo) dissolution time for a solid dosage 
form (Equation 5.5) enables the contribution of the dissolution 
process to be separated from the apparent absorption and disposition 
processes. 
MDT prod = MATprod, uncorr - MATsoln, uncorr Equation 5.5 
Where MAT prod, uncorr and MAT so ln, uncorr are the uncorrected 
mean absorpt i on times for the product and for the so 1 ut i on of 
the drug, respectively . 
However, as a result of the poor water solubility of mephenoxalone, 
solution data were not available in this investigation . Equation 5.5 
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was therefore adapted for dispersion studies (Equation 5.6). Although 
this is not ideal, it does provide an estimate of the in vivo 
dissolution time of the tablet dosage form relative to that of the 
dispersed dosage form. 
MDTtablet = MATtablet - MATdispersion Equation 5.6 
In cases where a negative result is obtained, it can be assumed that 
the in vivo dissolution of mephenoxalone proceeds more rapidly from 
the tablets than from the dispersion. 
5.2.2 Results and Discussion 
The values of Cmax, tmax, AUC , 1. and tl/2, obtained from the serum 
~ 
data for Trial 1 and Trial 2, are presented in Table 5.4. 
In the 400mg single dose dispersion study (Trial I), the absorption of 
mephenoxalone was rapid, with peak blood concentrations occurring 40-
70 minutes (57 ~ 10 minutes) after ingestion of the dose. Peak 
concentrations ranged between 6.46 and 11.42~g/ml (8.24 ~ 1.58~g/ml). 
The AUC values for two of the subjects (KR, KD) were almost double 
~ 
the AUC va 1 ues for the other 4 subjects, suggest i ng that KR and KD 
~ 
either absorbed the administered dose to a greater extent or that they 
el iminated the parent drug more slowly than did the other subjects. 
Although the elimination half-life for KD was slightly longer than the 
average elimination half-life for the other four subjects, it is 
unlikely that this was the sole factor responsible for the high AUC 
~ 
value. Conversely, the elimination half-life for KR was 
significantly longer than the other tl/2 values, indicating that a 
slow rate of elimination may, indeed, be the major factor responsible 
for the high AUC value in this case. This subject had a large tl/2 
ro 
value and a high AUC value in both Trial 1 and Trial 2. 
ro 
TABLE 5.4 
TEST DOSE 
Mephenoxalone 
Dispersion 
(400mg) 
Mephenoxalone 
-conta i ning 
Tablets 
(2 x 200mg) 
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Bioavailability parameters for mephenoxalone dispersion 
and t ablet data. 
SUBJECT PARAMETERS 
t C AUC ).< t Y2 
max max '" (hrs) (~g/ml ) (~g/ml.hr) (hr-1 ) (hrs) 
WA 0.67 8.85 22.30 0.312 2.22 
OW 0.83 6.46 19.49 0.314 2.21 
MG 1.00 7. 66 27 . 00 0.312 2. 22 
KZ 1. 17 7.41 31.82 0.264 2.63 
KR 1.00 7.65 59.38 0.147 4.71 
KO 1.00 11.42 59 . 97 0.224 3. 09 
MEAN 0.95 8.24 36.66 0.262 2.85 
(SO) (0.16 ) (1.58 ) (16.72) (0.061) (0.89) 
WA 0.33 12 . 14 31.56 0.284 2.44 
DW 0.50 7.77 25 . 12 0.297 2.33 
MG 2.50 6.10 26 . 29 0.309 2.24 
K2 0.83 14.39 63.49 0.180 3.85 
KR 0.83 11.00 58.35 0.177 3.92 
MEAN 1.00 10 . 28 40.96 0.249 2. 96 
(SO) (0 . 78) (3.00) ( 16.52) (0 . 058) (0.76) 
MEAN 
excluding 
subj ect 
MG 0.70 11.33 44 . 63 0. 235 3. 14 
(SO) (0 .25 ) (2.39) (16.55 ) (0.056) (0.75) 
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Mephenoxalone is reported to be eliminated primarily by hepatic 
biotransformation; the major metabolites are the glucuronic acid 
conjugated forms of two hydroxylated derivatives (6). It may 
therefore be postulated that subject KR had a long elimination half-
life as a result of either a slow rate of conjugation or a slow rate 
of excretion of the biotransformation products. It is more likely 
that the former appl ies because the subject suffered from an 
hereditary pathological disorder. Gilberts' syndrome. which is 
characterized by reduced levels of glucuronyl transferase in the 
liver. 
In the 400mg single dose tablet study (Trial 2). peak serum 
concentrations occurred 20-50 minutes after ingestion of the dose in 
all but one of the subjects. The peak concentration for subject MG. 
occurred at 2.5 hours and was of a much lower concentration 
(6 .10~g/m 1) than the Cmax va 1 ues for the other subjects (11. 33 2:. 
2. 39fjg/ml) . Th i s discrepancy cannot be eas ily exp 1 a i ned as the same 
restrictions were practised prior to both trials. However. the trials 
were conducted 4 months apart and changes in the physical state of the 
subject cou 1 d have taken place . The s lower rate of absorpt i on from 
the tablets could also be attributed to the effect of codeine 
phosphate (which was included in the dosage form) on the gastro-
intestinal tract (GIT). Codeine is known to cause an increase in the 
muscle tone of the stomach and of the small and large intestines; this 
delays both gastric empty i ng and the passage of contents through the 
GIT (117). 
Excluding the results of MG. it was found that mephenoxalone was 
absorbed more rapidly from the tablet dosage form than from the 
d i spers i on; peak concentrat ions of mephenoxa lone were reached 10-20 
minutes earlier and ranged from 17 to 94 percent higher. A possible 
explanation for this phenomenon is that the dissolution of 
mephenoxalone from the tablet dosage form is superior to the 
dissolution from the dispersed dosage form dose. The results obtained 
in the in vitro dissolution testing of the dosage forms (Section 4. 3) 
support the in vivo resu lts. 
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The individual AUC values for each trial were compared in order to 
ro 
ascertain the relative bioavailability of the tablet dosage form with 
respect to the dispersed dosage form. Since it was not possible to 
determine the absolute systemic bioavailability of mephenoxalone 
because of the lack of i.v. data, the relative bioavailability, Frel, 
was calculated from the ratios of the AUC. values. The results are 
presented in Table 5.5. 
From the mean data, it appears that the tab 1 et dosage form has a 
greater b i oava i 1 abil ity, in terms of Fre 1, than the dispersed dosage 
form. However, the individual Frel values show that this was not true 
for two of the subjects (MG, KR), both of whom absorbed mephenoxalone 
to a simi 1 ar extent from both dosage forms. The Fre 1 resu lts for WA 
and OW are not easy to explain because the elimination half-lives of 
these subjects were of a similar magnitude for both of the trials. 
Subject KZ showed a significant increase in the extent of 
bioavailability for Trial 2 compared with Trial 1. However, the 
subject disclosed that in the period between trials she had severely 
restricted her dietary intake, which may have resulted in a decrease 
in metabolic rate; this would explain both the increase in the 
elimination half-life and the high AUC value for KZ . 
• 
Table 5.5 Relative bioavailability of tablet dosage form with 
respect to dispersed dosage form 
SUBJECT MEAN (SO) 
WA OW MG KZ KR 
Frel 1.41 1.29 0.97 1.99 0.97 1.33 (0.38) 
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From the semi logarithmic plots of the individual concentration-time 
data (F i g. 5.4), it was observed that the dec 1 ines in mephenoxa lone 
concentrations during the post-absorptive phases were generally mono-
exponential processes; biphasic elimination processes were observed in 
2 cases: WS (Trial 2), OW (Trial 2), but the initial phases were of 
extremely short duration. The terminal elimination rate constants 
were easy to determi ne because of the abundance of samp 1 es taken 
during the post-absorptive phase. However, very few data points were 
generally available during the absorption phases and it was therefore 
difficult to determine the values of the absorption rate constant, ka . 
However, in cases where 2 or more reliable data points were available, 
the ka va 1 ues were est imated us i ng the method of res i dua 1 s. The 
results are reported in Table 5.6, with the number of data points 
shown in parentheses. The ka values which were calculated using the 
Wagner-Nelson method (103) are also shown in Table 5.6, as are the 
pred i cted va 1 ues us ing NONLIN (inc 1 ud i ng those cases where va 1 ues 
cou 1 d not be ca 1 cu 1 ated us i ng either the method of res i dua 1 s or the 
Wagner-Nelson method). From these results, it appears that WA and DW 
absorbed mephenoxalone more rapidly from the tablet dosage form than 
from the dispersed dosage form. This finding correlates well with the 
va 1 ues of Cmax and tmax for these subjects. Us i ng the method of 
residuals and the Wagner-Nelson method , two ka values were calculated 
for MG in both trials; an in it ial slow rate of absorption was followed 
by a faster rate. This effect could not be explained. The ka values 
obta i ned for KZ i nd i cate that mephenoxa lone is absorbed more slowly 
from the tablets than from the dispersion; although this may be true 
in the ear ly stages of absorpt i on , peak concentrat ions were reached 
more rapidly and were higher for the tablet dosage form. It can also 
be seen that large variations exist in the ka values which are 
ca 1 cu 1 ated us i ng the different methods. These find i ngs demonstrate 
the inadequacy of using ka to describe the absorption of 
mephenoxalone after oral dosing. 
In contrast to the findings for ka, the results from statistical 
moment analysis of the data have a good correlation with the Cmax and 
tmax data . The statistical moment parameters for Trial 1 and Trial 2 
are shown in Table 5.7. The mean MAT values indicate that 
mephenoxa lone is rapi d ly absorbed from both the di spers i on and the 
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FIGURE 5.4 Semi logarithmic plots of serum concentration versus time 
after the ingestion of 400 mg mephenoxalone administered 
as (.) a dispersion, and (0) tablets. 
10.0 
5 . 0 
SUBJECT WA SUBJECT ow 
2.0 
, .0 
0.5 
0.2 
0., 
10.0 
5.0 
SUBJECT Me SUBJECT KZ 
2.0 
'.0 
0.5 
0.2 
0.' 
10.0 
5 . 0 
SUBJECT KR SUBJECT KO 
2.0 
, .0 
0.5 
0.2 
a.' 
-2 0 2 ~ 6 B 10 12 '4 16 18 20 22 2<4 -2 0 2 .. 6 8 10 12 14 16 18 20 22 24 
T 1 HE (HOURS) T 1 HE (HOURS) 
105 
TABLE 5.6 Values of ka(h-l) calculated using different methods 
SUBJECT METHOD OF RES IDUALS WAGNER-NELSON PREDICTED VALUES USING 
NONLIN 
IBCM 2BCM 
DISPERSI ON STUDY (TRIAL 1) 
WA 1.091 (2) 0.499 (2) 2.152 1.475 
OW 
-
(1) 3.177 (3) 3.000 2.314 
1.437 (2) 1.266 (2) 
MG 5.040 (3) 4.509 (3) 1. 307 1. 231 
KZ 1.293 (4) 1.157 (2) 1.053 0.679 
KR 1.273 (4) 1.082 (4) 1.452 1. 347 
KD 1.637 (3) 1.549 (3) 1.211 1.098 
MEAN (SO) 1.346 {0 . 182)a 1.445 {0.811)a 1.696 (0.679) 1. 357 (a. 495) 
TABLET STUOY (TRIAL 2) 
WA - (1) - (1) 5.930 4.708 
OW 
-
(I) 
-
(I) 4.777 3.459 
0. 433 (8) 0 .168 (7) 
MG 2.180 (3) 2.022 (3) 0.500 0.436 
KZ 0.324 (3) 0.331 (3) 1.145 0.695 
KR 3.093 (3) 3.112 (3) 1.295 1. 252 
MEAN (SO) 1.283 {1.280)a 1.204 {1.351)a 2.729 (2.190) 2.100 (1.680) 
a Mean values were calculated by excluding the second ka value for subject MG 
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tablets, wi th a more rapid absorption occurring from the latter. After 
ingestion of the tablets, subject MG displayed a significantly longer 
MAT than the other subjects. 
TABLE 5.7 
SUBJECT 
WA 
DW 
MG 
KZ 
KR 
KD 
MEAN (SO) 
Parameters obtained from statistical moment analysis 
of trial data 
PARAMETER 
MRT (hours) MAT (hours) MDTTablet 
Dispersion Tablet Dispersion Tablet 
3.58 3.54 D.38 0.02 -0.36 
3.38 3.56 0.20 0.19 -0.01 
3.71 4.78 0.50 1.15 0.65 
4.50 5.99 0.71 0.44 -0.27 
7.76 5.98 0.96 0.33 -0.63 
5.04 - 0.58 - -
4.66 (1.50) 4.77 (1.09 ) 0.55 (0.24) 0.43 (0.39) -0.12 (0.43) 
The mean (in vivo) dissolution time for the tablet dosage form was, on 
average, a negat i ve va 1 ue, whi ch shows that mephenoxa lone d i sso 1 ves 
more rapidly from the tablets than from the dispersion. An explanation 
for this phenomenon is provided in Section 4.3. From the values of the 
transit time for mephenoxalone through the body (MRT po). it can be 
seen that the mean values did not differ to any significant extent. 
However, within the individual values there were large inter-trial and 
intra-trial variations. The long transit times found for KR have 
already been explained in terms of her pathological disorder. It was, 
however, interest i ng to note that the MRT va 1 ue obta i ned for the 
tab 1 et study was shorter than the value obta i ned for the d i spers i on 
study. The tablets contained not only mephenoxalone but also 
paracetamol and codeine phosphate; both paracetamol (118) and codeine 
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phosphate (119) are extensively metabolized in the liver, with the 
major metabolites being their respective glucuronide derivatives. 
Administration of the tablets to a patient with reduced levels of 
glucuronyl transferase (i.e. KR ) could lead to saturation of the 
conjugation processes. This was not, however, found to be the case for 
KR who, conversely, showed a shorter elimination half-life and, 
consequently, a shorter transit time for the tablet study. This 
discrepancy can only be explained by individual variability. 
The longer transit time for KZ in Trial 2 can be partly explained by a 
longer elimination half-life. Subject MG also displayed a longer MRT 
value in the tablet study than in the dispersion study. This cannot 
be attributed to a longer elimination half-life because the t1/2 
values for Trial 1 and Trial 2 were of a similar magnitude. However, 
this subject absorbed mephenoxalone very slowly from the tablet dosage 
form and this may have caused an increase in the mean transit time of 
the drug through the body. A reduction in gastro-intestinal motility 
(effect of codeine) could also have contributed to a longer transit 
time for mephenoxalone after tablet ingestion. 
Computer fitting of t he data using NONLIN was performed by 
constra i n ing the va 1 ue of the termina 1 e 1 imi nat ion rate constant, 
while the other parameters were altered to try and find fits for each 
set of data. The serum data sets were fitted to both a 1BCM (Model A) 
and a 2BCM (Mode 1 B). The observed and pred i cted va 1 ues for the 
individual data sets, resulting from fits to both models, are listed 
in Tables AS.4 - AS .7, while the predicted parameter values are shown 
in Table A5.S. The observed values and predicted fits to the models 
for the mean data are graphically presented in Figs.5.S. The values of 
the correlation coefficient , r, used as an indication of the goodness 
of fit, for the mean dispersion data, were 0.969 and 0.971 for Model A 
and Model B, respectively. For the mean tablet data, a correlation 
coeffi c ient of 0. 961 was obta i ned for both mode 1 s. A lthough these 
figures are not indivative of poor fits, the absorption phase was 
poorly characterized, with an initial large over-estimation of 
concentration followed by an inability to attain the high peak 
concentrations. There was a more rounded peak and a longer time to 
reach maximum concentration. These effects are more clearly seen from 
FIGURE 5.5 
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Observed values ( .. ,0) and predicted fits (-) to the mean 
serum data after the ingestion of (a) a dispersion of 
mephenoxalone, and (b) mephenoxalone-containing tablets, 
using Model A and Model B. 
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FIGURE 5.6 Observed values (AI,,,) and predicted fits (-) to the 
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the fits for the individual data sets (Fig . 5.6) . Since the fits to 
Mode l A and Model B were extremely similar, only the fit to Model A 
were plotted . The predicted fits of the data in the terminal phases 
were genera lly good, but the pred icted fi ts in the absorpt i on phases 
were poor, thus showing the i nadequacy of using a single ka value to 
describe the absorption process. The use of a model which can 
accommodate two or more absorpt i on rate constants may produce better 
fits, but was not investigated in this study . 
The difficulties experienced in characterizing the fast absorption 
phase are not un i que to mephenoxa lone. Numerous stud i es have been 
reported on drugs which exhibit extremely rapid absorption profiles 
after oral administration (120-125) . In most cases the data were 
fitted to compartmental models in order to obtain an estimate for the 
absorption rate constant, ka (120-123). Only one of these studies 
reported using the "stripping" method of Wagner to determine ka (12). 
Si efert et a I (125) conducted a study of the pharmacokinetics of 
ciprofloxacin in rats and monkeys and characterized absorption as the 
time needed for an increase in plasma concentration from 25 to 75 
percent of the maximum concentration. In a clinical study to evaluate 
the pharmacokinetic profile of pyrazinamide, Bareggi et al. (122) 
analyzed to plasma concentration-time date by computer fitting of the 
exper i mental values to various compartment models . However, 
absorption of the drug was found to be extremely rapid such that i n 
several subjects comput i ng the rate of absorption was impossible, and 
on ly Cmax and tmax data were t her efore used . In all of the above-
mentioned studies, Cmax and tmax data were used to express the 
absorption profiles and in t his study, these parameters together with 
stat i stica 1 moment parameters provided the best means of assess ing 
mephenoxalone absorption . 
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CHAPTER SIX 
THERMOSPRAY HPLC-MS OF MEPHENOXALONE AND ITS METABOLITES 
6. 1 INTRODUCTION 
The combination of high-performance liquid chromatography (HPLC) with 
mass spectrometry (MS) provides a powerful analytical method, 
combining the benefits of two well-established and complementary 
techniques. Liquid chromatography (LC) achieves separation of the 
sample into its components and the mass spectrometer, unlike the more 
common HPLC detectors e.g. UV detectors, can be operated either as a 
universal detector or as a very selective detector (126-129). 
The LC-MS systems adopted in the past have been mainly off-l ine 
systems. These involve a non-continuous process in which an 
intermediate sample-collection step is required prior to MS analysis. 
Off- 1 ine methods have, however, been large ly superseded by on-l ine 
techniques in which the LC eluent is transferred directly to the mass 
spectrometer via an interfacing device. The direct coupl ing of the 
two systems offers a more convenient means of analyzing multi-
component mixtures; there is a reduced danger of sample losses, a more 
precise quantitative analysis is achieved, and partially resolved 
chromatographic peaks can be deconvoluted by taking advantage of the 
high selectivity of the mass spectrometer (128, 130). 
On-line LC-MS operation, however, involves the coupling of two highly 
incompatible disciplines; mass spectrometry requires both a high 
vacuum and the ion i zat i on of mo lecu 1 ar spec ies in the gas phase, 
whereas LC operates under high pressure and is intended for the 
analysis of substances not volatile enough to be handled by gas 
chromatography (GC). The developments and approaches aimed at 
overcoming the difficulties of interfacing LC and MS have been amply 
reviewed (127, 130, 131). The interfaces which are commercially 
available include mechanical transport devices and direct introduction 
methods, both of which have been successfully applied to a wide range 
of analyses. The moving belt is the most popular mechanical transport 
dev i ce wh il e direct i ntroduct i on methods such as the diaphragm-type 
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interface (commonly called direct liquid introduction), electrospray 
and thermospray are also widely employed. 
The progress made in overcoming the difficulty of coupling LC to MS 
has been accompanied by the development of new, more gentle ionization 
techniques which produce ions characteristic of the molecular mass (M) 
(132). These ionization modes include field desorption (133), laser 
desorption (134), secondary ion mass spectrometry (135), electro-
hydrodynamic ionization (136), fast atom bombardment (137), liquid ion 
evaporation (138) and thermospray (139). The majority of these are, 
however, used exclusively in off-line LC-MS systems. An exception is 
thermospray (TSP) ionization which was principally designed as an on-
line system by Vestal and co-workers (139-142). The advantages of this 
technique over other coupling methods include its ability to handle 
conventional LC flow rates, mild ionization conditions, the capacity 
to use volatile ionic modifiers and high percentages of water in LC 
solvents, and the ease with which the interface can be adapted to fit 
existing GC-MS instruments. Most other LC-MS interfaces cannot 
accommodate either conventional HPLC flow rates or eluents with a high 
water content. The mechanism of TSP ionization has been investigated 
but is not yet fully understood (140, 143-146) . 
The versatility of the TSP technique is reflected not only by its 
potential for analyzing polar, non-volatile and thermally labile 
compounds but also by its suitability for the determination of 
volatile compounds (147), neutral analytes (146) and for in situ 
degradation studies (148). TSP HPLC-MS has been applied to the 
qualitative and quantitative analysis of numerous compounds of 
environmental, biological and pharmaceutical importance including dyes 
(149), pesticides and herbicides (150, 151), mycotoxins (152), 
peptides (153), phosphol ipids (154), glucuronides (129), B -lactam 
antibiotics (148), several drugs and their metabolites in biological 
fluids (155), and other compounds of pharmaceutical interest (156) . 
The role of LC-MS in the analysis of pharmaceuticals has been 
identified by Erni (157) . Table 6.1 depicts the areas of application 
that were highlighted in the report; the primary goals of the 
technique are to obtain structural information, to identify substances 
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and to enable the selective , sensitive detection of compounds of 
interest. 
TABLE U Applications of LC-MS in the pharmaceutical industry 
By-products 
Degradation products 
Bio-assays 
Metabolism 
Screening 
identification 
quantification of trace compounds 
of drug substances in the dosage 
form 
quantification of special 
compounds 
plasma 
urine 
other biological materials 
identification 
stable isotopes 
The application of TSP HPLC-MS to the identification of mephenoxalone 
metabol ites is presented below. 
precedes the experimental study. 
5.2 THEORY OF THERMOSPRAY 
A review of thermospray theory 
5.2.1 Mechanism of Thermospray Ionization 
Thermospray is defined as the controlled, partial or complete 
vaporization of a liquid as it flows through a heated capillary (139, 
140) . The capillary is located in a probe which serves as a vehicle 
for introducing the sample into the ion source of the mass 
spectrometer. A schematic diagram of a typical TSP interface and ion 
source is shown in Fig.5.1 . 
TSP ionization of a compound may occur in two different ways, namely, 
direct (filament-off) ionization and external (filament-on) 
ionization (139). Both require the presence of an electrolyte in the 
HPLC mobile phase. The term "direct" ionization refers to the 
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generation of ions directly from the buffered mobile phase without the 
assistance of an external source of energy (140, 143, 146) . As the LC 
effluent flows into the heated capillary, a high proportion is 
vaporized to produce a superheated mist carried in a jet of vapour. 
Non-volatile molecules are preferentially retained in the mist 
droplets and in the presence of the electrolyte, the statistical 
distribution of charge ensures that each droplet carries a sl ight 
excess of positive or negative charge . The charge density increases 
as the droplets continue to vaporize and shrink and sample molecules 
held in these droplets are often ionized (as in regular chemical 
ionization). The electric fields generated by the charge on the 
droplets are sufficient to cause evaporation of sample ions together 
with a few solvent molecules. Ion-molecule reactions may subsequently 
occur in the gas phase if exothermic channels are available. Finally, 
the ions are transported to the mass analyzer and a spectrum is 
generated. 
FIGURE 6.1 Thermospray ion source 
Adapted from Goodley P.C. (145). 
TSP PROElE-)~\-~=~ 
FROM LC 
ELECTRON ENTRANCE 
ELECTRON 
FILAMENT 
ION EXIT 
j 
TO COLO TRAP 
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The fi 1 ament-on mode ut il i zes a source of high energy electrons to 
promote the format i on of chemi ca 1 ion i zat ion reagent ions from the 
solvent molecules (140, 143-145). These, in turn, ionize the sample 
molecules. The method of ionization chosen for an analysis depends on 
the sample and on the type of information required (145). The direct 
ionization mode appears to be applicable only to polar compounds or to 
pre-formed ions in solution. For non-polar compounds and most medium 
polarity substances, an external source of electrons is necessary to 
produce sample-derived ions. Each mode provides a variant of the 
chemical ionization process but much less energy is transferred to the 
ions in the direct mode as compared to the fi 1 ament-on techn i que 
(144) . Both processes result in the production of very few fragment 
ions of the analyte molecules; the ammoniated or protonated molecular 
adduct ions are the most common products (150). 
Optimization of TSP Operating Parameters 
The sensitivity of an analysis and the quality of the spectra obtained 
by TSP HPLC-MS have been demonstrated to be dependent on several 
operating parameters, the most important being vaporizer probe 
temperature, solvent composition and the use of a high energy filament 
(145, 150, 158). Optimization of these factors will greatly enhance 
the sensitivity of the TSP technique and extend its range of 
application. 
6.2.2.1 Vaporizer Probe Temperature 
The TSP ionization process is dependent on temperature; maximum 
analyte ion abundance is always obtained at a temperature which allows 
almost complete vaporization of the LC effluent as it flows through 
the probe. Optimum probe temperature can be ascertained by various 
methods (144, 145, 150). By measuring sample ion abundance at 
different probe temperatures, an optimum response temperature can be 
determined. Alternatively, solvent ions, rather than solute ions, can 
be used in a similar manner. This is because all ions have a maximum 
abundance in the same narrow temperature range . A th ird method is 
based on measuring the temperature change of the LC eluate at the 
probe exit as the probe stem is progressively heated. Figure 6. 2 
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depicts the temperature change as the LC effluent flows through the 
cap ill ary . A computer program is ut i 1 i zed to generate a hard copy 
plot of the vaporizer tip temperature versus the stem temperature, as 
depicted in Fig.6.3(b). The plot is called a probe survey scan or 
vaporizer plot. From this, the temperature at which the liquid/vapour 
mixture at the probe exit changes to 100% vapour can be ascertained. 
The phase change is i nd i cated by a steep change in the slope of the 
plot, referred to as the inflection point. A stem temperature of 90 
to 95% of the inflection point value gives the greatest sensitivity in 
terms of ion abundance, as shown in Fig.6.3(a). 
FIGURE 6.2 
VAPOOIz.i,.TIOtoi 
Fluid temperature in a TSP probe 
Reprinted from H.P 5998A Thermospray User's 
Manual (144). 
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The optimum probe temperature for analysis varies according to the 
composition of the mobile phase (145, 150, 159) . As the water content 
increases, the heat of vaporization increases and higher temperatures 
are requ i red to ach i eve maximum i on format ion . A new probe survey 
scan must therefore be conducted for each different LC solvent 
employed. 
FIGURE 6.3 
6. 2. 2. 2 
118 
(a) Signal abundance of an arbitrary ion (m/z 422 
[M + HJ+) versus vaporizer stem temperature ; 
tip temperature versus stem temperature 
inflection point . 
Reprinted from Goodley P.C. (145). 
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The use of an external source of high energy electrons to enhance TSP 
sensitivity has been previously ment ioned. Electrons from the 
filament penetrate into the vapour chamber and assist in the formation 
of reagent ions from the buffered mobile phase. The abundance of 
analyte ions for the filament-on mode always exceeds that obtained for 
the filament-off mode and, therefore, the use of a filament is 
advocated in cases where maximum sensitivity is required. It is also 
recommended in cases where a high proportion of organic solvent is 
employed in the LC mobile phase (this effect is discussed in Section 
6.2.2.3) . 
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6.2.2 . 3 Solvent Composition 
Thermospray operation requires the presence of a volatile buffer in 
the HPLC solvent (150) . The mobile phase must, therefore, readily 
dissolve the buffer. Solvents such as acetonitrile in water and 
methanol in water comply with this requirement. Methanol, however, 
provides greater sensitivity in terms of ion abundance than 
acetonitri le because of the proton affinity differences between the 
two solvents (145) . 
It is well known that TSP sensitivity is enhanced as the proportion of 
buffer in the LC effluent is increased (145). In cases where it is 
mandatory to use a high percentage of organic solvent, the subsequent 
reduction in ion abundance (i . e . sensitivity) can be minimized by 
operating the TSP-MS in the filament-on mode . 
The sensitivity of TSP analysis and the characteristics of a TSP 
spectrum are influenced by both the type of buffer and the 
concentration of buffer used in the mobile phase (150, 158) . Although 
the information content of a spectrum does not appear to be 
significantly altered by the type of buffer utilized, an ammonium 
acetate buffer has been shown to provide the greatest sensitivity. It 
provides the best results when used at a O.lM concentration . 
6.3 STUDY OBJECTIVES 
The purpose of this study was to determine the molecular masses of 
the t wo metabolites of mephenoxalone that were present in extracts of 
human urine samples using combined HPLC - MS under TSP ionizing 
conditions. The filament - on mode was employed for more efficient 
ionization . The use of a reverse-phase column enabled both the rapid 
analysis of the urine extracts and the resolution of mephenoxa l one and 
the t wo met abo 1 ites. The TSP spectra that were generated permitted 
not only the determination of molecular masses but also enabled a 
disti nction to be made between conjugated and unconjugated 
metabo 1 ites. 
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6.4 THERMOSPRAY ANALYSIS OF MEPHENOXALONE AND ITS METABOLITES 
The human biotransformation products of mephenoxalone have been 
identified by Morrison (6) and by Eckhardt et al. (28) and are 
depicted in Fig.l.2. Morrison isolated four transformation products, 
Metabolites IlIa, Illb and their glucuronic acid conjugates, using a 
countercurrent d i stri but i on procedure. The i dent it i es of the free 
phenol ic compounds were establ ished by paper chromatographic 
techniques, while the conjugates were subjected to enzymatic cleavage 
and acid hydrolysis prior to chromatographic analysis. Eckhardt et al. 
(28) isolated numerous metabolites by a series of acidic, basic and 
neutral chloroformic extractions of urine. Of the recovered 
compounds, Metabolites I and II were identified by thin layer 
chromatography (TLC) . Five other metabol ites were ascertained to be 
conjugated derivatives; their free form structures (Metabo l ites III, 
IV, V, VI and VII) were identified after acid and enzyme hydrolysis of 
urine followed by extraction and TLC analysis. 
Uri ne samp 1 es that were co 11 ected from human subjects after ora 1 
administration of mephenoxalone and subsequently analyzed according to 
Section 3.6.1 . 3 revealed the presence of two UV-absorbing metabolites. 
Their ultraviolet spectra (Fig.6 .4) were determined using an HP 1040A 
photodiode array detector placed in-line with the HPLC system. The 
spectra of the metabolites show absorption maxima similar to those of 
the parent drug . From these spectra, however, it was not poss i b 1 e to 
ascertain whether or not these metabolites were conjugates because the 
conjugating moiety (glucuronic acid) has no effect on the 
characteristics of the absorption spectrum (160). It was, however, 
possible to determine the molecular mass of each compound using 
thermospray analysis, thereby enabling a distinction to be made 
between conjugated and non-conjugated metabolites. 
The use of the thermospray technique for the analysis of several drugs 
(and their metabolites) in biological fluids has been reported (155). 
Data were acqui red in the scan mode and the molecular masses of the 
compounds were thus determined. The TSP spectra generated were simp le 
and few fragment ions were observed. 
FIGURE 6.4 
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Three-d imens iona 1 "spectrochromatogram" (absorbance versus 
wavelength versus time) showing a urine extract (Section 
6.4.1.2) conta ining Metabol i tes IIIa1 and IIIb2 , 
mephenoxalone3 and phenacetin4 
Chromatographic conditions 
Injection volume 
Bandwidth at sample wavelength (200nm) 
Bandwidth at r eference wavelength (320nm) 
Scan rate 
Viewed at an angle of 350 J from the left. 
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as in Section 
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Data acqu is i t i on modes offered by the TSP system ut i 1 i zed in th i s 
study comprise both a scan mode and a selected ion monitoring (SIM) 
mode . For quantitative purposes, SIM is preferable because of the 
enhanced sensitivity and selectivity that this acquisition process 
affords (126). Qualitative analysis, however, is routinely 
accomplished by repetitive mass scanning over a range of molecular 
masses. A total ion count (TIC) chromatogram is then generated by 
summation of all the ions in each mass spectrum. The identification 
of a compound is achieved by examining the mass spectrum at the time 
corresponding to the top region of the chromatographic peak. To 
confirm the presence of the ions observed in this spectrum, a 
reconstructed mass (ion) chromatogram can be generated, after the LC 
run, by means of computer reconstruction methods. 
In this study, positive ion spectra were obtained using the filament-
on mode, and mephenoxalone and its metabolites were separated by 
isocratic elution using a buffered mobile phase. TIC chromatograms 
were generated by scanning a suitable mass range and the spectrum of 
each compound was subsequently obtained using computer reconstruction 
methods. Prior to the analysis, verification of TSP operating 
conditions and optimization of parameters was necessary. 
6.4.1 Materials and Apparatus 
6.4.1.1 Materials 
Mephenoxalone (experimental powder batch) was supplied by Adcock-
Ingram Laboratories Ltd., Johannesburg, South Africa. 
Analytical grade ammonium acetate (Saarchem (Pty) Ltd, Muldersdrift, 
South Africa) was obta i ned commercially. 
Methanol and acetonitrile (Burdick and Jackson Laboratories, Muskegon, 
Mich., USA) were distilled-in-glass grade. HPLC-grade water was 
prepared as in Section 2. 3.1. 
TSP ionization reagent (part number 8500-4410) and polypropylene 
glycol (part number 8500-4409) were supplied by Hewlett-Packard 
Co. Palo Alto, Cal . , USA. 
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6.4.1.2 Source of Biological Samples 
Urine collected six hours after oral administration of 400mg 
mephenoxalone dispersed in 150ml water to a human volunteer (as in 
Section 5.1.1) was stored at -20oC until required. It was thawed at 
room temperature prior to use. 
6.4.1.3 Apparatus 
The TSP HPLC-MS system used throughout this study is depicted in 
Fig.6.S. Data acquisition and processing was performed using the 
Chemstation data system provided by Hewlett-Packard. 
6.4 . 2 Experimental 
6.4.2.1 Sample Preparation 
Mephenoxalone stock solution (lmg/ml) was prepared as in Section 
3.4.1.1. This solution was diluted 1 in 50 with water to produce a 
0.02mg/ml solution. 
Ionization solution (O.lM ammonium acetate) was prepared by mixing 
490ml of water with 2 ampoules of TSP ionization reagent. 
Human urine samples (see Section 6.4.1.2) were extracted as in Section 
3.6.1.3. 
6.4.2.2 TSP HPLC-MS Conditions 
TSP HPLC-MS system As in Section 6.4.1.3. 
Mass Spectrometer Operating Conditions: 
Mass filter quadrupole type 
Ionization mode filament-on 
Ionization energy 2100 eV 
Ion source temperature 2700C 
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Analyzer manifold pressure 2 x 10-6 Torr 
Low vacuum pump pressures Tel ; 0.1 Torr 
TC2 ; 0.7 Torr 
Data acquisition mode scan 
Mass ca 1 i brat i on and tuni ng were ach ieved through the data system 
using the TSP Tune file called TXTUN1.U., a pre-programmed instruction 
on the Chemstation data system. 
HPLC Operating Conditions: 
Temperature 
Mobile phase flow rate 
ambient 
1.0ml/min 
The mobile phases used for this study were as follows: 
Eluent A. 
Eluent B. 
Eluent C. 
Probe survey solution 
Standard tuning solution 
Acetonitrile - O.lM ammonium acetate (35/65) 
Mobile Phase Preparation 
Eluent A was prepared by mlxlng 375ml ionization solution (Section 
6.4.2.1) with 125ml methanol . 
Eluent B was prepared by mixing 375ml HPLC-grade water, 115ml 
methanol, 2 ampoules of ionization reagent and 1 ampoule of 
polypropylene glycol. 
Eluent C was prepared by mixing 175ml acetonitrile with 325ml O.lM 
ammonium acetate buffer. 
No corrections were made for volume changes which occurred upon 
mix i ng. The so 1 vent mi xtures were degassed and filtered through a 
0.45~m filter (Type HVLP, Millipore Corp., Bedford, Mass . , USA) prior 
to use. 
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FIGURE 6.5 TSP HPLC-MS system 
(1) Model 112 solvent delivery system (Beckman Instruments, Inc., 
San Ramon, Cal., USA) 
(2) Model 3XL soft seal injector equipped with a 10ul loop 
(Scientific Systems, Inc., Philadelphia, Pa., USA) 
(3) C18 reverse-phase Sum column (as in Section 2.5.2.2) 
(4) Model 5988A mass spectrometer (Hewlett-Packard Co" Palo Alto, 
. Cal., USA) interfaced to the HPLC system 
(5) Standard Hewlett-Packard thermospray interface (Option 015) 
(6) Standard computer hardware (Hewlett-Packard Co., Palo Alto, 
Cal., USA). 
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6.4.2.3 Thermospray Verification 
After sett i ng up the LC-MS system accord i ng to the manufacturer's 
instructions, it was necessary to verify that the system was operating 
correctly . An isocratic probe survey using Eluent A was performed. 
The 95 percent vapori zat i on temperature was ca 1 cu 1 ated and recorded. 
The thermos pray system was then tuned in the positive ion, filament-
on, extended 
temperature. 
mass range mode using Eluent B and the optimum control 
The tune report was automatically generated. 
6.4 .2.4 TSP Analysis of Mephenoxalone and its Metabolites 
Using Eluent C a probe survey was conducted, starting at a stem 
temperature of 1000C and ending at 1300C, at a rate of 30e increase 
per minute. The 95 percent vaporization temperature was then 
calculated and this value was employed as the stem temperature 
setpoint for all further TSP analyses. 
To determine the sensitivity of the TSP technique for the analysis of 
mephenoxalone, 10~1 aliquots containing 10~g mephenoxalone (in water) 
were injected onto the column. Data were initially acquired by 
scanning across a mass range of 3 to 350amu. A sample containing 
200ng of mephenoxalone was then injected. The mass range was then 
reduced so as to scan from 200 to 250 amu and the samples were re-
injected . 
Urine samples, extracted according to Section 3.6.1.3, were analyzed 
by injecting 10fll aliquots of the extracts into the HPLC-MS system. 
Data were acquired by scanning the following mass ranges: 
3 to 275amu 
150 to 220amu 
220 to 265amu 
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6.4.3 Results and Discussion 
6.4 . 3.1 Verification of Correct TSP Operation 
No interpretation is required of the TSP tune results (144). If a 
report is generated, the system has passed the TSP tune and is ready 
to run samp 1 es. However, it is usefu 1 to compare the report to 
previous tune reports so that developing problems can be ascertained. 
Severa 1 spec ifi cat ions for the resu lts of the report have been 1 aid 
down; the three ions (m/z 268.1, 442.6 and 558.6) should have relative 
abundances of >20%, 100% and >20%, respectively, with an abundance for 
m/z 442.3 of over 6000. In addition the peaks should be evenly spaced 
in the spectrum. The tune report generated us i ng a probe stem 
setpoint of 1200C (obtained from the probe survey scan) is depicted in 
Tab 1 e A6.1. It shows even ly spaced peaks and comp 1 ies with a 11 the 
specifications except for that concerning the abundance of the m/z 
442.6 ion. However, this had no serious implications. 
6.4.3.2 Choice of Mobile Phase 
An ammonium acetate buffer (O.lM) was adopted for this study for the 
reasons previously discussed (Section 6. 2.2.3). A preliminary 
investigation using HPLC with UV detection was conducted to determine 
how the elution profile of mephenoxalone and its metabolites would be 
affected by the addition of this buffer to the mobile phase. 
Ultraviolet detection at 220nm was employed because this represents a 
wavelength of maximum absorbance for mephenoxalone and the two 
metabo 1 ites without interference from the buffer . The mobile phase 
used was acetonitrile-0.1M ammonium acetate buffer (35/65). The 
chromatogram obtained from a urine extract using this phase was 
compared to a chromatogram obta i ned from the same extract us i ng a 
mobile phase consisting of acetonitrile-water in the same proportions . 
It was found that the retention times were unaltered by the presence 
of buffer and this mobile phase was therefore adopted for TSP analysis 
of mephenoxalone. 
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6.4. 3.3 Probe Survey Results 
Figure 6.6 shows the probe survey plot obtained using an acetonitrile-
O.lM ammonium acetate (35/65) mobile phase . The inflection point 
(100% vaporization temperature) occurred at 1190C and the optimum stem 
setpoint (95% vaporization temperature) was therefore 1120C. 
FIGURE 6. 6 Probe survey plot using an acetonitrile-0.1M ammonium 
acetate (35/65) mobile phase 
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6.4 . 3.4 TSP Spectrum of Aqueous Mephenoxalone 
The TIC trace obtained by full mass scanning from 3 to 350amu of a 
1 OfJ 1 inject i on conta i n i ng lOfJg mephenoxa lone in water was devo i d of 
any read i ly identifiable peak (Fig.6 . ?). A high solvent ion abundance 
was evident and the baseline fluctuations were large . The poor 
qua 1 ity of the acquired chromatogram was attributed to several 
factor s. The regu lar osc ill at ions in background i ntens i ty were the 
res ult of flow fluctuations introduced by the HPLC pump. This effect 
has been previously reported in the literature and should be avoided 
as far as possible by using a constant-flow pumping mechanism. It is 
known that the mass scan range must often be limited to a small range 
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in order to increase the scanning rate and thereby enhance the 
sensitivity of the analysis (146, 155) . Useful mass spectra below m/z 
150 are often difficult to obtain even with the aid of computer 
background subtraction methods. The detection limit of an analysis is 
therefore enhanced by both reducing the range of masses scanned (with 
scann i ng above m/z 150 wherever poss i b 1 e) and us ing an LC de 1 i very 
system which provides minimal flow fluctuations. 
FIGURE 6.? TIC trace obtained by full mass scanning from 3 to 350amu 
of a 10~1 injection containing 10~g mephenoxalone in water . 
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Despite the lack of a mephenoxalone peak in the TIC (Fig.6.?), a mass 
spectrum of the compound was generated with the aid of computer 
reconstruction methodsi a specific mass ion chromatogram of an 
expected ion m/z 241 (the molecular mass of ammoniated mephenoxalone) 
was generated (Fig.6.8) and, using the retention time of this ion, a 
mass spectrum was obta ined from the correspond i ng time on the TIC. 
However, the high abundance of solvent ions necessitated the use of a 
computer background subtraction technique to generate the final mass 
spectrum of mephenoxalone (Fig.6.9). The primary ions observed are 
the [M + H]+ ion and the [M + NH4]+ ion, with masses of 224 and 
241amu, respectively. The base peak comprised the ammoniated ion . 
! 
I 
I 
I 
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FIGURE 6.8 Reconstructed ion range (m/z 241.0-241.9) chromatogram 
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FIGURE 6.9 Subtracted mass spectrum of mephenoxalone 
Average of 5.054 to 5.425 m1n. 
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The above procedure was 1 aborious and an a lternat i ve approach for 
generating spectra , using a smaller scanning range, was investigated. 
A markedly improved TIC trace was thereby obtained. By re-injecting 
the 10~g aqueous mephenoxalone sample and scanning from 200 to 250 
amu, a distinct peak was observed in the TIC trace (Fig.6.10). The 
mass spectrum, taken at the top of the chromatographic peak, is shown 
in Fig.6.11. The ammoniated and protonated molecular adduct ions are 
formed, as are ions corresponding to m/z 242 and 243. 
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FIGURE 6.10 TIC trace obtained by mass scanning from 200 to 250amu of a 
10~1 injection containing 10~g mephenoxalone in water 
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FIGURE 6.11 Mass spectrum of mephenoxalone 
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A 10~1 aqueous injection containing 200ng mephenoxalone was injected 
to determine the feasibility of using TSP for analyzing the low levels 
of the drug found in biological fluids. The TIC trace (Fig.6 . 12) 
shows that mephenoxalone can be detected at this level despite the 
high background noise. Figure 6.13 depicts the mass spectrum, which 
had to be acquired by computer background subtraction because of the 
effect of pump-induced flow fluctuations. The oscillations in 
background noise made it difficult to distinguish between solvent ions 
and sample ions in a spectrum taken directly from the TIC 
132 
chromatogram, and a subtracted spectrum was therefore obtained by 
subtracting an average spectrum of background ions from an average 
spectrum of the chromatograph i c peak, both spectra bei ng taken over 
the peak of interest. The subtracted spectrum clearly shows the m/z 
241 and 242 ions. An m/z 222 ([M - H]+) ion was also observed but no 
protonated samp le mo 1 ecu 1 e (m/z 224 )was seen. It appears that a 
concentration-dependent phenomenon exists, where protonation does not 
occur at low concentrations of mephenoxalone. 
FIGURE 6.12 TIC trace obtained by mass scanning from 200 to 250amu of a 
10~1 injection containing 200ng mephenoxalone in water 
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TSP Spectra of Mephenoxalone and its Metabolites in Human 
Urine 
A model LC-UV detector (pye Unicam Ltd., Cambridge, England), was 
employed in line with the TSP system. Figure 6.14 shows the UV 
chromatogram for the separation of the parent drug from its 
metabolites after a 10~1 injection of a human urine extract, while the 
TSP HPLC-MS TIC trace (obtained at the same time using a scan range 
from m/z 220 to 260) is shown in Fig.6.15. Both the UV and the TSP 
traces revealed the presence of 3 sample components, with retention 
times of 3.4, 4.3 and 5.3 minutes. The first two compounds to be 
eluted were later identified as Metabolite IlIa and Metabolite IIIb, 
respectively. 
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FIGURE 6 . 14 UV chromatogram showing a urine extract (section 6 . 4.1 . 2) 
containing Metabolites IIIa1 and IIIb2 , and mephenoxalone3 
(chromatographic conditions as i n Section 2 . 4 . 2; 10~1 
injection volume) 
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The subtracted average mass spectrum of Metabolite IlIa (Fig.6.16(a)) 
reveals the presence of ions of mass 242, 257 and 258amu. The 242amu 
ions are not significantly abundant . The only possible metabolite 
that these ions can be derived from is Metabolite IlIa in its 
unconjugated form. If the metabo 1 ite was a conjugated derivative 
which had been fragmented by TSP to produce the above ions, then 
glucuronic acid fragments would also have been present. However, data 
acquired from a mass scan range of 150 to 200amu showed that no ions 
of mass 176 or 194amu were present (these ions would represent the 
glucuronide fragment and its ammoniated derivative, respectively). 
FIGURE 6. 15 TIC trace obtained by mass scanning from 220 to 260amu of 
10ul inject of a urine extract containing Metabolite IlIa, 
Metabolite IIIb2, and mephenoxalone 3. 
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The average mass spectrum of Metabolite Illb is shown in Fig.6.16(b). 
Ions with masses of 239, 240, 257 and 258amu, corresponding to [MJ+, 
[M + 1J+, [M + 18J+ and [M + 19J+, respectively, are formed. 
Metabolite Illb was confirmed as being the free phenolic derivative as 
described earlier . 
The mass spectrum of mephenoxalone isolated from urine (Fig.6 . 16(c)) 
shows the same ionization products as those formed after TSP analysis 
of 200ng of the drug in water . Both Metabolites IlIa and IIIb produce 
spectral base peaks at m/z 257. These ions correspond to the 
ammoniated derivative of the unconjugated phenolic metabolites. 
However, there is a difference between the spectra of the two 
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FIGURE 6. 16 Subtracted mass spectra of Metabolites IIIa(l) and IIIb(2), 
and mephenoxalone (3) 
Average of 3.246 to 3.699 m1 n. (1 ) 
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6.5 CONCLUSIONS 
The molecular masses of the two mephenoxalone metabol ites that were 
extracted from urine were examined by TSP HPLC-MS . A mobile phase of 
acetonitrile - O.IM ammonium acetate buffer provided adequate 
resolution between the 3 peaks of interest, and chromatographic 
integrity was unaffected by the TSP interface. 
The metabo 1 i tes were ascerta i ned to be un conjugated pheno 1 s, each of 
molecular mass 239amu. These results are in good agreement with the 
metabolite data published by Morrison (6). The thermospray spectra of 
mephenoxalone and its biotransformation products were relatively 
simple, consisting primarily of an [M + NH4J+ ion peak. The lack of 
fragment ions made structural elucidation impossible, thereby 
preventing the assignment of ring positions to the hydroxyl groups of 
the metabo 1 i tes . Since the ammoni ated ions were the base peaks, the 
ana lyte molecular ions would appear to react more favourably with 
ammonia than with water (140, 152). 
In this study, two metabolites were extracted by liquid-liquid 
extraction of human urine samples. It has been reported that 
conjugates are not amenable to solvent extraction (56) and this 
confirms earlier findings that the metabolites present in the urine 
extracts were unconjugated. The difference in molecular mass between 
the metabolites and mephenoxalone was 16amu, which was ascertained to 
be the result of hydroxylation of the parent compound. The phenol ic 
isomers thereby produced would be weakly acidic and, therefore , would 
not be extracted into an organic phase under alkal ine conditions as 
was reported by Morrison (6) . 
As a detector for the HPLC ana lys i s of drugs, the mass spectrometer 
has enormous potent ia 1. TSP is we 11 su ited to the ana lys i s of 
biological fluids provided that the system is operated under optimum 
conditions. The spectra generated in this study were of the required 
quality for the molecular mass determinations but could have been 
improved by utilizing a solvent delivery system having better flow 
contro 1. 
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metabolites in that IIIb forms the [M]+ and [M + H]+ ions, whereas 
II I a does not. Th ismay be the resu It of 
the latter . 
the greater relative 
abundance 
dependent 
of the former compared to This concentration-
ionization 
the ions formed upon 
effect has already been discussed. A summary of 
TSP HPLC-MS of mephenoxalone and its metabolites 
is presented in Table 6.2. 
TABLE 6.2. Summary of results obtained by TSP analysis 
of mephenoxalone and its metabolites. 
COLUMN LOAD TIC PEAKS COMPONENTS MOLECULAR SEPCTRAl 
PER INJECTION (RETENTION MASS m/a IONS 
VOLUME TIME IN 
MINUTES) 
Aqueous 10pg/l0~1 Mephenoxalcne 233 224 
mephenoxalone (5.3) 241* 
242 
243 
Aqueous 200ng/IO",1 Mephenoxalone 223 241* 
mephenoxa lone (5.3) 242 
, b c 
Urine extract 10~1 3 1. Metabolite IlIa 239 257* 
(3.4) 258 
C 
2. Metabolite II Ib 239 239 
(4.3) 240 
257* 
258 
3. MephenoxaJone 233 241* 
(5.3) 242 
* Most abundant ion (Sase peak) 
PROPOSED STRUCTURE 
+ 
[M + H] 
[M + NH J+ 
(M + NH! + 1]+ 
(M + NH4 + 2J+ 
[J.1 + NH ]+ 
[M + NH! + 11+ 
[M + NH ]+. 
[M + Nil! + 1]+ 
[M]+ 
[M + H)+ 
[M + NH )+ 
[M + NH:+1]+ 
+ 
(M+NHJ 
[M + NH! + 1] + 
a Urine collected from subject OW after oral administration of mephenoxa lone (Section 5.1.1.7) 
b Exact column load unknown because no pure metabolites were available for Quantification 
c Proposed structures of Metabolites are shown in Fig.1.2 
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CHAPTER SEVEN 
CONCLUSION 
There is a severe 1 ack of pharmacok i net i c studi es on mephenoxa lone 
reported in the 1 iterature, poss i b ly due to the 1 ack of a rapi d, 
sensitive, precise analytical method for the determination of the drug 
in biological fluids . The method which was developed during the 
course of this study was found to be readily applicable to 
pharmacokinetic studies in humans. The drug was extracted from serum 
and urine using simple liquid-liquid extraction procedures, and the 
concentrations were subsequently determined by reverse-phase HPLC 
using UV detection at 200nm. The detection limits for mephenoxalone 
in serum and urine were 0.04 and 0.2~g/ml, respectively. 
Mephenoxa lone is usua lly admi n i stered in ora 1 doses of 400mg three 
times a day. However, prior to multiple dose pharmacokinetic studies, 
it is important to characterize single dose kinetics. Since it was 
not possible to perform intravenous studies, an oral dose study was 
conducted instead. Solution data were not avai lable because of the 
poor so 1 ub i 1 ity of mephenoxa lone in water and the test dose was, 
therefore, administered as a dispersion of the pure powder in 150ml 
water. 
The concentrations of mephenoxalone which could be expected in serum 
and in urine following a single oral dose of the dispersion were 
established in the pilot study; this study also yielded information on 
the samp 1 i ng frequency requ i red to characteri ze the absorpt i on and 
disposition curve. 
A single dose dispersion study was then conducted using six young, 
healthy volunteers. Five of these subjects participated in a 
subsequent clinical study to assess the bioavailability of 
mephenoxalone from a newly developed solid oral dosage form containing 
a comb i nat i on of mephenoxa lone, paracetamo 1 and codei ne phosphate . 
The most meaningful results were obtained from the statistical moment 
parameters MRT, MAT and MDT, and from the model-independent parameters 
Cmax, tmax, Az , t,/. and AUC 00 The tri a 1 data were a 1 so fi tted to 
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one-body and two-body compartment mode 1 s us i ng the computer program 
NONLIN but neither of these models, which incorporated only one 
absorption rate constant, were able to account for the rapid 
absorption phase; the predicted peak concentrations were always lower 
and later than the experimentally observed values. The incorporation 
of a discontinuous absorption phase to more accurately characterize 
the absorption process was not investigated. 
The absorpt i on of mephenoxa lone from the d i spers ion was rapi d, wi th 
the peak concentration of approximately 8~g/ml appearing after about 1 
hour. Absorpt ion of the compound from the tab 1 et dosage form was 
slightly faster, with the peak concentration being higher (l2~g/ml) 
and ear 1 i er (O. 6 hours) ina 11 but one of the subjects. The tab 1 et 
had a shorter in vivo dissolution time and consequently was absorbed 
more rapidly than the dispersed dosage form. The in vitro dissolution 
studies showed that mephenoxalone dissolved more rapidly from the 
tablet than from the dispersion, thus supporting the in vivo findings. 
It was subsequently revealed by the manufacturer that various 
excipients had been included in the formulation to promote the release 
and dissolution of mephenoxalone from the tablet. However, the faster 
in vivo dissolution of the tablet is not expected to be clinically 
significant since mephenoxalone is a low potency agent with a moderate 
dose-response curve (16,24). 
In this study, the compound was extensively metabol ized with only 
about 1 percent of the administered dose being excreted as unchanged 
mephenoxalone in urine after 24 hours. Two of the metabolites present 
in extracted urine samples were subjected to thermospray HPLC-MS 
analysis and were ascertained to be the unconjugated hydroxylated 
deri vat i ves of mephenoxa lone . However, e luc i dat i on of the prec i se 
structures of these metabolites was not possible because of the lack 
of molecular fragmentation associated with the thermospray technique. 
From the clinical trial data, the post-absorptive phase was generally 
characterized by a fairly rapid mono-exponential decrease in the serum 
concentrat i on of mephenoxa lone. The e 1 imi nat i on ha If- 1 ife for the 
compound was approximately 3 hours. 
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There were, however, cons i derab 1 e i nd i v i dua 1 vari ab i 1 it i es, both 
intra-subject and inter-subject, in the trial data. While subjects WA 
and OW consistently displayed rapid rates of absorption and 
elimination in both trials, subject KR displayed a consistently slow 
rate of elimination. The long elimination half-life for mephenoxalone 
in KR may be explained either by inter-subject variation or because 
she had a mi ld case of Gi lberts' Syndrome. Intra-subject variations 
may be responsible for the results obtained from subjects KZ and MG. 
Thus, although KZ absorbed mephenoxalone rapidly from both test doses, 
she had a much slower rate of el imination after ingestion of the 
tab let dosage form. Th i s discrepancy can a 1 so be exp 1 a i ned by a 
reduction in the metabolic rate as a result of dieting during the 4 
month separation period between trials. Subject MG had a consistently 
rapid elimination half-life for both trials but absorbed mephenoxalone 
more slowly from the tablet dosage form than from the dispersion; no 
explanation other than individual variation or the effect of codeine 
on gastro-intestinal mobility can be offered for these results . 
It is obvious that the difficulties of interpreting the data obtained 
in these studies lie not only with the inadequate characterization of 
the absorption process but also with the variations amongst the 
individuals. In addition, the sample sizes used for the clinical 
trials were not large enough to draw valid conclusions regarding the 
sign if i cance of any differences between the resu lts of rna les and 
those of females. 
The inclusion of paracetamol and codeine phosphate into the tablet 
dosage form did not appear to alter the pharmacokinetic 
characteristics of mephenoxalone. Furthermore, these compounds did not 
interfere with the analytical procedure because they were not 
extracted using the liquid-liquid extraction technique employed for 
isolating mephenoxalone from biological fluids. 
A major drawback of the c 1 i ni ca 1 studies was the 1 ack of i. v. data 
which would have enabled the calculation of absolute bioavailability, 
vo 1 ume of d i stri but ion and clearance . The parameter va 1 ues reported 
by Morri son (6) for beag le dogs ind i cate that mephenoxa lone has a 
volume of distribution of 110 to 120 percent of body mass, and that it 
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is almost completely absorbed after oral administration. It was also 
reported that mephenoxalone exhibits non-linear elimination kinetics 
upon repeated administration of high doses. 
In this study, there was no evidence of non-linear elimination 
kinetics. However, only single oral dose pharmacokinetics were 
investigated and the behaviour of the drug in humans after multiple 
dos i ng is not known. The possibil ity of non-l inearity does exist 
because the conjugation process, i.e. the primary elimination route of 
mephenoxalone, may become saturated, especially in hepatically 
compromised patients . 
No protein binding data for mephenoxalone appear in the literature and 
an investigation was therefore conducted using the equilibrium 
dialysis method. The binding of the drug to human serum proteins 
appeared to be variable but no conclusive results were obtained . 
The work remaining to be conducted on mephenoxalone seems endless but, 
as a beginning, this thesis will hopefully provide a background as 
well as some insight into the pharmacokinetic behaviour of this drug 
in humans . 
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APPENDIX 
TABLE A3.1 Statistical intepretation of storage stability data. 
The measured percentage response difference (D) between stored and 
freshly prepared samples was calculated using the following equation: 
D = GMy GMx 100 (%) 
GMx 
Where GMx is the geometric mean of xl. x2 Xm 
GMy is the geometric mean of Yl. Y2 Yn 
GMx and GMy were calculated as follows : 
ui = ln Xi ( i = 1,2 .. m) 
vi = ln Yi ( i = 1,2 .. n) 
m 
u = z: u' -, 
i=l m 
n 
v = L v' 
-, 
i=l n 
GMx = exp (u) 
GMy = exp (v) 
The true percentage change of concentrat i on ( to. ) was ca 1 cu 1 ated as 
follows: 
m 
S2 = z: 
i=l 
( U i - u)2 + 
m + n - 2 
z: n 
i=l 
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a = v - u t. Sv-u 
b = v - u + t. Sv-u 
Where t is the 95th percentile of the 1 distribution with (m + n -2) 
degrees of freedom. 
LL = (exp (a) 
UL = (exp (b) 
1). 100 (%) 
1). 100 (%) 
where LL and UL are the lower and upper limits of the 90% confidence 
i nterva 1 for t, 
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TABLE A3.2 Statistical calculations for stability of 
mephenoxalone in spiked serum (10.0~g/ml, 24 
hr, ambient temperature) 
SAMPLE CONCENTRATION LN CONC 
NUMBER (~g/ml) 
Freshly Prepared Samples 
1 10.95 
2 1 0.81 
3 10.84 
4 10.92 
5 10.75 
Stored Samples 
1 10.78 
2 10.75 
3 10.82 
4 1 0.91 
5 10.85 
2 GM = 10.86; GM = 10.83; s 
x Y 
(X ) 2.393 (U) 
1 1 
(X ) 2.380 (U ) 
2 2 
(X ) 2.383 (U) 
3 3 
(X ) 2.391 (U) 
4 4 
(X ) 2.375 (U ) 
5 5 
2.385 (U) 
(y ) 2 .378 (V ) 
1 1 
(y ) 2.375 (V ) 
2 2 
(y ) 2.381 (V ) 
3 3 
(y ) 2.390 (V ) 
4 4 
(y ) 2.384 (V ) 
5 5 
2.382 (V) 
-5 4.39 x 10 ; s- - = 0.0118; 
v-u 
df 8; t 0 1.860; a = -0.0249; b = 0.0198; D = 0.29%; 
LL -2.46%; UL = 1.91% 
TABLE A4.' 
------
DISSOLUTION 
MEDIUM 
lOOOml 
WATER 
1 aOOml 
LF. 
1 aOOml 
G.F. 
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Dissolution results from powder in 3 dissolution media 
(USP paddle me t hod) 
TIME FRACTION OF POWDER MEAN (SD) 
(HOURS) (200mq) DISSOLVED 
1 2 3 
0 . 00 0.000 0.000 0.000 0.000 (0 . 000) 
0.17 0.616 0.517 0.621 0.585 (0.048) 
0.33 0 . 882 0.671 0.685 0.746 (0.096) 
0.50 0.961 0.759 0.802 0.841 (0.087) 
0.67 1.015 0.898 0.912 0 . 957 (0.059) 
0 . 83 1.030 1 .001 1 .013 1.015 (0.012) 
1.00 1.039 1 .022 1.013 1.025 (0.011 ) 
0.00 0.000 0.000 0.000 0.000 (0.000) 
0.17 0.861 0.695 0.721 0.759 ( 0.073) 
0.33 0.976 0.851 0.897 0.908 (0.052) 
0.50 1 .001 0.924 0.985 0.970 (0.033) 
0.67 1 .002 0 . 998 0.992 0.997 (0.004) 
0.83 , .004 1 .000 1 .010 '.005 (0.004) 
1.00 1.004 1.004 1 _ 0 17 1.008 (0 . 006) 
0.00 0.000 0.000 0.000 0 . 000 (0.000) 
0.17 0 . 661 0 .584 0.512 0.586 (0 . 061 ) 
0.33 0.979 0 . 818 0 .782 0 . 860 (0.086) 
0.50 1.006 0.898 0.895 0.933 (0.052) " 
0.67 1.014 0 . 910 0.912 0.945 (0.049) 
0.83 1.021 0.942 0.989 0.984 (0.032) 
1.00 , .047 1 . 001 0 .992 1.013 (0.024) 
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TABLE A4.2 Dissolution results from tablets in gastric fluid Cusp paddle method) 
[rIME FRACTION (OF STATED AMOUNT) DISSOLVED FROM A SINGLE MEAN (SO) 
Or) TABLE CONTAINING 200mg MEPHENOXALONE 
1 2 3 4 5 6 
0.00 0.000 0.000 0.000 0.000 0.000 0.000 0.000 (0.000) 
0.17 0.910 0.874 0.942 0.790 0.850 0.931 0.833 (0.057) 
0.33 0.930 0.889 0.948 0.900 0.926 0.938 0.922 (0.023) 
0.50 0.942 0.930 0.953 0 .953 0.929 0 .941 0.941 (0.011) 
0.67 0.945 0.934 0.956 0.955 0.942 0.970 0.950 (0.013) 
0.83 0.956 0.941 0.960 0.957 0.951 0.972 0.956 (0.010) 
1.00 0.958 0.949 0.971 0.961 0.967 0.974 0.963 (0.009) 
1.17 0.968 0.954 0.976 0.963 0.969 0.980 0.968 (0 .009) 
1.33 0.976 0.963 0.978 0.973 0.975 0.983 0.975 (0.007) 
1.50 0.977 0.964 0.979 0.973 0.980 0.984 0.976 (0 .007) 
1.67 0.989 0.979 0.988 0.977 0.980 0.996 0.985 (0.007) 
1.83 1 .022 0.989 1.003 0.983 0.989 0.998 0.997 (0.014) 
2.00 1 .026 1 .002 1 .026 0.988 0.989 1.000 1.005 (0.018) 
TABLE AS.l 
TIME 
(HOURS) 
0 
0.17 
0.33 
0.50 
0.67. 
0.83 
1.00 
1 .17 
1.33 
1.50 
1.75 
2.00 
2.50 
3.00 
4.00 
5.00 
6 .00 
8.00 
10.00 
12.00 
24.00 
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Mephenoxalone serum concentrations after the administration of 
mephenoxalone dispersion (Trial 1) 
CONCENTRATION OF MEPHENOXALONE IN SERUM MEAN (SD) 
(pg/ml) 
WA DW MG KZ KR KD 
0 0 0 0 0 0 0 (0 ) 
0.49 2.55 0.40 0.45 0.37 0 . 64 0 . 82 (0 . 78) 
1.04 3 . 91 1.77 1.67 2. 52 3.25 2.36 (0.98) 
4 . 52 4.33 3.75 2.56 3.74 5.49 4.07 (0.89) 
8.85 5.60 6 . 20 3.63 7 . 30 8 .21 6.63 (1 .74) 
6.27 6.46 6.61 4.35 7.40 10. 22 6.89 (1 .75) 
5.70 6.24 7.66 5.98 7.65 11.42 7.44 (1 .94) 
5.66 4. 51 7.00 7.41 7.48 11 .31 7.23 (2.1 n 
5 .04 4.32 6.30 6.97 7.33 10.80 6.79 (2.07) 
4.75 4.02 6.02 6.68 6.99 10.70 6.53 (2.14) 
4.51 3.99 5.68 6 . 30 6.95 1 0.15 6.26 (2.01) 
4.28 3.57 5.39 5.95 6.67 9.80 5.94 (2.00) 
3.55 3.05 4.60 5.50 6.45 8.45 5.27 (1 .82) 
3.05 2.50 3 . 95 4.73 5.95 7 . 99 4.70 (1 .85) 
2 . 10 1.84 2.89 3.33 5.26 6.25 3.61 (1 .62) 
1. 7 0 1.31 2.07 2.72 4.75 5.06 2.94 (1 . 46) 
1.18 0.89 1.48 1.88 4.25 3.89 2.26 (1.32) 
0.64 0.51 0.78 1.20 2 .99 2 . 70 1.47 (1 .00) 
0.34 0.30 0.45 0.91 2.15 1.60 0.96 (0 .70) 
0.18 0.15 0.24 0.37 1.52 1.02 0 .58 (0 . 51) 
0 0 o . 0 0.36 0 0.06 (0.13 ) 
TABLE AS . 2 
TIME 
( HOURS) 
0 
0.17 
0.33 
0.50 
0 . 67 
0 . 83 
1.00 
1.17 
1.33 
1.50 
1. 75 
2 . 00 
2.50 
3 . 00 
4 . 00 
5 . 00 
6 . 00 
8.00 
10.00 
12.00 
24 .00 
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Mephenoxalone serum concentrations after the administration of 
tablets (Trial 2) 
CONCENTRATION OF MEPHENOXALONE IN SERUM MEAN (sn) 
(pg/ml) 
WA OW MG KZ KR 
0 0 0 0 0 0 (0) 
3.13 0.78 0 0 0 . 15 0.81 (1.19) 
12.14 9.45 0.36 0.19 3.17 5.06 (4.87) 
9.83 7.77 0 . 91 0 . 49 6 . 06 5.01 (3.72) 
8 . 69 6 . 70 0.90 2 .51 7.24 5 . 21 (2.98) 
7.68 6 . 00 1.00 14 . 39 11.00 8.01 (4.54) 
7.42 5.73 1 . 19 11 . 93 9 . 75 7 . 20 (3.67) 
6.91 5.50 1.01 10.72 9.52 6 . 73 (3.40) 
6.55 5.21 1. 28 NS 9.38 5 . 61 ( 2.92) 
6.33 4 . 98 3 . 22 10.09 9.28 6.78 (2 . 58) 
5.71 4.49 4.76 9.40 9 . 1 5 6.70 (2.14) 
5.47 4.39 5 .39 9. 08 8 .59 6.58 <1 . 88) 
4.67 3.53 6.10 8 .61 7 . 84 6 . 15 (1 . 90 ) 
3 . 94 2 . 81 5. 26 7.85 6.73 5 . 32 (1 . 82 ) 
2.73 2.42 3.84 6.74 5.75 4 . 30 (1.69) 
2 . 10 1.96 3 . 09 5 .70 4 . 93 3 . 56 (1 .51 ) 
1.39 1.39 1 . 90 4 . 23 3 . 81 2 . 54 ( 1 . 23 ) 
0 . 89 0.71 1.. 1 2 2. 8 0 2 . 6 0 1.62 (0 .89) 
0 . 56 0 . 41 0 . 67 1. 93 1. 65 1.04 (0 . 62 ) 
0 . 32 0 . 20 0 . 30 1. 23 1. 09 0.63 (0 . 44) 
0 0 0 0 .19 0 .1 9 0.08 ( 0.09) 
NS = no sample drawn 
TABLE A5.3 
TIME 
INTERVAL 
(HOURS) 
0 
o to 2 
2 to 4 
4 to 6 
6 to 10 
10 to 14 
14 to 24 
- --
The cumulative urinary excretion of mephenoxalone after 
administration of 400mg mephenoxalone powder dispersed 
water 
the 
in 150ml 
CUMULATIVE AMOUNT OF MEPHENOXALONE EXCRETED MEAN (SD) 
IN URINE (MG) 
WA DW MG KZ KR KD 
0 0 0 0 0 0 0 (0 ) 
3.91 2.26 1 .22 4.54 2.52 1 .24 2.62 (1 .25) 
4.50 2.82 1 .81 6.87 5 .34 1 .85 3.87 (1 . 87) 
4.69 3.00 2.02 7.25 6.19 2.07 4.20 (2.01 ) 
4.92 3.00 2.31 7.55 7 .08 2.33 4.53 (2.16) 
4.92 3.00 2.31 7.55 7.90 2.33 4.67 (2.33) 
4 .92 3.00 2.31 7.55 7.90 2.33 4.67 (2.33) 
.0> 
"" 
TABLE A5.4 
TIME 
(HOURS) 
0 
0.17 
0.33 
0.50 
0.67 
0.83 
1. 00 
1.17 
1.33 
1.50 
1.15 
2 . 00 
2.50 
3.00 
4.00 
5.00 
6.00 
8.00 
10 . 00 
12.00 
24.00 
Observed and model-predicted serum concentrations of mephenoxalone (using model A) following 
administration of a 400mg dispersed dose of the drug. 
W' OW MG K2 KR KO 
OB5. PRED. OBS. PRED. OBS. PRED. OBS. PRED. OB5. PREC. OB5. PRED. 
0 0 0 0 0 0 0 0 0 0 0 0 
0 . 49 2.74 2.55 3 . 19 0.40 2.05 0.45 1.99 0.37 2.36 0.64 2.96 
1.04 3.62 3.91 4 . 05 1.77 3 . 48 1.67 2.68 2.52 3.53 3.25 5.12 
4.52 4.54 4.33 4.81 3.75 4.58 2.56 3.88 3.74 4.99 5.49 6.87 
8.85 5.07 5 . 60 5.13 6.20 5 . J.4 3.63 4.38 7.30 5.96 8.21 8.16 
6.27 5.32 6.46 5.19 6.61 5.82 4.35 4.92 7.40 6.28 10.22 9 . 04 
5.70 5.42 6 . 24 5.11 7.66 6.13 5.98 5.34 7.65 6.67 11 .42 9.70 
5.66 5.40 4.51 4.95 7.00 6.28 7.41 5.63 7 . 48 6.91 11 .31 10.12 
5 . 04 5 .31 4.32 4 . 75 6.30 6.31 6.97 5.82 7.33 7.08 10.80 10.35 
4.75 5.16 4.02 4 . 53 6.02 6.26 6.68 5.94 6.99 7 . 19 10.70 10.45 
4.51 4.89 3.99 4.19 5.68 6.06 6 . 30 5.99 6.95 7.22 10.15 10.40 
4 . 28 4.59 3.57 3 . 86 5.39 5 .77 5.95 5.94 6.67 7 . 15 9.80 10.18 
3.55 3 . 99 3.05 3.25 4.60 5.06 5.50 5 . 64 6.45 6.97 B.45 9.43 
3.05 3.43 2.50 2.73 3.95 4.32 4 . 73 5.19 5.95 6.40 7.99 8.51 
2.10 2.44 1 . 84 1.91 2.89 3.02 3 . 33 4.12 5 . 26 5.49 6.25 6.65 
1. 70 1.84 1.31 1 . 36 2.07 2.05 2.72 3.29 4.75 4.71 5.06 5 . 08 
1.18 1.31 0.89 0.93 1.48 1.39 1.88 2.54 4. 25 3.95 3.89 3 . 84 
0.64 0.70 0.51 0.45 0.78 0.62 1.20 1.50 2.99 2.88 2.70 2.18 
0.34 0 . 38 0.30 0.24 0.45 0.28 0.91 0.88 2 . 15 2.07 1.60 1.23 
0 . 18 0.20 0.15 0.12 0.24 0.13 0.37 0.51 1.52 1.49 1.02 0.69 
0 0 0 0 0 0 0 0 0.36 0.21 0 0 
-- -
MEAN DATA 
OB5. PRED. 
0 0 
0.82 2.16 
2.36 3.66 
4.07 4.Bl 
6.63 5.62 
6.89 6.13 
7.44 6.47 
7.23 6.66 
6.79 6 . 73 
6.53 6.71 
6.26 6.57 
5.94 6.34 
5.27 5.74 
4.70 5.09 
3.61 3.89 
2.94 2.93 
2.26 2.20 
1.47 1 . 23 
0.96 0.69 
0.58 0.39 
0.06 0 
U1 
o 
TABLE 1.5.5 
TIME 
(HOURS) 
0 
0 . 17 
0.33 
0 . 50 
0.61 
0 . 83 
1.00 
1.17 
1.33 
1.50 
1. 15 
2.00 
2. 50 
3.00 
4. 00 
5.00 
6 . 00 
B. OO 
10 .00 
12.00 
24.00 
Observed and model-predicted serum concentrations of mephenoxalone (uBing mode1 1) following 
administration of a 400mg t ablet dose of the drug. 
W' OW MG K2 KR ME~N DATA 
OBS. PRED. OBS . PRED. OBS. PRED. OBS . PRED. OBS . PRED . OBS . PRED . 
0 0 0 0 0 0 0 0 0 0 0 0 
3.13 6.68 0 . 7B 4.42 0 0.64 0 2.90 0.15 3.44 0 . 81 2.29 
12 . 14 8.02 9.45 6.07 0.36 1.17 0 .19 4.05 3 . 17 4.79 5.06 3.81 
9 . 83 8.50 7 . 77 6 . 63 0.91 1.66 0.49 5.51 6.06 6.35 5.01 5.01 
8.69 8.39 6.70 6.66 0.90 2.08 2.5 1 6.65 1.24 1.58 5.21 5.90 
7 . 68 8.11 6.00 6.41 1.00 2.42 14.39 1.48 11 .00 8.19 8.01 6.42 
1 . 42 1.15 5 . 13 6.12 1.1 9 2.13 11.93 8.14 9.75 8.65 7 . 20 6.76 
6 . 91 1.38 5.50 5.B6 1. 01 2.99 10 . 72 8 . 80 9.52 B.97 6 . 13 6.95 
6.55 1 . 04 5.21 5.56 1.28 3.20 NS 
-
9. 38 9.18 5 . 61 7.01 
6.33 6.63 4.98 5 .30 3 . 22 3. 37 10.09 9.1B 9.28 9.25 6.78 6.99 
5 . 71 6 . 21 4.49 4.81 4.76 3.57 9.40 9.34 9.15 9.22 6.70 6.B4 
5.47 5.73 4.39 4.36 5.39 3 . 71 9.08 9.35 8.59 9.03 6.58 6 . 61 
4.67 4.96 3.53 3.10 6 . 10 3 .82 8.61 9.09 7 . 84 8 . 41 6.15 6.01 
3 . 94 4.18 2.81 3.11 5.26 3.79 7.85 8.60 6.13 7.65 5.32 5.36 
2.13 3.16 2.42 2.19 3.84 3 . 45 6 .74 7.25 5 . 15 6.11 4.30 4 . 11 
2.10 2 .40 1.96 1.61 3.09 3 . 0B 5.70 6.52 4 . 93 4.88 3.56 3 .20 
1.39 1.63 1.39 1.03 1.90 2.45 4 . 23 5 . 05 3 . 81 3.57 2.54 2.45 
0.89 0.93 0.71 0.53 1.12 1.52 2.BO 3.61 2.60 2.25 1.62 1.44 
0.56 0.52 0.41 0.27 0.67 0.95 1.93 2.50 1.65 1.35 1.04 0.B4 
0.32 0.29 0.20 0.13 0 . 30 0 . 56 1.23 1.72 1.09 O.Bl 0.63 0.49 
0 0 0 0 0 0 0.19 0.19 0.19 0 . 04 0.08 0 
--- ---
NS _ no sample withdrawn 
Ul 
TABLE JIr.5.6 
TIME 
(HOURS) 
0 
0.17 
0.33 
0.50 
0.67 
0.83 
1.00 
1.17 
1.33 
1.50 
1.75 
2.00 
2 . 50 
3.00 
4.00 
5 . 00 
6.00 
8.00 
10.00 
12.00 
24 ~ 00 
Observed and model-predicted serum concentrations of mephenoxalone (using model B) following 
administration of a 400mg dispersed dose of the drug (Trial 1). 
W. DW MG KZ KR KD 
OBS. PRED. OBS . PRED. OBS. PRED. OBS. PRED. OBS. PRED. OBS . PRED. 
0 0 0 0 0 0 0 0 0 0 0 0 
0.49 2.63 2.55 3.08 0.40 2.05 0.45 1.92 0.37 2.34 0.64 2.88 
1.04 3.52 3.91 3 . 99 1.77 3.47 1.67 2.60 2.52 3.50 3.25 4.99 
4.52 4.53 4 . 33 4.83 3,75 4.58 2.56 3.82 3.74 4.97 5.49 6.70 
8.85 5 . 15 5.60 5.22 6.20 5 . 34 3 . 63 4 . 34 7.30 5.96 8.21 7.97 
6.27 5.47 6.46 5.31 6.61 5 . 81 4.35 4.90 7 . 40 6.29 10 . 22 8.84 
5.70 5 . 62 6 . 24 5 . 23 7 . 66 6 . 11 5.98 5.35 7.65 6 . 69 11.42 9 . 48 
5.66 5.61 4.51 5.04 7 . 00 6 . 25 7.41 5.67 7.48 6 .93 11.31 9 . 89 
5.04 5.51 4 . 32 4 . 81 6.30 6 . 27 6.97 5 . 87 7.33 7.10 10 . 80 10.11 
4.75 5 . 33 4.02 4.53 6.02 6 . 20 6 . 68 6.01 6 . 99 7.20 10.70 10.20 
4 . 51 4.99 3.99 4 . 10 5 . 68 5 . 98 6.30 6 .07 6.95 7 . 23 10.15 10.12 
4.28 4 . 50 3 . 57 3.69 5 . 39 5 . 67 5.95 6.01 6 . 67 7.14 9 . 80 9.88 
3.55 3.80 3 . 05 2 . 97 4 . 60 4.93 5.50 5 . 65 6 . 45 6.93 8 .45 9 . 09 
3 . 05 3 . 09 2.50 2 . 40 3.95 4 .17 4 . 73 5.10 5.95 6 . 30 7.99 8.13 
2.10 1 . 96 1.84 1.62 2.89 2.88 3 . 33 3.80 5 . 26 5.33 6 . 25 6.28 
1. 70 1.40 1.31 1.18 2.07 1.98 2.72 2.82 4.75 4.53 5.06 4.78 
1.18 1.00 0 . 89 0.90 1.48 1.39 1.88 2 . 00 4.25 3.78 3.89 3.69 
0.64 0.66 0.51 0.64 0.78 0 . 77 1.20 1.01 2.99 2.81 2.70 2.35 
0.34 0.54 0.30 0 .53 0.45 0.51 0.91 0 . 57 2.15 2.13 1.60 1.67 
0.18 0 . 47 0 . 15 0.45 0.24 0.40 0.37 0.38 1. 52 1.67 1.02 1.31 
0 0 0 0 0 0 0 0 0.36 0.59 0 0 
, 
MEAN DATA I 
OBS. PRED. I 
I 
0 0 
I 
0.82 2.06 
2.36 3.53 
4.07 4 . 71 
6 . 63 5 . 56 
6.89 6 . 12 
7.44 6 .50 
7 . 23 6.72 
6.79 6.81 
6 . 53 6.80 
6.26 6.65 
5.94 6 . 39 
5.27 5.69 
4 . 70 4.93 
3.61 3.58 
2.94 2.59 
2.26 1.94 
1.47 1.23 
0.96 0.92 
0.58 0.75 
0 . 06 0 . 21 
Ul 
N 
TABLE AS . 7 
TIME 
(HOURS) 
0 
0.17 
0.33 
0 . 50 
0 . 61 
0 . 83 
1.00 
1.17 
1.33 
1.50 
1. 75 
2 . 00 
2.50 
3 . 00 
4 . 00 
5.00 
6.00 
8 . 00 
10 . 00 
12 . 00 
24.00 
Observed and model-pred i cted serum concentrations of mephenoxalone (using model B) following 
administration of a 400mg tablet dOBe of the drug (Trial 2) . 
W' OW MG KZ KR MEAN DATA 
OBS. PRED . OBS. PRED . 085 . PRED . 08S . PRED . OBS. PRED. OBS. PRED . 
0 0 0 0 0 0 0 0 0 0 0 0 
3 . 13 6.66 0 . 78 4 .20 0 0.59 0 2 . 72 0.15 3 . 54 0.81 2 . 20 
12 . 14 8 . 25 9 . 45 6 . 04 0.36 1.08 0. 19 3 . 84 3.17 4 . 92 5 . 06 3 . 80 
9 . 83 ' 8.91 7.77 6.78 0.91 1.53 0 .49 5.32 6.06 6 . 51 5.01 5.04 
8 . 69 8 . 79 6.70 6.B7 0.90 1.93 2 . 51 6.52 7 . 24 7 . 75 5.21 5 . B7 
7 . 68 8 . 42 6 . 00 6 . 58 1.00 2 . 25 14.39 7.43 11.00 8 . 35 8.01 6.39 
7 . 42 7 . 91 5.73 6.22 1.19 2 . 54 11.93 8 . 19 9 . 75 8 . 80 7.20 6.74 
6 . 91 7.38 5.50 5.B7 1.01 2 . 79 10.72 B. 99 9.52 9.09 6 . 73 6 . 93 
6.55 6 . 90 5 . 21 6.04 1.28 2 . 9B NS 
-
9.3B 9 . 28 5.61 6.99 
6 . 33 6 . 34 4.98 5 . 14 3.22 3.16 10 . 09 9.48 9 . 2B 9 . 32 6 . 7B 6.97 
5.71 5 . 79 4 . 49 4 . 53 4.76 3 . 35 9 . 40 9 . 73 9 . 15 9 . 24 6.70 6 . 82 
5.47 5 . 1 B 4 . 39 4 . 03 5 . 39 3 . 49 9.08 9 . 79 8 . 59 B. 98 6.58 6 . 58 
4.67 4 . 30 3 . 53 3 . 36 6 . 10 3 . 61 B.61 9 . 52 7.B4 S . 27 6.15 5.96 
3.94 3.50 2 . Bl 2.B6 5 . 26 3 . 59 7 . 85 8.91 6.73 7.43 5 . 32 S.30 
2 . 73 2 . 61 2 . 42 2 . 12 3 . B4 3 . 30 6 . 74 7.12 5 . 75 5 . 82 4.30 4.09 
2. 10 2 . 05 1.96 1.87 3 . 09 2 . 96 5 . 70 6.14 4 . 93 4.61 3 . 56 3 . 14 
1.39 1.57 1.39 1. 54 1.90 2 . 36 4.23 4 . 26 3.Bl 3.40 2 . S4 2 . 41 
0 . 89 1.18 0 . 71 1.21 1.12 1.48 2.80 2 . 71 2 . 60 2.29 1.62 1.45 
0 . 56 0.95 0 . 41 0 . 96 0 . 67 0 . 93 1 . 93 1. 78 1. 65 1.63 1.04 0.89 
0 . 32 0 . 78 0 . 20 0.76 0 . 30 0 . 56 1. 23 1. 31 1.09 1.26 0 . E)3 0.56 
0 0 0 0 0 0 0.19 0.76 0 . 19 0 . 66 O. OB 0 . 18 
NS _ no sample withdrawn 
'" W 
154 
TABLE AS.S Parameter estimates f r om computer modelling of dispersion and tablet dosage data 
MODEL PARAMETER SUBJECTS PARAMETER 
ESTIMATES FROM 
MEAN DATA 
W, OW MG KZ KR KD 
400mq DISPERSION STUDY 
1eCM ka 2.152 3.000 1.307 1 .053 1.452 , .21 1 1 .471 
1ka V 64.085 8 3.718 66.284 51.539 56.119 51 .207 68.643 
1 
l inear k 0.314 0.350 0.400 0.268 0.165 0.286 0.289 
10 
elimination tlag 0.879 0 . 122 0.434 0.'98 0 . 20 1 0 . 610 0.368 
-, 
r 0.879 0.970 0. 957 0 . 953 0.959 0.969 0.959 
2BCM ka 1 . 475 2.31 4 1.231 0.679 1 .347 1.098 1 .045 
--
1ka V 61 .888 82.383 65.680 46.07 1 55 . 490 50.547 61 .'90 
1 
linear k 0 .247 0.229 0.155 0.225 0.609 0.135 0 .1 93 
12 
elimination k 0.086 0.131 0.583 0.022 0.116 0.OB6 0.116 
21 
k 0.312 0.314 0.3 1 2 0 . 264 0 . 147 0 . 224 0.298 
10 
tlag 0 . 304 0.299 0 . 501 0 . 712 0 . 252 0.720 0.671 
r 0.855 0.974 0.960 0.955 0.917 0.973 0.971 
40 0mg TABLET STUDY 
18CM ka 5 .930 4.777 0.500 1 .145 1 . 295 - 1.551 
1ka V 76.303 87.900 56.068 54.484 54 . 227 
-
67 . 068 
1 
linear k 0.300 0.350 0.286 0.185 0 . 254 
-
0 . 268 
10 
elimination tlag 0 . 1083 0.124 0.248 0 . 519 0.483 
-
0.341 
r 0.925 0.899 0.833 0.834 0.953 
-
0 . 961 
2BCM ka 4.708 3.459 0 . 436 0.695 1.252 
-
1 .484 
1ka V 61 . 530 85.672 54.440 55.111 53.811 
-
67.687 
1 
l inear K 0.203 0.348 0 .1 28 0.191 0.132 
-
0.026 
12 
elimination K 0.174 0.334 0.973 0.039 0.058 
-
0.300 
21 
k 0.280 0.297 0 . 309 0.180 0.177 
-
0.272 
10 
tlag 0.122 0.221 0.333 1.457 0.543 
-
0.383 
r 0.930 0.904 0.840 0.836 0.907 
-
0.961 
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